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Background: Proton Pump Inhibitors (PPIs) are commonly used for the 
treatment of acid-related disorders. They are generally well tolerated, 
with a low incidence of adverse effects (1 %). Omeprazole is the most 
common PPIs used and its intake has tripled from 2003 to 2012 in Spain. 
Although hypersensitivity reactions to PPIs are rare, they are being more 
reported in recent years maybe due to the growing use of these drugs.
The aim of this study was to review our experience with the use of PPIs 
in the last 16 years.
Materials and methods: We undertook a retrospective analysis of 
10,858 patients who attended to the Drug Allergy Unit of Hospital de 
la Cruz Roja-Madrid, from 1999 to 2014.
We divided our patients in two groups according to the increase of intake 
of PPIs. Group 1 from 1999 to 2008 and Group 2 from 2009 to 2014.
We consider positive cases those who had Positive skin Prick test or 
positive drug provocation test or positive basophil activation test or 
suggestive history of PPIs allergy. We excluded patients who quit or 
refused the study.
Results: A total of 253 patients (2.3  %) were attended in the Allergy 
Unit with suspected history of PPIs allergy in the last 16  years. From 
those, 16 (6.3 %) were positive cases.
In group 1, we included 5563 patients, from those, 91 were suspected 
cases, and 4 (4.4 %) of them were positive.
In group 2, we included 5295 patients, from those 162 were suspected 
cases, and 12 (7.4 %) of them were positive.
Conclusions: In our experience, we found an increase in the number 
of reactions due to PPIs in the last years. Our results are according to 
the literature: Hypersensitivity reactions to PPIs are rare.
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Background: The increasing use of quinolone antibiotics is associ-
ated with an increase in hypersensitivity reactions. The objective of 
this study is to analyse the cases of suspected allergy to quinolones 
referred to an allergy department in a tertiary level centre during 2015.
Materials and methods: We performed a descriptive, retrospective 
study. Cases were identified from the medical record administrator 
programme by searching the terms “quinolone, norfloxacin, moxi-
floxacin, levofloxacin or ciprofloxacin”. We collected demographic 
and medical data, information of the adverse events, results of the 
allergy evaluation and the recommendations for the future use of 
quinolones.
Results: We analysed 60 cases (26 male/34 female) with an average 
age of 60.5  years (6–88). The most frequent clinical manifestations 
were cutaneous (70 %), 11 % digestive, 7 % respiratory, 7 % neuro-
logical, 4 % cardiovascular and 1 % renal. The most common symp-
tom were pruritus (25  %) and erythema (24  %). The reaction was 
immediate (within minutes) in 37  % and delayed in 45  %. The type 
of reaction was not described in 18  % of cases. The involved qui-
nolones were ciprofloxacin (40  %), levofloxacin (37  %), norfloxacin 
(8  %) and moxifloxacin (8  %). The most frequent route of adminis-
tration was oral (66 %), followed by intravenous (30 %), topical (2 %) 
and otic (2  %). In two cases quinolones were directly banned after 
the adverse event due to the patient clinical condition or it was not 
considered necessary due to the lack of evidence on the reliability of 
the tests. Skin tests were performed in 40  % of cases, with positive 
results for ciprofloxacin 78  %, moxifloxacin 77  %, levofloxacin 57  % 
and none for norfloxacin. In a case of a generalized delayed reac-
tion, patch tests were negative. In one case a fixed drug erythema 
due to norfloxacin was diagnosed without further check. In 10 cases 
of severe immediate reactions, BAT was performed 17 times with 4 
positive results for ciprofloxacin and 3 for levofloxacin. In these cases 
quinolones were banned. All patients tolerated alternative quinolo-
nes to the one eliciting the adverse event, even when skin tests were 
positive.
Conclusions: Ciprofloxacin and levofloxacin were the most frequently 
involved quinolones. Skin symptoms were the most common clinical 
manifestations. Allergy evaluation included skin tests, BAT and con-
trolled exposure in order to identify the responsible quinolones and 
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Background: Bupropion is a new-generation antidepressant, while 
its sustained release (SR) formulation is used in smoking cessation for 
a long time successfully. Urticaria, pruritus and rashes can be seen in 
1–4  % of the patients and anaphylactoid reactions like angioedema 
and dyspnea can be seen in 0.1–0.3 % of the patients using bupropion. 
We wanted to report a case with urticaria and angioedema due to SR 
bupropion treatment.
Report: A-27-year-old woman without any disease history admitted to 
a hospital for smoking cessation. She had 15-pack-year of smoking his-
tory and she had started using 150 mg of SR bupropion. In first 3 days, 
she had used it once a day, then she started using twice a day. On 
tenth day of treatment, generalized rash with pruritus had been devel-
oped. In physical examination, she had generalized plaques and pap-
ules with edema and erythema on his neck, trunk, upper and lower 
extremites (Fig. 1). She had swelling on her lips as well. With suspicion 
of adverse drug reaction, skin biopsy was made. Other physical exami-
nation, blood and urinary laboratory findings were normal. With these 
clinical and histopathological findings, urticaria and angioedema diag-
nosis were made. She was hospitalized and bupropion treatment was 
stopped. Systemic corticosteroid and antihistaminic treatments were 
started. On third day of treatment, her skin lesions were regressed.
How this report contributes to current knowledge: Buproprion is a 
commonly used drug in smoking cessation clinics. Although it is rare, 
physicians should be cautious about urticaria, angioedema and ana-
phylaxis as adverse drug reactions of bupropion treatment.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
P96 
Delayed type hypersensitivity and study of cross‑reactivity 
between proton‑pump inhibitors
Chien‑Yio Lin1, Chung‑Yee Rosaline Hui2, Ya‑Ching Chang2, Chih‑Hsun 
Yang2, Wen‑Hung Chung2
1Department of Dermatology, Chang Gung Memorial Hospital, Linkou, 
Taiwan; 2Department of Dermatology, Drug Hypersensitivity Clinical 
and Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan  
Correspondence: Chien‑Yio Lin
Clinical and Translational Allergy 2016, 6(Suppl 3):P96
Background: There are six PPIs available for clinical use, which 
could be set into two groups, omeprazole/esomeprazole/pantopra-
zole versus lansoprazole/dexlansoprazole/rabeprazole, based on 
the same basic skeleton, but differed by virtue of substitutions on 
both rings. The former three have changes in their benzimidazole 
ring, whereas the latter three have changes in their pyridine ring. 
Although proton-pump inhibitors (PPI) are relatively well tolerated, 
some patients may develop hypersensitivity reactions, which vary 
from mild symptoms to life-threatening severe cutaneous adverse 
reactions (SCARs), such as Stevens–Johnson syndrome (SJS), toxic 
epidermal necrolysis (TEN), acute generalized exanthematous pus-
tulosis (AGEP), and drug rash with eosinophilia and systemic symp-
toms (DRESS). Clinicians often overlook the potential of PPI-related 
SCARs.
Materials and methods: We retrospectively analyzed patients of 
PPI-related cutaneous adverse reactions from Chang Gung Memo-
rial Hospital health system during January 2003 to December 2015. 
We analyzed the causative PPIs, cutaneous manifestation, organ 
involvement, treatment, and complications. We also assessed the 
cross-hypersensitivity to other PPI after the hypersensitivity epi-
sode. The causality of the culprit drugs was further confirmed by 
in  vitro lymphocyte activation test (LAT) and patch test in some 
cases.
Results: There were 48 cases of PPI-related cutaneous adverse reac-
tions, with maculopapular eruption (MPE, n  =  20), DRESS (n  =  10), 
and SJS/TEN (n  =  9), contributing the most. Esomeprazole was the 
most common causative PPI (n =  23, 47.9  %), and the liver was the 
most frequently involved internal organ (26.7 %). One patient (2.1 %) 
died of esomeprazole-induced TEN. Seven patients allergic to one 
group of PPI would able to tolerate the other different structured PPI 
group, whereas two patients showed cross-hypersensitivity when 
shifting to alternative PPI of the same group with similar structure. 
The drug causality and cross-reactivity were confirmed by lympho-
cyte activation test in 53.8  % patient of whom tested; besides, 2 of 
5 patient with patch test performed showed corresponding result to 
the LAT.
Conclusions: The clinicians should be cautious of PPI-related SCARs. 
The potential of cross-hypersensitivity to similar structured PPI should 
be aware of, and shifting to different structured PPI could be consid-
ered when PPI is the treatment of choice (Fig. 2).
Fig. 1 Urticarial lesions on trunk
Fig. 2 Causative proton pump inhibitors, demographic data, and 
allergologic investigation of patients with PPI‑SCARs
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Background: Proton-pump inhibitors (PPI) are widely used in clinical 
practice and there are multiple reports of hypersensitivity reactions 
(HSR), most of them immediate, and cross-reactivity (CR) between PPI. 
Specificity of skin tests has to be determined and there are currently 
no specific recommendations from the ENDA group. Aim: We present 
a consecutive case series of patients with suspected PPI HSR.
Materials and methods: The present study is a case series of patients 
evaluated in our Drug Allergy Unit for suspected PPI HSR, in an 8-year 
period. CR in skin prick tests (SPT) and intradermal tests (IDT) was 
assessed using the commercially available parenteral PPI formulations 
(esomeprazole 20  mg/ml, omeprazole 4  mg/ml, pantoprazole 4  mg/
ml) and crushed tablets in saline (lansoprazole 15 mg/ml, rabeprazole 
10 mg/ml) for SPT. IDT were only performed with parenteral formula-
tions (1/1000–1/1 dilutions), due to safety and accuracy reasons.
Results: In the studied period, 19 patients (11 female; mean  ±  SD 
age 50.7 ± 14.2 years) were assessed for the suspected HSR. PPI were 
mainly prescribed for dyspepsia/stomach ache (n = 11) or Helicobac-
ter pylori eradication (n = 4). Implicated PPI were omeprazole (n = 13), 
esomeprazole (n = 4), pantoprazole (n = 2), lansoprazole (n = 2), with 
2 patients reacting to different PPI (omeprazole/lansoprazole and 
omeprazole/pantoprazole). Eight patients had immediate reactions (6 
anaphylaxis and 2 urticaria) and 3 of them had positive SPT (one had 
positive SPT to both omeprazole and pantoprazole). Seven patients 
(5 urticaria, 1 anaphylaxis and 1 MPE) had positive IDT to omeprazole 
only (undiluted) and 1 patient (anaphylaxis) had a positive IDT to pan-
toprazole alone (1/100). Cutaneous CR (this is, positive IDT for >1 PPI) 
was present in 3 patients, as described below:
  •  one patient with anaphylaxis to omeprazole and positive IDT to 
omeprazole (1/1000) plus esomeprazole (1/10);
  •  another patient with anaphylaxis to omeprazole and positive IDT 
to omeprazole (1/10) plus pantoprazole (1/1);
 •  and a patient with urticaria to esomeprazole and positive IDT to 
esomeprazole (1/10) plus pantoprazole (1/10).
Non-atopic controls were also tested for PPI.
Conclusions: Cross-reactivity in 4 patients can be explained by the 
similar chemical structure of PPI. Additional multicentre studies are 
needed to standardize procedures for skin tests with PPI. Oral chal-
lenges are also important to increase the diagnostic accuracy to this 
pharmacological group.
Keywords: Drug hypersensitivity; Proton-pump inhibitors; Skin tests; 
Cross-reactivity
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Background: Enzyme replacement therapy (ERT) has been used in the 
treatment of lysosomal diseases (LD). ERT with human recombinant 
enzymes has shown to slow disease progression and improve the qual-
ity of life. Infusion-related reactions (IRR) to ERT can occur and be severe, 
including hypersensitivity reactions (HSRs) such as anaphylaxis. A diag-
nostic and treatment protocol was proposed to manage those reactions.
Materials and methods: Patients under ERT for Mucopolysaccharido-
sis (I, II and VI), Gaucher, Fabry and Pompe diseases under treatment 
in 7 centers from Brazil were assessed from January 2011 through 
December 2015. In the presence of suggestive signs or symptoms of 
an adverse reaction, ERT was stopped and skin tests for specific IgE 
assay were performed. In patients with symptoms of acute infection 
after infusion and with negative skin tests, ERT was maintained at 
the same infusion rate. In patients without a history of infection and 
with negative tests, ERT was maintained with an increased infusion 
rate. For those patients with positive ST that continued reacting after 
adjustments in the IR, a 3 bags 12-steps desensitization protocol was 
generated.
Results: Thirteen patients presented a suggestive HSR with positive 
skin tests, during treatment with laronidase (n = 3), galsulfase (n = 2), 
betagalsidase (n  =  7), imiglucerase (n  =  1). Urticaria was the most 
commom symptom observed (50  %), followed by fever (20  %), chills 
(10 %), cough (10 %) and anaphylaxis (10 %). Of the 911 desensitiza-
tions performed, 20 % induced mild reactions, but all patients received 
their full target dose. No severe, life-threatening HSRs or deaths 
occurred during the procedure.
Conclusions: Considering the importance of ERT in the treatment of 
LD, a standardized diagnostic protocol for IRR allows us to establish a 
correct diagnosis and propose an efficient treatment algorithm, which 
includes infusion rate modification and desensitization.
Keywords: Desensitization; Lysosomal diseases
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Background: Insulin allergy is uncommon, particularly in patients 
with Type 2 diabetes mellitus (DM). Management of the condition can 
be difficult. We report a patient with Type 2 DM and insulin allergy 
successfully managed with continuous subcutaneous insulin infusion 
(CSII).
Report: 35  years old woman diagnosed as type 2 diabetes mellitus 
used detemir insulin at first. On the third day of detemir, 12 h after the 
dose, a pruriginous papule occured at the site of injection area. Local 
reaction was continued. On the seventh day, detemir was changed 
with NPH. Local reaction occured at first dose of NPH. All of the local 
reactions were late onset. Therapy was changed to glargine. One hour 
after the first dose of glargine, local reaction and generalize pruritus 
were occurred. All insulin types were stopped and 4 weeks later, skin 
tests were performed. Prick tests were negative. Intradermal tests were 
positive with the dilutions of 1/100 detemir, 1/100 glargine, 1/1000 
NPH, 1/1000 regular insulin. Glulisin, aspart and lispro were negative. 
Insulin specific IgE [194 Ku/l (0–87)] and anti-insulin antibody 47.8 % 
(reference <8.2) were high and specific Ig G4 was normal [35  mg/dl 
(0–125)]. The therapy started with glulisin and there wasn’t any reac-
tion at first. Therefore, since blood glucose and serum glycated hemo-
globin A1c levels (10  %) were still higher, as a long acting insulin, 
NPH had to be added together with antihistaminic. No reaction was 
observed with NPH. At the 20th day of glulisin, late onset local reac-
tions were seen again. Glulisin was changed to aspart. Similar reac-
tions were seen with those insulins. Finally, the only insulin which has 
Page 40 of 74Clin Transl Allergy 2016, 6(Suppl 3):30
never been used before was lispro. We suggested CSII pump with lis-
pro. After this method, insulin hypersensitivity was successfully treated 
and glycemic control was achieved.
How this report contributes to current knowledge: Allergy to insu-
lin analogues is rare and requires early diagnosis, leading to a major 
therapeutic challenge. In this case, local reactions continued although 
types of insulins and application areas were changed. Interestingly, 
blood glucose was increasing to uncontrolled levels always following 
by the cutaneous reactions, also. As we consider anti-insulin antibod-
ies and late onset local reactions, insulin allergy is thought to be medi-
ated by type 1 and type 2 hypersensitivity reactions in this case.
Consent: Written informed consent was obtained from the patient.
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Background: Angioedema is a serious, infrequent and well-known 
Adverse Drug Reaction (ADR) to antihypertensive drugs: Inhibitors 
of Angiotensin Converting Enzyme (ACEI), Angiotensin II Receptor 
Blocker (ARB) and Direct Inhibitor of Renin (DIR). ACEI/ARB/DIR are 
largely used worldwide, therefore, the morbidity and mortality from 
ADR could be considerable. No medications are currently approved for 
management of this ADR.
Icatibant, a bradykinin receptor type 2 antagonist, is a potential treat-
ment for a serious bradykinin-mediated angioedema associated with 
angiotensin inhibitors.
Materials and methods: Design: A case series of 100 patients with 
angioedema associated with ACEI/ARB/IDR.
Scope: Allergy service, Hospital Central de la Defensa, Madrid.
Period: March 2009 to December 2015.
Main Variables assessed: demographic and clinical variables, treat-
ment, and evolution.
The patients have given written informed consent for the publication 
research.
Results: One hundred patients with episodes of angioedema all 
of them associated with ACEI/ARB/DIR. In addition to angioedema, 
patients showed cough, conjunctivitis, pruritus and rhinitis.
Twenty had severe angioedema with airway compromise, speech 
impairment and hoarseness and poor response to antihistamines and 
corticosteroids which required hospitalization. They were treated with 
icatibant 30 mg subcutaneous injection improving in their symptoms 
after 20  min–3.3  h. All patients experienced complete resolution of 
angioedema and avoidance of intubation and tracheotomy.
Age 66.3 years (37–90), 12 females and 8 males. Ten patients had previ-
ously experienced serious angioedema attacks.
Eight drugs were involved: ACEI 15 (enalapril, captopril and lisinopril), 
ARBII 4 (valsartan, losartan, olemesartan and ibersartan) and DIR 1 
(aliskiren). More frequently involved drug was enalapril (9 cases).
Conclusions: Angioedema associated to angiotensin inhibitors is a 
serious ADR, it is rare but not unusual due to the widespread use of 
this class of drugs. Icatibant used off-label helped to improve the acute 
angioedema attacks and avoidance of intubation and tracheotomy.
Keywords: Angioedema; Angiotensin inhibitors; Icatibant
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Background: Thiocolchicoside is a sulfureted semi-synthetic mol-
ecule derived from colchicoside and is used frequently as adjuvant 
treatment for acute muscle contractures in spinal pathology. Immedi-
ate hypersensitivity reactions are rarely reported and only two docu-
mented cases of immediate anaphylaxis are described in the literature. 
Moreover, the allergy diagnosis with validated skin tests is lacking.
Materials and methods: We describe a first case of a 56-year-old 
woman that reported generalized pruritus, a rash involving palms and 
soles, dyspnea and colicky abdominal pain, 5  min after intramuscu-
lar (IM) administration of thiocolchicoside. These symptoms quickly 
reversed with IM adrenaline and intravenous (IV) hydrocortisone. 
A few months later we received a second case of a 52-year-old man 
who experienced dizziness, malaise and hypotension, 40 min after IM 
administration of thiocolchicoside and diclofenac. This clinical sce-
nario was inverted with volume reposition with saline, IV hydrocorti-
sone and adrenaline wasn’t administered.
Results: In the first case the emergency lab results showed serum 
tryptase 47  μg/l. Skin Prick test (SPT) (2  mg/ml) was negative and 
5  min after performing intradermal test (IDT) (2  mg/ml) the patient 
experienced throat tightness that was reversed with ebastine 20 mg. 
In the second case the SPT (2 mg/ml) was negative and IDT (2 mg/ml) 
was positive with a 7 mm wheal diameter. The skin tests and oral prov-
ocation with diclofenac were negative.
SPT and IDT with the same concentration were also negative in 6 
patients with suspected immediate reaction to thiocolchicoside, con-
firmed by negative drug provocation test.
Conclusions: Thiocolchicoside is often administered as an adjuvant 
therapy with non-steroidal anti-inflammatory drugs and is probably 
underestimated as a cause of immediate hypersensitivity reactions. 
Since the skin tests are not yet validated, many times it can be forgot-
ten on the diagnostic workup. To our knowledge, this is the third study 
reporting documented anaphylaxis to thiocolchicoside and the first to 
support this diagnosis with intradermal tests.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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A curious delayed reading: a case report of a β‑lactam allergy in a 
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Background: β-lactam antibiotics are commonly prescribed drugs 
worldwide and the most frequent cause of adverse drug reaction 
mediated by immunological mechanisms. Nonimmediate reactions, 
specially maculopapular and urticarial exanthems, are common. Skin 
tests are used to evaluate drug hypersensitivity and delayed reading 
might be useful in the diagnosis.
Report: A 2.5  year old girl, with no relevant past medical history, 
was referred to our outpatient clinic for suspected drug allergy to 
β-lactams. The patient had been admitted to the hospital for acute 
mastoiditis. Upon admission, amoxicillin-clavulanic acid (Ax/C), which 
she had been taking for 4 days, was discontinued due to vomiting and 
she was started on triple IV antibiotherapy with ceftriaxone, vancomy-
cin and metronidazole. On the 15th day of treatment, physical exami-
nation revealed a diffuse pruriginous maculopapular rash and fever, 
without palpable adenopathies. C-reactive protein was increased, 
eosinophil count was within normal range values and serologies for 
EBV and CMV were negative. An allergic reaction to ceftriaxone was 
suspected and the drug was discontinued by the 23rd day of treat-
ment. Due to persistence of symptoms, the remaining 2 antibiotics 
were also discontinued 3  days later. Skin biopsy was suggestive of 
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erythema multiforme and a course of systemic corticotherapy was 
started with resolution of symptoms. Skin prick tests and intrader-
mal tests (IDT) with Ax/C, penicillin, cefuroxime and ceftriaxone were 
performed, using the maximal non-irritant dose, all of which were 
negative on immediate reading. 48 h later, both the prick and IDT were 
positive for Ax/C as well as the IDT for ceftriaxone.
How this report contributes to current knowledge: Few nonim-
mediate reactions to cephalosporin are confirmed, due to the fact 
that most are caused by infections. Nonetheless, allergic reactions can 
occur even in young children, and in our case, the culprit agents were 
confirmed by a positive skin prick test on delayed reading. Skin prick 
tests and IDT with delayed readings seem to be useful in the evalua-
tion of these reactions.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Betalactams hypersensitivity remains overestimated 
because of the lack of an objective diagnosis tool leading to unjusti-
fied therapeutic alternatives.
This study has been performed in order to analyze the epidemiologi-
cal, clinical and chronological features of betalactams hypersensitivity, 
to evaluate the skin tests value, and to establish a practical approach 
exploring such drug hypersensitivity.
Materials and methods: We included all adverse effects suspected to 
be induced by betalactams and notified to the pharmacovigilance unit 
of Monastir during 11  years. The drug imputability was established 
according to Begaud et al. method. Skin tests were performed as rec-
ommended by ENDA.
Results: Betalactms hypersensitivity was diagnosed in 168 patients. 
Almost all reactions were cutaneous mainly maculo-papular rashes. 
The severity was estimated at 11.3 %. The delayed reactions occurred 
in 60.7  % of cases. All reactions resolved after drug withdrawal. We 
identified 19 positive rechallenges. Skin tests were performed in 386 
cases and were positive in 26.2 % of them. Penicillins were implicated 
in 62.5 % of cases. Almost all of immediate reactions were induced by 
penicillins. The hypersensitivity was selective to one betalactam in 
nearly half of cases. Cross-reactivity was objectified among penicillins 
in one-third of cases, between cefotaxime and cefazolin in one case, 
between penicillins and cephalosporins in 19  % of cases, involving 
piperacillin-tazobactam in two cases and imipenem in one case.
Conclusions: Through the current study, we have demonstrated that 
the betalactam hypersensitivity reactions are mostly delayed and non 
severe. The diagnosis was confirmed using skin tests which were use-
ful not only in identifying the culprit drug but also in assessing cross 
reactivity. These findings have to be improved by the drug provoca-
tion test which is still not performed in our centre.
Keywords: Betalactam; Skin tests; Diagnosis; Cross reactivity
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Background: Correct diagnosis of cefazolin hypersensitivity is not 
straightforward, mainly because of the absence of in  vitro tests and 
uncertainties associated with the optimal skin test concentrations. 
Cross-reactivity patterns involving cefazolin suggest that cefazolin 
hypersensitivity is an isolated hypersensitivity.
Objectives: As a first objective of this study, we sought to confirm 
whether the application of a higher than 2 mg/ml test concentration 
could increase skin test sensitivity, and add to the diagnosis of cefazo-
lin hypersensitivity. A second part of our study aimed at investigating 
the cross-reactivity between cefazolin and other β-lactam antibiotics.
Materials and methods: 66 patients referred to our outpatients’ clinic 
for diagnostic evaluation after experiencing perioperative anaphylaxis, 
and exposed to cefazolin, underwent skin testing with cefazolin up to 
20 mg/ml. Patients exhibiting a positive skin test with cefazolin had a 
panel of skin tests with other β-lactams and, if indicated, graded drug 
challenges in order to study cross-reactivity.
Results: Increasing the skin test concentration from 2 to 20  mg/ml 
identified an additional 7/19 (27  %) patients, who would otherwise 
have displayed negative skin testing. The concentration was proven to 
be non-irritating in 30 cefazolin exposed control individuals in which 
an alternative culprit for peri-operative anaphylaxis was identified. 
Graded challenge testing, following negative skin testing, displayed 
that all the patients tolerated alternative β-lactam antibiotics. Of them, 
11 individuals also tolerated an alternative cephalosporin, suggesting 
that cefazolin hypersensitivity (generally) is a selective allergy.
Conclusions: Increasing cefazolin skin test concentration up to 
20 mg/ml benefits the sensitivity of diagnosis. Furthermore, our data 
further confirm that cefazolin hypersensitivity seems to be a selective 
allergy with good tolerance to other β-lactam antibiotics.
Keywords: Drug hypersensitivity; Cefazolin; Diagnosis; Skin testing
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Background: Beta-lactams (BL) are frequently prescribed antibiotics. 
Allergic reactions to BL can be immediate (IgE reactions) and non-
immediate reactions (T cell reactions). There are two major types of BL 
allergic patients: cross-reactive patients that are allergic to common 
BL ring and selective patients, allergic to side chains. In the last years, 
several cases of clavulanic allergic patients were described. Frequently, 
the reactions to clavulanic acid (CL) are immediate and, until now, 
there are only reports of selective reactions to CL.
Materials and methods: The authors report two cases of unusual CL 
allergic patients. The patients were submitted to skin tests (ST) with 
penicilloylpolylysine (PPL), minor determinant mixture (MDM), amoxi-
cillin (AX), CL (Diater laboratory), benzylpenicillin, ampicillin, cefuro-
xime, ceftriaxone, cefipime, determination of specific IgE to BL and oral 
provocation tests to alternative and culprit drugs.
Results: 1st case: male, 45  years old, presented to our allergy clinic 
with maculopapular rash, 7  days after beginning treatment with 
amoxicillin-clavulanic acid (AX/CL) and ibuprofen for pharygintis. He 
had previously received AX/CL with good tolerance. Drug provocation 
with ibuprofen was performed with negative results. Specific IgE to BL 
were negative. ST with PPL, MDM, AX, benzylpenicillin and AX/CL were 
negative and the patient was performed an oral AX/CL drug provoca-
tion. On the 5th day after drug provocation, he developed a general-
ized maculopapular rash. ST with CL was performed with a positive 
late reaction in the intradermal test (20 mg/ml) and a new drug provo-
cation only with AX was negative then.
2nd case: female, 40  years old described 2 previous allergic reac-
tions: generalized urticaria 10 min after the intake of one AX tablet at 
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36 years and an episode of anaphylaxis 5 min after one AX/CL tablet at 
39 years. Specific IgE to BL were negative. ST with PPL, MDM, AX and 
CL and benzylpenicillin revealed positive results with a positive imme-
diate prick test to AX and a intradermal test to CL (20 mg/ml). ST and 
drug provocation with cefuroxime and ceftriaxone were negative.
Conclusions: The first case concerns a rare delayed reaction to CL. To 
the best of our knowledge, the second case describes the first case of 
positivity to both AX and CL.
Keywords: Clavulanic acid; Delayed reactions; Selective reactions; 
β-Lactams
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Betalactams (BL) are still the most frequent drugs 
implicated in allergic reactions. All BL currently available may cause 
these reactions. Immediate hypersensitivity (IH) reactions usu-
ally appear within 1  h of drug intake and are mediated by specific 
IgE (sIgE) antibodies. They can be evaluated by different methods: 
clinical history, skin tests (ST), in  vitro quantification of sIgE and 
drug provocation tests (DPT). The determination of sIgE has safety 
advantages over ST and DPT, but has low sensitivity. ST should be 
performed with PPL, MDM, penicillin G, amoxicillin and ampicillin. If 
these are all negative, a DPT should be executed to ultimately con-
firm or exclude allergy.
Materials and methods: Retrospective study that included patients 
who had undergone ST with PPL and MDM for investigation of BL 
allergy in 2014 and 2015. Data were then collected regarding the 
results of ST (PPL, MDM, penicillin G, amoxicillin, ampicillin and a ceph-
alosporin), sIgE (penicillin G, penicillin V, ampicillin, amoxicillin and 
cefaclor) and DPT (to amoxicillin and/or a cephalosporin).
Results: One hundred and one patients (24 % male), with a mean age 
of 42 years old. The suspected BL was: penicillin G (40), amoxicillin (37), 
cephalosporins (6), ampicillin (2) and unknown (16). Eleven percent of 
the patients had positive ST to PPL or MDM, with only 1 having positive 
sIgE. Five of these patients underwent ST with an alternative cephalo-
sporin (cefuroxime): 2 were positive and 3 were negative. Two of these 
underwent DPT, that were negative. Out of 90 patients with negative ST 
to PPL and MDM, 55 were submitted to ST with ampicillin and/or peni-
cillin G and/or amoxicillin, being positive in 7  % of the patients; they 
all had negative sIgE. ST with amoxicillin didn’t add any extra informa-
tion. Out of 84 patients with negative ST, 36 proceeded to DPT, which 
were positive in 6 % of the cases. Twelve patients underwent ST with a 
cephalosporin, being positive in 2 (when the suspected BL was also a 
cephalosporin). IH to BL was confirmed in 19 % of the cases.
Conclusions: Of the 19 cases of confirmed IH to BL, only 1 had posi-
tive sIgE, corroborating the extremely low sensitivity of the method. 
Only 19 % of the suspected cases of BL IH were confirmed, emphasizing 
the importance to refer patients to an Allergy Centre for investigation. 
Some patients never concluded the BL allergy study, and some are still 
undergoing. We highlight the need for new less expensive and time 
consuming tests, which would also reduce the number of dropouts.
Keywords: Betalactam allergy; Immediate hipersensitivity
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Background: The aim of this study was to characterize the activity 
developed at our drug allergy outpatients’ center with patients (pts) 
referred with suspicion of hypersensitivity (HS) to betalactam antibiot-
ics (BL).
Materials and methods: Retrospective analysis of clinical files, in vivo/
in vitro test results and drug provocation tests (DPT) from January 
2011 to December 2015. All pts were studied according to standard-
ized diagnostic procedures of ENDA/EAACI: serum specific IgE (sIgE) 
(ImmunoCAP®, ThermoFisher) to penicillin G/V, amoxicillin and ampi-
cillin; skin prick and intradermal tests (IDT) to PPL/MD (DAP®, Diater), 
penicillin G, amoxicillin and cefuroxime with immediate and delayed 
reading. Other penicillin derivatives/cephalosporins were tested if 
they were the culprit drug. DPT with culprit drug was performed if pre-
vious investigation was negative. In confirmed cases an alternative BL 
was tested.
Results: 410 pts with suspicion of HS to BL were included: mean age 
was 34.6 (SD ±18) years, 21 % had <18 years and 68 % were female. 
Penicillins/derivatives were the main culprit drugs (314  pts), mostly 
amoxicillin (229 pts), 149 in association with clavulanic acid. Cephalo-
sporins were mentioned by 42 pts, namely cefazolin (15 pts). Mucocu-
taneous symptoms were the most frequent manifestations (81  %); 
anaphylaxis occurred in 54  pts, 18 with loss of consciousness. HS 
to BL was confirmed in 88 pts (21.5 %), all with a DPT negative to an 
alternative BL. HS was excluded in 289 pts (70.5 %); 33 pts are under 
study. Confirmation of HS was made by: sIgE in 10 pts; skin testing in 
65 pts and DPT in 13 pts (amoxicillin-11, clavulanic acid-2). Skin tests 
were positive to: amoxicillin-33, penicillin-16, PPL-15, MD-3, flucloxa-
cilin-1 cefazolin-5, cefuroxime-1. Delayed reading of IDT was positive 
in 7  pts: penicillin-3, amoxicillin-4. A systemic reaction during skin 
testing occurred in 13 pts, in 3 with anaphylaxis: one child during IDT 
with amoxicillin (2.5 mg/ml) and 2 adults during IDT with amoxicillin 
(25 mg/ml).
Conclusions: To investigate the suspicion of HS to BL is of outmost 
importance because in most of these pts allergological workup is 
negative and HS to BL is excluded. Although the majority of confirmed 
cases are IgE-mediated, in about one-fourth a non-IgE mediated 
mechanism seems to be involved (positive DPT or positive delayed 
reading of IDT). Systemic reactions during IDT and DPT also reinforce 
the need of referral these pts to specialized centers.
Keywords: Adults; β-Lactams; Drug allergy; Children; Skin tests
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Background: Clavulanic acid (CLV) is b-lactamases inhibitor with weak 
antibacterial activity and low immunogenic capacity widely used in 
combination with beta-lactam antibiotics. Despite there is a number 
of reports of allergy to CVL in the combination with amoxicillin (AX-
CVL), it is important to distinguish this kind of hypersensitivity as of 
the clinical implications of an amoxicillin allergy diagnosis.
Materials and methods: We present here 23 patients (14 women 
and 9 men, aged 23–62) with immediate hypersensitivity reactions 
to amoxicillin-clavulanic acid. Clinical symptoms occured within 
30–60  min after AX-CLV intake and included urticaria/angioedema, 
bronchospasm and anaphylaxis.
Skin prick and intradermal tests with: major determinant benzylpeni-
cilloyl poly-l-lysine (PPL-0.04  mg/ml), minor determinant mixture 
(MDM-0.5 mg/ml), CLV (20 mg/ml) and amoxicillin (20 mg/ml), all pro-
vided by Diater (Madrid, Spain), along with benzylpenicillin (10,000 IU/
ml; Normon SA), ampicillin and cefuroxime (20  mg/ml; GlaxoSmith-
Kline Beecham) were performed. In those cases with a positive skin 
test to CLV the AX-CLV (20/4 mg/ml) (GlaxoSmithKline Beecham) was 
also tested. Specific IgE antibodies against penicillin V, penicillin G, 
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amoxicillin and ampicillin were measured by ELISA. Drug provocation 
test (DPT) with amoxicillin was performed in selective CLV hypersensi-
tivity patients group.
Results: Specific IgE antibodies against penicillin V, penicillin G, amoxi-
cillin and ampicillin were <0.35 UI/ml in all patients.
Among 23 patients with immediate hypersensitivity reactions to AX-
CLV only 2 patients (8.7 %) had a positive skin test to benzylpenicillin 
determinants and 14 patients (60.8 %) to amoxicillin.
Among 7 patients (30.4  %) who had a positive intradermal test to 
selective CLV component and good tolerance to amoxicillin in DPT 
only 4 patients (17.4 %) were detected by AX-CLV.
Conclusions: Our investigation show: Immediate selective hypersensi-
tivity reactions to CLV found in around 30 % of patients with immedi-
ate allergic reactions to AX-CLV combination.
Although allergy to clavulanic acid is infrequent, this molecule should 
be used in diagnostic assessment when evaluating an immediate reac-
tion to AX-CLV and conventional skin testing with benzylpenicillin and 
amoxicillin determinants are negative.
Testing with selective CLV component is more sensitive and reliable 
than detection by AX-CLV for proving allergy to clavulanic acid.
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Background: Penicillin remains one of the most widely used antibiot-
ics in the world. Hypersensitivity reactions are more common adverse 
effects to this antibiotic.
Materials and methods: Records with allergy status of penicillin (ICD-
10 code Z880) and adverse effects to penicillin (ICD-10 code Y400) of 
Information System of Social Protection (SISPRO) between 2010 and 
2014 were included. To determine the prevalence and incidence of 
AHR, population estimates from the National Statistics Department of 
Colombia (DANE) were used.
Results: 781 cases with allergy status of penicillin and adverse effects 
to penicillin (PHR) between 2010 and 2015 were identified. 148 
cases were confirmed news diagnoses in the same period. On aver-
age 156 cases of PHR per year were estimated. The estimated annual 
prevalence PHR were 3.3 cases per million (2010  =  4.3; 2011  =  3.3; 
2012 =  3.8; 2013 =  2.7 and 2014 =  2.7). The estimated annual inci-
dence PHR were 0.4 cases per million (2010  =  0.53; 2011  =  0.43; 
2012 = 0.60; 2013 = 0.55 and 2014 = 0.25). Most cases it presenting 
in adult aged 60 years or younger, in children aged 5 years or younger 
and between 19 and 26  years age in 2010–2011; and in adult aged 
60 years or younger and between 19 and 26 years age in 2012–2014.
Conclusions: Both under-diagnosis and over-diagnosis PHR are com-
mon in the world. Population studies with confirmatory tests PHR in 
Colombia are required (Table 1).
Keywords: Penicillin; Allergy; Hipersensitivity
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Background: Beta-lactam (BL) antibiotics are the drugs most fre-
quently involved in IgE-mediated allergic reactions.
Differences in the pattern of consumption are related with the specific 
BL involved in the allergic reactions and vary among countries and 
over the time. Since specific recognition of the amoxicillin (AX) side 
chain was described, a significant increase in the number of selective 
immediate reactions to AX and more recently selective reactions to 
Clavulanic acid (CLV) have been reported.
Patients with allergic reactions after AX-CLV administration can react 
to either AX or CLV. No evidence of cross reactivity between CLV and 
other BL has been reported.
Report: We present an atopic 44 year-old man referred to our allergy 
unit due in 2008 he took amoxicillin 500 mg/day as treatment for res-
piratory infection, 30  min after the first tablet he developed pharyn-
geal pruritus, cutaneous erythema and flushing following generalised 
itching and erythema.
Method: Skin prick test (SPT) and intradermal test (IDT) were per-
formed using classic penicillin determinants, amoxicillin, ampicillin 
and clavulanic acid determinants according ENDA protocol.
Total IgE and specific IgE (Thermo Fisher Scientific) with penicillin 
determinants (penicilloyl G, amoxicilloy, penicilloyl V and ampicilloyl) 
were performed.
Drug provocation Test (DPT) if skin and in vitro test were negatives.
As reaction was several years before, we performed second work up 
1 month later.
Results: Total IgE 270  KU/l, Specific IgE with penicillin determinants 
were negative.
Skin tests show positive results only to CLV (20 mg/ml IDT).
DPT was positive to AX, 30 min after first dose (125 mg) patient devel-
oped pruritus, facial erythema and cutaneous rash in thorax and back.
DPT with BP following 3 days domiciliary intake was negative.
Second work up.
Skin tests show positive results only to CLV 20 mg/ml IDT.
DPT and with BP following 3  days domiciliary intake was negative 
again.
How this report contributes to current knowledge
Conclusions
We present a double selective sensitization to clavulanic acid and 
amoxicillin with tolerance to BP.
We confirm that tolerance to BP is a stable phenomenon performing 
a second BP administration 1 month later, according recently studies, 
Table 1 Prevalence and  incidence PHR Colombia 2010–
2014








 1–5 años 20.4 (12) 13.9 (17) 3.5 (26) 6.9 (33) 2.9 (32)
 6–9 años 3.0 (35) 1.4 (24) 2.1 (6) 0.5 (12) 3.0 (5)
 10–14 años 4.1 (13) 1.5 (6) 2.6 (9) 1.5 (2) 1.8 (13)
 15–18 años 5.4 (14) 3.2 (5) 4.1 (9) 2.3 (5) 3.3 (6)
 19–26 años 12.7 (24) 10.2 (14) 12.5 (18) 7.7 (10) 7.7 (14)
 27–44 años 6.1 (45) 4.8 (36) 4.9 (44) 2.8 (27) 2.8 (27)
 45–59 años 1.2 (39) 1.5 (31) 3.0 (32) 1.6 (19) 1.3 (19)
 >60 años 28.5 (13) 21.3 (17) 24.5 (34) 17.0 (19) 17.2 (15)
Total 4.3 (195) 3.3 (150) 3.8 (178) 2.7 (127) 2.7 (131)
Incidence PHR Colombia
Cases per million
 1–5 años 0.47 (2) 0.47 (2) 1.17 (5) 0.93 (4) 0.47 (2)
 6–9 años 0.58 (2) 0.58 (2) 1.46 (5) 1.17 (4) 0.59 (2)
 10–14 años 1.36 (6) 0.91 (4) 0.23 (1) 0.92 (4) 0.00 (0)
 15–18 años 1.70 (6) 1.13 (4) 0.28 (1) 1.14 (4) 0.00 (0)
 19–26 años 0.16 (1) 0.31 (2) 0.46 (3) 0.15 (1) 0.30 (2)
 27–44 años 0.09 (1) 0.18 (2) 0.26 (3) 0.09 (1) 0.17 (2)
 45–59 años 0.44 (3) 0.28(2) 0.69 (5) 0.54 (4) 0.26 (2)
 >60 años 0.67 (3) 0.43 (2) 1.04 (5) 0.81 (4) 0.39 (2)
Total 0.53 (24) 0.43 (20) 0.60 (28) 0.55 (26) 0.25 (12)
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where selective patients tolerate subsequent administrations of other 
BL.
Our exceptional case highlights the need to be aware of new patterns 
of beta-lactams sensitization.
We recommend using AX and CLV separately for skin test.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Infliximab (IFX) carries potential risk of immunogenicity, 
with the expansion of memory T cells and the production of anti-drug 
antibodies (ADA). Little is known about the possibility that sensitiza-
tion to IFX may occur also in treated ADA− patients. This study was 
aimed to evaluate whether IFX may be immunogenic in the latter 
group of patients.
Materials and methods: Seventy-one IFX-treated patients, includ-
ing both ADA+ and ADA− patients were enrolled. Untreated patients 
and healthy donors were also selected as controls. Memory T cells 
was evaluated by the proliferation of drug-stimulated PBMC or co-
cultures of IFX-pulsed DC plus autologous CD4+ T cells. Measurement 
of drug-induced cytokines production was performed in the culture 
supernatants by ELISA. Cytokines mRNA expression was also studied.
Results: T cell proliferation and cytokine production were mainly 
detectable in ADA+ patients, but cytokines were observed in about 
25  % of non-proliferating cultures as well. IL-10 was the most fre-
quently detectable cytokine. Additionally, the proportion of patients 
expressing IL-10 mRNA in IFX-stimulated PBMC was significantly 
higher in ADA− than in ADA+ patients. IL-10 mRNA levels resulted 
higher in ADA− than in ADA+ patients. Anti-IL-10 mAbs were able to 
significantly increase both IFX-driven proliferation and expression of T 
cell-related cytokines in PBMC.
Conclusions: Cell sensitization to IFX may be detectable in a propor-
tion of ADA− treated patients. Proliferation assay combined with 
cytokines evaluation may work better than the single test in evaluat-
ing cell sensitization. In ADA− patients IFX-induced IL-10 may over-
come the effects of other T cell-related cytokines.
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Background: Adalimumab, recombinant fully humanized anti-tumor 
necrosis factor (anti-TNF) antibody, had been using for the patients 
with inflammatory artritis and bowel diseases. Adverse reactions to 
adalimumab are limited mainly to injection site, immediate systemic 
reactions are very rare. Generalise skin reactions to this antibody are 
around 1 %. Certolizumab is humanized from mouse, anti-TNF recom-
binant antibody with the same indications. Systemic adverse reactions 
to certolizumab is very rare, also.
Report: We report a 59-year-old woman with spondylartritisi (SpA) 
who was treated with adalimumab every 2 weeks for 4 years. At the 
4th year, adalimumab was changed to prefilled ready to use form. 
30  min after the first application of this form, local reaction and 
also vomiting, dispnea, laryngeal edema, hipotension with gener-
alise itching happened. Than adalimumab was stopped. Therapy 
was changed to certolizumab pegol. 30 min after the first injection 
of certolizumab, she had nause, dizziness and visual disturbances 
without skin reactions. 15 days later she injected the second certoli-
zumab dosage and the same reactions repeated. She was referred 
to allergy clinic. Skin prick test with 50 mg/ml of adalimumab was 
found negative. Intradermal test with (5 mg/ml) 1/10 dilusion was 
10/45 mm and 1/100 dilusion was 8/40 mm (histamin intradermal: 
10/50 mm). Both skin prick and intradermal tests with certolizumab 
pegol were negative. Depending on the uncertainty of her history 
about certolizumab, drug provocation test was administered with 
total therapy dose. No adverse or allergic reaction occured dur-
ing provocation. The patient was continued certolizumab therapy 
seamlessly.
How this report contributes to current knowledge: Although 
adverse systemic reactions to adalimumab are rare, we describe a 
immediate systemic reaction to adalimumab; fully humanized recom-
binant biological. We thought the reaction was not due to the new 
form, because the contents are completely same. Allergic reaction 
after changing the form seems to be coinsidental. Alternative mono-
clonal antibodies should be searched for those patients.
Consent: Written informed consent was obtained from the patient for 
publication of this case report and any accompanying images.
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Background: Although true allergy to local anesthetics (LA) is rare, 
patients often report unwanted reactions after the administration of 
LA, requiring allergy consultations. Diagnosis of hypersensitivity reac-
tion to LA is made after skin tests followed by exposition tests. The aim 
of this study was to determine the negative predictive value (NPV) of 
skin tests to LA.
Materials and methods: A retrospective chart review was performed 
on patients undergoing local anesthetic skin testing. A total of 50 
patients tested for hypersensitivity to LA in the period from January to 
August 2015 at the Division of Clinical pharmacology at the University 
Hospital Zagreb were enrolled in this study. All patients underwent 
skin tests (‘prick’ and intradermal tests with 1:100 dilution) followed 
by incremental subcutaneous challenge with undiluted LA. Skin 
tests were performed with lidocaine, articaine, bupivacaine or artic-
aine + adrenaline, while exposition was performed using mainly lido-
caine. Telephone follow-up visits were performed during December 
2015. On the basis of the follow-up results, the NPV of skin tests was 
calculated.
Results: Skin tests were performed using two or more LA (lidocaine 
in 50 patients, articaine in 35 patients, bupivacaine in 27 patients, 
articaine  +  adrenaline in 11 patients). All skin tests were negative. 
Subcutaneous challenge was performed with lidocaine in 41 pts, artic-
aine in 7 pts, bupivacaine in 1 pt, and articaine + adrenaline in 1 pt. 
All patients had negative subcutaneous challenge. In the follow-up 
period 20  pts received LA, 20  pts have not received LA while 10  pts 
were unavailable for follow-up. Of the patients who received LA after 
testing, 19 had no reactions during exposure while 1 pt experienced 
a severe hypertensive reaction with generalized exanthema. The NPV 
of skin tests to LA was 95 %. NPV for subcutaneous challenge tests was 
not calculated due to incomplete data on specific LAs used in subse-
quent exposures.
Conclusions: Skin tests to LA are safe and have an excellent negative 
predictive value which allows the selection of a local anesthetic that 
can be safely administered in the future.
Keywords: Local anesthetics; Skin test; Hypersensitivity; Negative pre-
dictive value
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Background: Molecular targeted agents are widely used in various 
inflammatory and immune diseases and tumors. Differently from 
adverse reactions induced by conventional drugs, these drugs dem-
onstrate various new types of adverse reactions. Some of events may 
be induced by cross-reactions related to the expression of the same 
antigen on different tissue. Immune imbalance caused by a depletion 
of specific antigen may be a trigger of unpredictable reactions. It is 
important to know the prevalence, clinical types, and severity of the 
side-effects in each drugs.
Materials and methods: We retrospectively analyzed patients who 
visited our department due to cutaneous adverse reactions caused 
by molecular targeted agents from 2010 to 2015. Types of drugs, clini-
cal features of cutaneous adverse reactions, and subsequent outcome 
were evaluated.
Results: One hundred and fifty patients were evaluated in this study. 
High frequency agents were EGFR inhibitors (63 %), multikinase inhibi-
tors (8  %), TNF-a inhibitors (6  %), and programmed death-1 (PD-1) 
inhibitors (5  %). Regarding clinical phenotypes, acneiform eruptions 
and perionychia were highly observed (68 %) mainly caused by EGFR 
inhibitors as the target antigen EGFR is also involved in skin homeo-
stasis. Maculopapular drug eruption (10  %) and hand-foot syndrome 
(7  %) were observed in users of multikinases inhibitors and EGFR 
inhibitors. Of note, systemic drug eruption (erythroderma, erythema 
multiforme, maculopapular) was highly observed in patients treated 
with multikinase inhibitors. Psoriasis-like and palmoplantar pustulosis-
like eruptions (5 %) were caused by TNF-a inhibitors and IL-6R inhibi-
tors. Although the frequency was low, lupus-like reaction, vitiligo, and 
other unexpected reactions were caused by inhibitors of TNF-a or 
PD-1, supposedly those inhibitors lead to immune imbalance further 
causing autoimmunity and inflammatory reactions. As for the out-
come, 85  % of patients continued molecular targeted agents, while 
15 % of patients required discontinuation of the drug.
Conclusions: Predicteable cutaneous reaction, like acneiform erup-
tions by EGFR inhibitors, would be possible to manage without dis-
continuation of the drug. Some drugs, such as immune checkpoint 
inhibitors, may cause unexpected immune responses. Since adverse 
reactions of molecular targeted agents are variable depending on 
drugs. It is important to recognize the function of targeted antigen, 
and close monitoring is recommended.
Keywords: Molecular targeted agents; Biologics
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Background: Local anesthetics, such as lidocaine, are widely used 
for numbing. Adverse drug reactions related to lidocaine are variable, 
unpredictable, and rarely reproducible, with the exception of some 
typical cases.
Report: A 42-year-old female who had shown a bizarre neurological 
reaction after lidocaine injection for dental procedures was referred 
for diagnosis and safe anesthetic alternatives. Within a few minutes 
after exposure to lidocaine, she was unable to move any extremity, 
or to speak, while sensory and high cranial nerve functions were pre-
served. She was alert and able to communicate with eye blinks. This 
reaction was repeatedly reproduced after intradermal injection of 2 % 
lidocaine, with complete recovery within 1  h without treatment. No 
cross-reactivity with mepivacaine and bupivacaine was observed.
How this report contributes to current knowledge: This is the first 
report of immediate and transient generalized paralysis related to 
lidocaine.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: True allergy to local anaesthetics (LA) is uncommon. 
Allergic reactions account for <1 % of all adverse reactions. Immediate 
reactions are rare. The aim of this study was to describe the main char-
acteristics of the population with confirmed LA allergy among patients 
referred to our outpatient clinic for suspected hypersensitivity (HS) to 
LA.
Materials and methods: Retrospective analysis of the medical files 
of patients with suggestive history of immediate HS reactions to LA, 
referred to our outpatient centre between January 2006 and Decem-
ber 2015. In order to confirm the diagnosis, we conducted skin prick 
tests and subcutaneous drug provocation test (DPT) with the undi-
luted commercial solution of the culprit or an alternative LA. DPT was 
performed in increasing doses, every 15 min, up to a cumulative dose 
of 3.6 ml. Sensitization to latex was excluded.
Results: A total of 65 patients with history of an adverse reaction 
to LA underwent DPT, 75  % female with a median age of 44  years 
(±17.4). Only 5 patients (7.7  %) had positive DPT (lidocaine in 2 
patients, mepivacaine in 2 patients and ropivacaine in 1 patient). Of 
those patients, 60  % were female and the median age was 35  years 
(±20.6  years). Sixty percent of the patients had past history of mul-
tiple surgical interventions (with general anesthesia) and allergic 
diseases, asthma and rhinitis being the most frequent. Cutaneous 
symptoms (urticaria and angioedema) were the main manifestation, 
in 4 patients (66 %). There was no registry of severe adverse reactions. 
All reactions started within 2 h following LA application and regressed 
spontaneously without any treatment. Sensitization to both lidocaine 
and mepivacaine was determined in 2 patients. Comorbidities such 
as hypertension (2 patients), diabetes (1 patient) and thyroid disease 
(1 patient) were also seen. Eighty-three percent of these reactions 
occurred during dental procedures and 60 % of these after adminis-
tration of lidocaine.
Conclusions: As stated in other studies, we find a low positivity rate 
to DPT. And our findings were similar to those found in the literature: 
adverse reactions to LA are more prevalent in the mid-age and with 
cutaneous symptoms being the most frequent manifestation of HS. 
Although rare, consequences of true allergy to local anaesthetics can 
be serious, considering a patient’s future management and therapy.
Keywords: Local anaesthetics; Hypersensitivity
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Background: Local anaesthetics (LA) are widely used drugs with an 
exceptional benefit-risk profile. Adverse reactions are scarce. Hyper-
sensitivity reactions are especially rare, accounting for <1  % of all 
adverse reactions. When a reaction occurs, an allergy work-up should 
be performed in order to exclude an allergic reaction or to identify an 
alternative drug.
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Materials and methods: Retrospective analysis of data from patients 
referred to our drug allergy unit with suspected LA allergy in the past 
5 years. The analysis was performed using SPSS, version 21.
Results: We studied 47 patients for suspected LA allergy (83  % 
females, with median age 49, and interquartile range 23). Six patients 
were atopic. Thirty-six percent of patients were referred by their family 
physician and 26 % by dentists.
Of the 47 patients, 38  % had a suspected reaction during a dental 
procedure, 14 % had positive patch tests with LA and 13 % had per-
operative anaphylaxis. Considering the patients who had a suspected 
reaction, 74 % had immediate reactions. In 49 % of these cases, there 
was mucocutaneous involvement, 33  % had respiratory symptoms 
and 33 % vasovagal response. The LA used was known in 70 % of these 
cases, none of them were an ester. Lidocaine was the culprit in 20 
cases, mepivacaine in 5, articaine in 5 and ropivacaine in 4.
Skin prick tests (SPT) and intradermal tests (ID) were performed with 
validated concentrations, without vasoconstrictor. Only 2 patients 
had positive tests: 1 positive SPT to mepivacaine and one positive ID 
to procaine; the other patient had a positive ID to ropivacaine. All 45 
patients with negative skin tests were submitted to subcutaneous 
challenges that were negative.
None of the patients referred because of positive patch tests to LA had 
a positive study.
Conclusions: The majority of adverse reactions to LA may be attrib-
uted to non-immune mediated mechanisms, pharmacologic, psycho 
or neuro-vegetative reactions. When LA are used, the patients are usu-
ally under stress. Our experience is in agreement with literature since 
hypersensitivity was excluded in the majority of the patients with sus-
pected LA reactions.
Keywords: Local anaesthetics; Local anaesthetics hypersensitivity
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Background: A 44  year-man was urgently admitted to our allergy 
clinic with complaints of pain in the area of scrotum, painfulness in 
oral cavity, rash on hands, eyelids and foot. Anamnesis excerption: 
Alcohol abuse for a long time. About 2  years ago, following one of 
patient’s drinking-bouts, episode with loss of consciousness emerged, 
qualified as secondary epilepsy; carbamazepine was administered. The 
patient described vesicular rash on lips and hands following the carba-
mazepine medication; he did not seek medical attention, though. The 
therapy was cancelled. Within 2 weeks the skin rash passed. The pre-
sent episode had also been related with a prolonged period of alcohol 
ingestion, whereupon a detoxification treatment was administered, 
and, taking into account the possibility of episyndrome, carbamaz-
epine was ordered, too. On the second day vesicular rash appeared on 
hands, thereupon in the scrotum area, on eyelids and on mucous tunic 
of mouth, forcing the patient to seek medical attention. Condition on 
admittance: of moderate gravity. Rash on hands with big serous fluid-
filled vesicles; negative Nikolsky symptom. There were erosion with 
diapedetic bleeding and scrotal oedema in the area of scrotum and 
penis. Cheilitis, multiple aphthae on the internal surface of cheeks, 
on hard and soft palate and on tong were revealed, as well as haem-
orrhagic crustings on eyelids, moderate injection in scleral vessels. 
Physical state: with no specific findings. Systemic glucocorticoids and 
antihistamine preparations were administrated, as well as antibacte-
rial, infusion therapy and topical treatment. On the second day a total 
relief of diapedetic bleeding in the scrotal area was achieved. To the 
end of the 10th day a total epithelization in the area of penis and scro-
tum occurred. Aphtae on hard and soft palate relieved totally within 
the first 3 days. Laboratory results have shown increasing levels in cir-
culating thrombocytes according to the relief of diapedetic bleeding. 
Maximal levels were attained by the 6th day (667*109/l) with the fol-
lowing return to normal values. On admission C-reactive protein levels 
were elevated up to 136.65 mg/l, by the 7th day they returned to nor-
mal values.
No eosinophilia or leukocytosis had been revealed. The described 
case represents a favorable variant of clinical course of carbamazepine 
intolerance, with a quick epithelisation, and no injury in liver, kidneys 
or blood islands.
Keywords: Stevens–Johnson syndrome; Clinical case
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: The increasing use of radiocontrast media (RCM) is asso-
ciated with an increase in adverse reactions with these preparations.
Materials and methods: We revised a total of 249 cases referred dur-
ing 2012–2014 for allergic evaluation due to adverse with RCM. We 
collected information about the radiological procedures, adverse reac-
tions and results of allergy study of patients who developed severe 
anaphylactic reactions.
Results: We analysed 5 men and 8 women with an average age of 
63 years (37–86). In 69 % respiratory symptoms were reported, 62 % 
neurological, 54 % cutaneous, 31 % cardiovascular and 31 % digestive 
symptoms. 31 % complaint of subjective symptoms (general discom-
fort, heat or flushing). The reaction was immediate (within minutes) 
in 69 % of cases. One patient required admission to the intensive care 
unit and another had a repeated episode of anaphylaxis after readmin-
istration of RCM despite of the premedication. In 4 cases the reaction 
occurred during a computed tomography (CT), in 4 with intravenous 
urography (IVU), and 3 with magnetic resonance (MR). In 2 cases the 
radiological procedure was not specified. In 2 of the 13 patients (15 %), 
intradermal tests were positive with the RCM involved: iomeprol and 
dimeglumine gadopentetate. The basophil activation test (BAT) with 
the RCM was positive in 4 cases: 2 with iomeprol and iodixanol, 1 with 
iopamidol and 1 with gadobenate and gadopentate.
Conclusions: TC and IVU were the most frequently involved radiologi-
cal procedures. Respiratory symptoms were the most common clini-
cal manifestations. Skin tests and BAT helped to identify the agents 
responsible for the reactions. The sensitivity and specificity of these 
tests are still undetermined.
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Background: Iodinated contrast media (ICM) are one of the most 
commonly used in the field of diagnostic medicine today. Though con-
sidered generally safe, they can cause hypersensitivity reactions that 
can either be immediate or non-immediate. Anaphylactic shock reac-
tions to ICM are rare but serious and could be life threatening. Hence, 
urgent and timely treatment should be administered.
Report: We present a case of a 64 year old hypertensive patient with 
ischemic cardiopathy who presented with intense cephalic heat, 
tachycardia, hypoxemia and hypotension of 50/30  mmHg without 
any cutaneous lesions immediately after the administration of 35  g 
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of Iomeprol contrast medium for cardiac catheterization. Epinephrine 
IM, Dexchlorpheneramine and corticosteroid IV and intravenous fluid 
therapy were administered which afforded the reversal of the hypo-
tension. The tryptase at the time of the reaction and 2  h post reac-
tion were both elevated, 85.70 and 88.70  μg/l respectively. Baseline 
tryptase was normal (6.86 μg/l). Skin prick test and basophil activation 
test to different contrast media were negative while intradermal test to 
Iomeprol showed a positive result and negative to Iohexol, Iodixanol 
and Meglumine. Thus, challenge test to Iodixanol reaching a total dose 
of 47  g as an alternative medium was done which he tolerated well. 
One month later, the patient underwent another cardiac catheteriza-
tion. However, 10  min after the administration of 15  g of Iodixanol, 
he presented another episode of anaphylactic shock. He was given 
the same medications he had received previously which reversed the 
anaphylactic shock. Tryptase level was positive (30.20 μg/l). Due to the 
episode of anaphylactic shock, the contemplated cardiac catheteri-
zation was discontinued. Skin tests the next day resulted positive to 
Iohexol, Iodixanol and Iomeprol.
How this report contributes to current knowledge: Despite that 
the patient tolerated well the challenge test with Iodixanol and skin 
test was negative, possible hypersensitivity reactions can still occur. 
Although challenge test is considered the gold standard in drug 
allergy, it can also provoke sensitisation to the drug or increase the 
sensitivity that could not be detected prior due to cross reaction. As of 
the present, the pathophysiological mechanism of these allergic reac-
tions still needs to be exemplified.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Gadobenate Dimeglumine and Gadoteric Acid are two 
gadolinium-based contrast agents that enhance the contrast images 
obtained by magnetic resonance imaging. Allergic reactions to them 
are rare.
Materials and methods: We report two cases of IgE-mediated ana-
phylactic shock, induced by these gadolinium-based contrast agents 
and documented by positive allergy assessment. The first case is a 
26-year-old woman with no previous drug allergy who developed 
dizziness, generalised erythrodermia and throat tightness, when a 
nuclear magnetic resonance with MultiHance (Gadobenate Dime-
glumine) was being performed. On physical examination, she had 
hypotension, tachycardia, tachypnea, 69  % of basal oxygen satura-
tion and generalized pulmonary hypoventilation. She recovered after 
treatment with corticosteroids and adrenaline. Nine months later the 
patient was referred to the allergy unit. The second case is a 51-year-
old woman with a history of high blood pressure treated with beta-
blockers, rhinoconjunctivitis and asthma due to sensitization to house 
dust mites and dog dander. Immediately after the intravenous infu-
sion of Dotarem (Gadoteric Acid) she developed dizziness, loss of 
consciousness and cardiac arrest. On physical examination, she had 
universal rash without wheals, 90  % of basal oxygen saturation and 
generalized wheezing. CPR was started and 1  mg of Adrenaline was 
administrated. She recovered after 15  min and was admitted to the 
ICU. Two months later she was referred to the allergy unit.
Results: Case 1: Basal serum tryptase was normal. Skin prick tests 
(SPTs) were positive with Gadobenate Dimeglumine and negative with 
other paramagnetic contrasts agents and latex. The patient tolerated 
an MRI with Gadobutrol 2 years later. Case 2: Basal serum tryptase was 
normal. Basophil activation test (BAT) was positive with Gadoteric 
Acid, and negative with other paramagnetic and iodinated contrast 
agents.
Conclusions: We report two cases of an anaphylactic shock, one 
with cardiac arrest, immediately after the intravenous infusion of a 
paramagnetic contrast agent. Positive SPTs to Gadobenate Dimeg-
lumine and positive BAT to Gadoteric Acid suggest an IgE-mediated 
mechanism. Hypersensitivity reactions with paramagnetic contrasts 
are very unusual. There are few cases with positive SPTs or BAT 
reported in literature. We should take into account that SPTs and 
BAT can be helpful to identify the responsible agent and the alterna-
tive contrasts that could be administered safely to the patient in the 
future.
Keywords: Paramagnetic contrast agents; Anaphylaxis
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: The frequency of adverse reactions to gadolinium-based 
contrast media is estimated to be 0.07–2.4 %. True allergic hypersen-
sitivity reactions are very rare, presenting usually as urticarial exan-
thems of minor severity. The reported incidence is 0.004–0.007  %. 
Severe life-threatening reactions were extremely rare (0.001–0.01 %). 
Prior allergic reactions to gadolinium contrast media (GCM) are consid-
ered risk factors for new sensitizations to other GCM. We report on two 
female patients with severe immediate type reactions to Gadobenate, 
with cross reactivity to other GCM.
Materials and methods: Patient 1 (48  years): An MRI with Gado-
benate was performed for diagnosis of pancreatitis. Immediately after 
application of the GCM she developed generalized itch and erythema, 
dyspnoea and cardiac arrest after 10 min. Mechanical and drug resus-
citation was successfully performed. No definite prior exposure.
Patient 2 (74 years): MRI with Gadobenate was performed for cardiac 
diagnostics. Within few minutes after application of the drug she 
developed a generalized sensitization of head, erythema, dysphagia, 
dyspnoea and swelling of the tongue. Prior exposure to an unknown 
GCM.
Results: Pricktests were negative for Gadoterate, Gadobutrol, Gadox-
etate and Gadopentetat in both patients. Gadobenate was postive 
in patient 2. Intradermaltests were positive for Gadobenate and 
Gadobutrol in both patients, and Gadoxetate, Gadoterat and Gado-
pentetat in patient 1. Mastcell tryptase and Basophil activation tests 
were normal/negative in both patients.
Conclusions: We report on two cases of rare severe hypersensitivity 
reactions to Gadobenate with skin test cross-reactivity to Gadobutrol 
in both patients, and further GCM in one patient. Gadopentetat, a lin-
ear non-ionic GCM, was skin test negative in both patients, whereas 
the linear ionic culprit Gadobenate was cross-reactive with the cyclic 
Gadobutrol in both patients, and cross-reactive to other linear ionic 
and cyclic GCM in patient 1.
Keywords: Anaphylaxis; Gadolinium; Gadobenate
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Glatiramer acetate (GA) or Copaxone® (marketed by 
Teva Pharmaceuticals Europe B. V.) is an injectable immunomodulatory 
treatment approved for relapsing-remitting multiple sclerosis (MS) in 
preventing relapses and slowing the disability progression. Rare cases 
of hypersensitivity reactions to this drug have been published in the 
literature. The authors describe a case of systemic symptoms associ-
ated with GA and the diagnostic workup of the patient.
Report: The authors report the case of a 34  year-old woman diag-
nosed with MS in 2008, initially treated with interferon-β1a (Avonex®). 
As relapses were frequent despite treatment, this was changed in 
January/2013 to natalizumab (Tysabri®), which is a monoclonal anti-
body (α4-integrin antagonist) with similar therapeutic indications to 
those described for GA. After 12  months of treatment, natalizumab 
was stopped because the patient developed persistent anti-drug anti-
bodies. Considering that the patient was planning a pregnancy a new 
treatment (with GA) was started in March/2015. Four months later, the 
patient presented a generalized skin-burning sensation, dyspnoea and 
palpitations, 1 min after GA administration with no additional signs or 
symptoms. At this point, the patient was referred to our Drug Allergy 
Department for assessment. Skin tests were performed with GA plus 
the inactive ingredient of Copaxone® with allergenic potential, man-
nitol; the dilutions were prepared with saline solution. For skin prick 
tests we used GA 20 mg/ml in the 1/100, 1/10 and 1/1 dilutions, and 
mannitol 100  mg/ml (undiluted). Intradermal tests were performed 
with 1/1,000,000–1/10 dilution of GA (20 mg/ml), with a strong posi-
tive result at 1/10 concentration. Intradermal test to mannitol (1/10 
dilution) was negative.
How this report contributes to current knowledge: We also tested 
three (2 atopic and 1 non-atopic) controls for GA at 1/10 dilution with 
negative results. These results point to an underlying immunological 
mechanism in this case. A desensitization approach with GA might be 
considered for this patient.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
P124 
Delayed hypersensitivity reaction to radiocontrast media
Fabrícia Carolino1, Diana Silva2, Leonor Leão1, Josefina R. Cernadas1
1Serviço de Imunoalergologia, Centro Hospitalar São João E.P.E., Porto, 
Portugal; 2Serviço de Imunoalergologia, Centro Hospitalar São João E.P.E.; 
Laboratório de Imunologia, Faculdade de Medicina, Universidade do 
Porto, Porto, Portugal  
Correspondence: Fabrícia Carolino
Clinical and Translational Allergy 2016, 6(Suppl 3):P124
Background: Iodinated contrast media (ICM) may associate with dif-
ferent types of adverse events including allergic and non-allergic 
hypersensitivity reactions as defined by the European Academy of 
Allergy and Clinical Immunology. Immune-mediated reactions are 
either immediate or non-immediate reactions that become apparent 
later than 1 h (and up to several days) after exposure and these are less 
frequently reported.
Report: The authors report the case of a 46 year-old woman, with his-
tory of Hodgkin’s lymphoma, evaluated in our Drug Allergy Unit for 
two suspected hypersensitivity reactions to ICM. In 2014, the patient 
underwent a contrasted CT scan with iomeprol (Iomeron®) and 72  h 
later developed a generalized pruritic micropapular exanthema that 
resolved completely in a week (with antihistamine and corticosteroid 
medication). She had been previously exposed to ICM with tolerance. 
In 2015, a new high-resolution CT scan was performed using the same 
ICM (iomeprol), and again a diffuse pruritic exanthema developed 
(6 h later) but this time with facial angioedema and fever (39 °C); the 
symptoms resolved in 4  days under medication (antihistamine and 
corticosteroid), leaving residual purplish lesions that eventually disap-
peared (after weeks). Skin prick tests with idopovidone (Betadine®), 
and undiluted ioversol (Optiray®), iobitridol (Xenetix®), iopromide 
(Ultravist®) and iomeprol (Iomeron®) were negative. Intradermal tests 
were performed with 1/100 and 1/10 dilutions of ioversol (Optiray®), 
iobitridol (Xenetix®), iopromide (Ultravist®) and iomeprol (Iomeron®); 
immediate reading was negative for all tested ICM but late reading (at 
48  h) was positive to ioversol (Optiray®) and iomeprol (Iomeron®) in 
both dilutions.
How this report contributes to current knowledge: The results con-
firmed a delayed hypersensitivity to ICM, with cutaneous cross-reactiv-
ity between ioversol and iomeprol.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: We describe a case of a Drug Reaction with Eosinophilia 
and Systemic Symptoms (DRESS) following a coronary catheteriza-
tion with iodixanol. Late reactions to iodinated contrast media are fre-
quent. We describe the tests used for the diagnosis in this case.
Report
Method: We report a case of a 74-year-old man admitted to the coronary 
unit with cardiac arrest. A cardiac catheterization was performed without 
complications. Three days later he received another cardiac catheteriza-
tion and within 24  h he presented a generalized maculopapular exan-
thema with pruritus and facial angioedema. Over the next few days the 
body temperature rose up to 38.5  °C. Blood tests showed eosinophilia 
(1200/mcL), total white blood cell count 19000/mcL, neutrophils 16,700/
mcL, renal impairment (creatinine 1.89 mg/dl, previously being normal). 
The contrast used for catheterization was iodixanol. The patient also 
received ticagrelor, carvedilol, enalapril, furosemide, fondaparinux and 
lorazepam. Assessment of causality was established using the Spanish 
Pharmacovigilance System Algorithm. Results were (+6) “probable” for 
iodixanol and (+4) “possible” for carvedilol and ticagrelor. A multidisci-
plinary group composed by a dermatologist; a pharmacologist and an 
allergist evaluated the patient. This case was included in the Piel en RED 
registry. Six months after the reaction the patient was referred to the 
allergy unit and tests were performed. The allergy study included epicu-
taneous tests and the lymphocyte transformation test (LTT) according to 
Pichler et al. An stimulation index (SI) was calculated.
Results: The diagnosis of a “probable” DRESS was established accord-
ing to the scoring system described by Kardaun et  al. Our patient 
received a score of 4. A skin biopsy showed spongiotic dermatitis with 
eosinophils. The patient had a positive LTT to iodixanol; the SI was over 
8 in two concentrations. LTT showed also positive results for other 
iodinated contrast media. We also tested carvedilol and ticagrelor with 
a lightly positive result. Epicutaneous test showed remarkable positiv-
ity to iodixanol beginning at the 48 h reading. The test was negative to 
carvedilol, iobitridol and iomeprol.
How this report contributes to current knowledge: LTT and patch 
test were useful to identify this agent as responsible for the reaction. 
DRESS requires a multidisciplinary approach and an allergy study is 
essential to determine the etiology of the disease.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Patients with a previous history of radiocontrast media 
(RCM) hypersensitivity could be overlooked, resulting in repeated 
reactions. To avoid this, ‘consultation support system for RCM hyper-
sensitivity’ has been embedded to Seoul National University Bundang 
Hospital (SNUBH) since Dec 2011. We analyzed the influence of this 
system on doctors’ practice pattern.
Materials and methods: A retrospective study was conducted with 
the patients with previous RCM reactions (Dec 1st 2010–Nov 30th 
2012). Control period was between Dec 2010 and Nov 2011 and inter-
vention period was Dec 2011 and Nov 2012. Primary outcome was 
composite outcome of premedication and consultation. Premedica-
tion was defined as the preventive medication prescribed by the doc-
tor who ordered RCM enhanced CT (CT) at the same time. Secondary 
outcomes were the recurrence rate after the consultation support sys-
tem and ther rate of premedication using systemic steroid for those 
with previous history of moderate to severe RCM reactions.
Results: In the control period, 189 clinicians prescribed 913 CT scans 
and 225 clinicians did 1.153 examinations in the intervention period. 
The odds of achieving composite outcome increased significantly 
after the consultation support system (OR 1.54, 95  % CI 1.15–2.05). 
Clinicians in both medical (OR 1.48, 95  % CI 1.06–2.07) and surgical 
(OR 2.07, CI 1.24–3.46) part showed significant changes in their behav-
ior, but emergency department did not (OR 1.07, 95 % CI 0.41–2.78). 
Professors (OR 1.47, 95  % CI 1.06–2.04) and trainees (OR 1.97, 95  % 
CI 1.22–3.18) showed significant changes in their behavior to the 
patients with previous RCM reactions. The rate of premedication using 
systemic steroid for the patients with previous history of moderate to 
severe RCM reactions did not changed significantly (OR 1.68, 95 % CI 
0.70–0.404). The results of analyses with 86 clinicians who ordered CT 
scans during both control and intervention periods were not altered.
Conclusions: The consultation support system for those with previous 
RCM hypersensitivity reactions changed doctor’s practice patterns and 
decreased recurrent RCM hypersensitivity reactions as well.
Keywords: Drug hypersensitivity; Radiocontrast media; Clinical deci-
sion supporting system
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Background: Iodinated contrast media (ICM) are frequently used to 
enhance radiological procedures. Hypersensitivity reactions to ICM 
can be classified as immediate or nonimmediate. Skin tests have been 
performed in the diagnosis of both types of reactions to ICM. The sen-
sitivity of skin tests has not been adequately validated.
Materials and methods: A retrospective chart review was performed 
on patients (pts) undergoing ICM skin testing. A total of 45 pts tested 
for ICM allergy at the Division of Clinical Pharmacology at the Uni-
versity Hospital Zagreb between July 2014 and October 2015 were 
enrolled. All pts underwent skin tests (prick test and intradermal test 
with immediate and delayed reading) to iohexole and/or iodixanole. 
Pts were contacted during December 2015 and questioned about 
exposure to ICM after testing. Eligible pts (n = 40) were classified into 
three groups: nonimmediate or immediate hypersensitivity reaction to 
ICM, and previously unexposed group.
Results: The nonimmediate group comprised 15  pts with hystory of 
exanthema (53.3  %), urticaria (20  %), angioedema (13.3  %) and pru-
ritus (6.7 %) to ICM. One pt had positive skin tests to iodixanole and 
negative to iohexole. All other performed tests were negative. In the 
follow-up period 4 pts were exposed to ICM without adverse reactions; 
10 pts were not exposed to ICM; 1 pt was unavailable for follow up.
The immediate group comprised 11 pts with hystory of gastrointesti-
nal symptoms (27.3 %), urticaria (27.3 %), angioedema (18.2 %), gen-
eral symptoms (18.2 %) and flush (9.1 %) to ICM. One pt tested positive 
to iohexole. All other performed tests were negative. In the follow-up 
period 7 pts were exposed to ICM; 6 pts experienced no adverse reac-
tions; 4 pts were not exposed to ICM and 1 pt developed angioedema.
The previously unexposed group comprised 14 pts. All skin tests were 
negative. The reason for referral to ICM testing was a hystory of seri-
ous allergic reaction to different allergens. In the follow-up period 
5 pts were exposed to ICM without adverse reactions; 4 pts were not 
exposed to ICM; 5 pts were not available for follow up.
Conclusions: Overall, 16  pts were exposed to ICM in the follow-up 
period and of those, 1 pt developed an immediate reaction. The calcu-
lated negative predictive value in this study is thus 93.8 %.
This study adds further knowledge to the field of ICM hypersensitiv-
ity. Studies including follow-up data on sebsequent ICM exposure are 
needed in order to adequately validate ICM skin tests.
Keywords: Iodinated contrast media; Hypersensitivity; Skin test; 
Follow-up
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Background: Allergies to povidone iodine (PVI) are related to povi-
done (PV), those due to radio contrast media (RCM) to cyclic structures 
and those with seafood related to animal protein such as tropomyosin. 
The iodine allergy is a mythical entity, but nevertheless!
Materials and methods: A 39  year old diabetic man, with end stage 
renal disease undergoing peritoneal dialysis, was referred for immedi-
ate hypersensitivity (IH) reactions. Betadine dermique® containing povi-
done iodine triggered an immediate contact pruritic rash disappearing 
in 30  min (mns). Angioedema and urticaria occurred a few mns after 
ingestion of shrimps, mussels, oysters, whelks, trout and salmon. Await-
ing kidney transplant, having never received RCM, a predictive assess-
ment of RCM IH was required. Patch and prick tests (pt), IDT, specific IgE 
and RCM reBackground were performed under hospital supervision.
Results: While all patch tests were negative, pt were positive for pure 
Betadine dermique® and iodized alcohol at 1 % in water but negative 
for Lugol 2 % (potassium iodide) and PV. Pt to a native oyster was posi-
tive but negative for crab, mussel and shrimp. IgEs were negative for 
salmon, mussel, oyster and shrimp. Pt and IDR were negative for iobitr-
idol, ioxaglate and iodixanol in pure form (use concentration), but the 
intravenous administration of 1  ml iobitridol induced a generalized 
pruritus, a trunk and face erythema with ear edema, occurring after 
30  mns and resolution in 60  mns after treatment with intravenous 
methylprednisolone and antihistamines.
Conclusions: This exceptional case of multiple reactivities to iodine 
products and oyster suggests that for this patient iodine itself could be 
the common allergen. The positive pt to oyster is probably not related 
to a tropomyosin sensitization. Unlike previous published cases of 
allergy to povidone iodine, in this case the IH does not appear due to 
PV. While IDT was negative, iobitridol induced an immediate reaction. 
We emphasize (1) in case of PVI IH, the need to do a pt to PVI and PV 
before concluding to the lack of iodine sensitization and thus allow 
RCM; (2) if negative IDT with RCM, we must continue investigations by 
an intravenous Background test with a limited volume of RCM and (3) 
even if it is exceptional, an iodine allergy may exist. Investigations are 
continued with in vitro tests.
Keywords: Allergy; Iodine; Multiples reactivity
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Drug hypersensitivity reactions represent a heterogene-
ous clinical entity with diverse pathogenesis and result in a consider-
able burden of morbidity and mortality. Diagnostic procedures rely 
on clinical history, skin testing and in some cases, provocation tests. 
Drug imputability is still difficult to establish due to the weakness of 
sensitivity of some skin tests and the impossibility to perform provoca-
tion test in case of severe reactions. The aim of our study is to evaluate 
delayed-type cutaneous allergic reactions associated with drug use.
Materials and methods: The data were obtained from a Tunisian 
pharmacovigilance database of adverse drug reactions (ADRs). Ana-
lyzed reports were retrieved from the pharmacovigilance unit of 
Monastir (Tunisia) database collected from 2004 to 2015. The associa-
tion between drugs and skin reactions was assessed using the case/
non-case method, calculating the adverse reaction reporting odds 
ratio (ROR) and their 95 % confidence intervals as a measure of dispro-
portionality. The “cases” were defined as reports of type III and IV skin 
allergic reactions (according to gelle and Coombs classifications). The 
“non-cases” were all other reports.
Results: Overall 1800 reports of adverse reactions related to drug use 
were analyzed; of which 1523 (84  %) were judged as type III and IV 
skin allergic reactions (cases) and the remaining were considered non-
cases. Drug classes associated with a significant increase of ROR were 
anticonvulsive agents [ROR = 2.2, 95 % CI (1.4–3.3), p < 10−3] and anti-
bacterial drugs [ROR = 1.6, 95 % CI (1.3–2), p < 10−3]. Among antibac-
terial agents, betalactams were associated with a significant ROR [1.5; 
95 % CI (1.2–1.8), p < 10−3]. Regarding betalactams, only oxacilline and 
the third generation cephalosporins were associated with a significant 
risk [ROR = 1.9; 95 % CI (1.1–3.2), p = 0.01] and [ROR = 1.81; 95 % CI 
(1.3–2.4), p < 10−3], respectively, while only carbamazepine [ROR = 3; 
95  % CI (1.6–5.7), p  <  10−3] and phenobarbital [ROR  =  2.3; 95  % CI 
(1.1–5.2), p = 0.03] have shown a significant ROR values among anti-
convulsive agents.
Conclusions: Results highlight the frequency of association of delayed 
hypersensitivity skin reactions with betalactams, carbamazepine and 
phenobarbital. Given the widespread use of these drugs, awareness 
should be raised among patients and prescribers about these risks.
Keywords: Case/noncase; Drug allergy; Delayed reactions; 
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Background: Delayed hypersensitivity reactions to cephalosporins 
are poorly described reactions that occur more than 1  h after drug 
administration. The mechanisms involved seem to be heterogeneous 
and not totally characterized.
Objectives: To characterize the delayed hypersensitivity to cepha-
losporins and determine the clinical profile of these patients and the 
cross reactivity with other antibiotics.
Materials and methods: Retrospective review from the patients 
with delayed confirmed hypersensitivity reactions to cephalosporins 
between 2013 and 2014. The patients were submitted to skin tests 
with penicilloylpolylysine (PPL), minor determinant mixture (MDM), 
benzylpenicillin, ampicillin, amoxicillin, cefuroxime, ceftriaxone, 
cefipime and other antibiotics that were eventually involved. Results 
for specific IgE to β-lactams and oral provocation challenge tests (OPT) 
with the alternative and/or culprit β-lactms were also reviewed.
Results: Within the 7 patients that were reviewed 71 % were female, 
with a median age of 56 (32.5–66) years and 43 % had personal history 
of atopy. The clinical manifestations reported by these patients were 
delayed urticaria in 57 % of the cases and 43 % described delayed rash. 
In all cases the symptoms appeared more than 24 h after the begin-
ning of the antibiotic. In 6 (85.7 %) the episodes occurred after cepha-
losporins intake. One patient had an adverse event with amoxicillin 
and the sensitization to cephalosporins was only found after investi-
gation. All had negative specific IgE for β-lactams. Four (57.1  %) had 
sensitization only to cephalosporins. The cephalosporins involved and 
the delayed results of the IDT and OPT are summarized on Table 1. All 
the suspected cephalosporins were confirmed: 6 (85.7 %) on the basis 
delayed IDT, in 1 (14.3  %) cephalosporins’ sensitization was deter-
mined after OPT. Regarding cross reactivity with other β-lactams 3 
(42.9 %) patients had reactivity to aminopenicillins.
Conclusions: Delayed reactions to cephalosporins are associated with 
delayed clinical manifestations and all had only skin involvement. The 
reactivity with other β-lactams, within the patients with delayed ceph-
alosporins hypersensitivity, was heterogeneous (Fig. 3).
Keywords: β-Lactams; Cephalosporins; Cross-reactivity; Delayed 
hypersensitivity reactions
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Background: Allergic contact dermatitis is an immune-mediated anti-
gen-specific skin reaction to an allergenic chemical that corresponds 
to a delayed-type hypersensitivity response (type IV reaction). Allergic 
contact dermatitis should be suspected when skin lesions are local-
ized to the site of previous applications of the culprit drug. The gold 
standard for diagnosis is patch testing; identification and removal of 
any potential causal agents is crucial.
Fig. 3 Delayed reactions to cephalosporins: patients’ skin tests and 
oral provocation tests results
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Diclofenac cream/gel contains propylene glycol, diclofenac, dimethyl 
sulfoxide, ethanol and glycerin. It is a widely used non-steroidal anti-
inflammatory drug, known to cause especially photoalergic contact 
reactions.
Report: We present four cases of diclofenac induced allergic contact 
dermatitis, diagnosed based on clinical grounds: intensly itchy eczem-
atous lesions on the sites of drug application, after several days of 
treatment. No allergic history, no other drug intake were reported by 
the patients. The application of topical diclofenac was strictly avoided 
in all cases, potent topical steroids proved to be effective in all cases 
within two weeeks of therapy.
Patch tests were performed in all cases with European standard batery 
and with patients’ own cream or gel 3 weeks after completion of local 
steroid therapy. Reading was performed at 96 h and proved to be posi-
tive only to diclofenac. No sun exposure was allowed during the test-
ing, any other treatments were forbidden.
How this report contributes to current knowledge: Patients and 
physicians must be aware of the risk of cutaneous sensitization 
induced by topical diclofenac, a drug extensively used also as self 
medication.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Hypertension is one of the most common worldwide 
diseases. Angiotensin II receptor blocker are one of antihypertensive 
drugs most prescribed. Some well-known adverse effects of irbesartan 
are dizziness, urticaria and angioedema. Irbesartan cutaneous non-
immediate reactions have been reported previously in a limited num-
ber of case reports.
Report: Sixty years old female patient referred to our clinic with a 
3  week history of an itchy erythematous maculopapular eruption 
affecting the torso (thorax and abdomen) and proximal part of upper 
and lower limbs which resolved with hyperpigmentation. The patient 
reported since then similar but short-lasting lesions that she related to 
atorvastatin intake.
The patient current medications were: atorvastatin, irbesartan, chlor-
diazepoxide, levothyroxine, estradiol patch, olanzapine and parox-
etine. All of them but irbesartan and paroxetine had been taken for 
several years. Irbesartan was the latest drug introduced, approximately 
2  months before the exanthematous rash beginning and paroxetine 
was only introduced after the symptoms appearance. There was no 
history of any infectious disease. Previously performed histopatho-
logic examination of the lesions showed lymphocytic infiltrate and 
eosinophils in the dermis, compatible to drug reaction.
Irbesartan was changed to diltiazem in patient therapy. Patch tests 
(PT) to irbesartan, candesartan and atorvastatin (5  % in petrolatum) 
were performed and a lymphocyte transformation test (LTT) to irbe-
sartan was executed.
Results: PT to irbesartan was positive at 48 and 96 h. LTT (irbesartan 
100 µg/ml) showed 6.3 stimulation index.
The patient did not refer new lesions after stopping irbesartan and 
was diagnosed as non-immediate drug reaction due to irbesartan 
based in clinical, histopathologic and analytic features.
Three months later candesartan was introduced in patient therapy, 
without skin reaction after 3 months.
How this report contributes to current knowledge: There are few 
reports about non immediate cutaneous side effects due to irbesar-
tan. PT and LTT proved useful in the diagnosis. In spite of the similarity 
of chemical structure, candesartan may be tried in patients allergic to 
irbesartan.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Betalactams (BL) are the most widely prescribed anti-
biotics and the most frequent cause of drug allergic reactions. Ben-
zylpenicillin, the major responsible for BL drug allergic reactions, has 
been progressively replaced by amoxicillin and to a lesser extent by 
cephalosporins or other BL. Our aim was to characterize a series of 
subjects with suspected nonimmediate hypersensitivity (NIH) to natu-
ral penicillins and aminopenicillins/clavulanic acid (CA) and evaluate 
the usefulness of different diagnostic procedures in the study of these 
reactions.
Materials and methods: A total of 391 patients with suspected beta-
lactam hypersensitivity (BH) were referred to our department from 
2009 to 2015 and those with suspected NIH to natural penicillins and 
aminopenicillins/CA were evaluated. Demographic data, atopy, aller-
gic diseases, comorbidities, clinical manifestations and diagnostic 
procedures were assessed. BH was confirmed by positive skin tests 
(ST), drug provocation test (DPT) or long term-challenge (LTC) and 
considered probable based on a suggestive history and/or positive 
lymphocytic transformation test (LTT). ST were performed with PPL, 
MDM, Amoxicillin, Amoxicilin/CA, Ampicillin and Penicillin G; DPT was 
performed with Amoxicillin, Amoxicilin/CA and Penicillin.
Results: 169 (43 %) patients had suspected NIH to natural penicillins 
and aminopenicillins/CA: 67  % female; median age 37  years (1–81); 
34 % atopic; 16 % had rhinitis/rhinoconjunctivitis, 14 % asthma/rhini-
tis and 8  % chronic urticaria/angioedema. Cutaneous reactions were 
reported by 84  % of patients. Skin prick tests were negative in all 
patients tested (129). Intradermal tests were performed in 110 patients 
and 11 had positive late-reading. Patch tests were positive in 7 out of 
111 patients. LTT was positive in 5 out of 11 patients. DPT performed in 
120 patients was positive in 10. LTC performed in 86 patients was posi-
tive in 8. BH was confirmed in 29 patients (11 by ST, 10 by DPT and 8 by 
LTC), considered probable in 7 patients, excluded in 103 and inconclu-
sive in 30.
Conclusions: As previously reported in the literature, our study sug-
gests that BH usually presents with cutaneous symptoms and affects 
mainly adults. BH was established in 17 % of the patients, 38 % by ST, 
34 % by DPT and 28 % by LTC. According to the ENDA guidelines, DTP 
is the gold-standard for definitive diagnosis of BH. Nevertheless, 8 
patients would not have been diagnosed if LTC was not included in the 
diagnostic work-up.
Keywords: Betalactams; Hypersensitivity; Nonimmediate reactions
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Background: Omeprazole is a proton pump inhibitor for the treat-
ment of gastric acid-related disorders. It is administered orally.
Materials and methods: We present 52-years-old chemist who worked 
in a pharmaceutical company for 5 years and she was exposed to ome-
prazole during the manufacturing process. When working in the labo-
ratory, she was wearing protective latex free gloves. Whenever they 
were manufacturing omeprazole she had eczema with scaling on the 
eyelids face and neck, later hands were also affected. When she was on 
sick leave or when she was on vacation she had completely regression 
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of skin dermatitis. The patient was treated with topical corticosteroids, 
which resulted with temporally regression of skin symptoms.
Results: We preformed lymphocyte transformation test (LTT) which 
was negative. Patch test to baseline series was negative, but patch test 
to omeprazole (0.1 and 0.5 % in saline solution) was positive at day 2 
(+) and day 3 (++).
Conclusions: Omeprazole constitute a high-sensitizing chemical. 
Although direct contact with the skin is not always present, distribu-
tion of dust containing omeprazole through the air and deposition on 
exposed areas may result in an airborne pattern of contact dermatitis. 
Our case confirms the risk of sensitization to omeprazole from occupa-
tional exposure.
Keywords: Omeprasole; Proton pump inhibitor; Eczema
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Ornidazole is a 5-nitroimidazole derivative commonly 
prescribed for the treatment of diarrhea caused by anaerobic bacte-
ria. Previous cases of fixed drug eruptions (FDE) from ornidazole were 
reported in the literature (1–6), however, in only one of them the diag-
nosis has been confirmed by a positive patch test (5); their patient had 
also shown a FDE following oral intake of fluconazole (5). In another 
case (6) cross-reactivity occurred following oral intake with secnidazole.
A 40-year-old male patient presented with two pigmented lesions, one 
on the upper arm, and one with a central erosion on the glans penis. 
These had occurred since the intake of ornidazole (Tiberal®, Labora-
toires SERB, Paris, France) and budesonide (Entocort®, AstraZeneca, 
Brussels, Belgium), 2  weeks previously. The provisional diagnosis of 
FDE was put forward.
Materials and methods: Five weeks later, patch tests with ornida-
zole (tablet crushed and diluted 30 % in petrolatum) and budesonide 
(0.01 % in petrolatum) were performed on a residual pigmented lesion 
on the upper arm, and also on a non-lesional skin site as a control, 
using vander Bend Chambers® (vander Bend, Brielle, The Netherlands).
Results: Only the patch test with ornidazole on the residual pig-
mented lesion showed a positive reaction at day 4, while the control 
on the non-lesional skin remained negative. Discontinuation of orni-
dazole resulted in clearance of the lesions.
Conclusions: In the unlikely event of a fixed drug eruption, clear iden-
tification of the culprit may be difficult, in particular when multiple 
medications are administered. Patch testing in a previously affected 
lesion may identify the causative agent, as in the present case.
Keywords: Fixed drug eruption; Ornidazole; Patch testing
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images (Fig. 4).
References
1. Gupta R. Fixed drug eruption due to ornidazole. Indian J Dermatol. 
2014;59(6):635.
2. Marya C, et al. Mucosal fixed drug eruption in a patient treated with 
ornidazole. J Dermatol. 2012;6(1):21–24.
3. Gupta S, et al. Fixed drug eruption caused by ornidazole. Contact Dermat. 
2005;53:300–301.
4. Gupta S, et al. Multiple fixed drug eruption caused by ornidazole. Derma‑
titis 2010;21:330–333.
5. Bavbek S, et al. Fixed drug eruption caused by ornidazole and fluconazole 
but not isoconazole, itraconazole, ketoconazole and metronidazole. J 
Dermatol. 2013;40(2):134–135.
6. Sanmukhani J, et al. Fixed drug eruption with ornidazole having cross‑
sensitivity to secnidazole but not to other nitro‑imidazole compounds: a 
case report. Br J Clin Pharmacol. 2010,69:703–704.
P136 
Repeated delayed reaction induced by amoxicillin and amoxicillin 
clavulanate
Inmaculada Andreu1, Ramon Lopez‑Salgueiro1, Alicia Martinez Romero2, 
Pau Gomez Cabezas2
1IIS La Fe, Valencia, Spain; 2CIPF, Valencia, Spain  
Correspondence: Inmaculada Andreu
Clinical and Translational Allergy 2016, 6(Suppl 3):P136
Background: There are no techniques validated for the diagnosis of 
drug induced delayed allergic reactions. In vivo tests are inconvenient 
and in vitro tests are neither sensitive nor validated.
We describe a case of recurrent delayed reactions related to therapy 
with amoxicillin and amoxicillin clavunalate by in  vivo and in  vitro 
tests.
Materials and methods: The patient developed repeated episodes of 
generalized skin rash, pruritus, malaise, chest pain and dysphagia after 
5–7 days of therapy with amoxicillin clavunalate or amoxicillin. Blood 
tests showed an elevation in CRP, GGT, fibrinogen and monocytosis 
during the acute phase. The reactions resolved with corticosteroids 
and antihistamines.
Intradermal and patch tests were performed with amoxicillin and 
amoxicillin-clavunalate. Total IgE and specific IgE and IgG to amoxi-
cillin were measured by ImmunoCAP®. Cell activation analysis by 
the culprit drugs and clavulanate was performed by flow cytometry. 
Basophil Activation Test (BASOTEST®) was considered positive if acti-
vation ≥5  % or SI (stimulation index) ≥2. Mononuclear cell activa-
tion was evaluated by the expression of CD69 after drug exposure for 
48  h. Antibodies anti-CMV, Herpes, Epstein-Barr and parvovirus were 
analyzed.
Results: Intradermal and patch tests with amoxicillin and amoxicil-
lin clavunate acid were negative. Total IgE: 198  kUI/l. Specific IgE for 
amoxicillin and penicillin were negative (0.07  kUI/l). Specific IgG was 
3.42 mgA/l. Basophil activation test was positive for amoxicillin (1/160: 
10.87  %; SI 16.73–1/40: 48.55  %; SI 35.69) and amoxicillin clavunal-
ate (1/160: 22.76 %; SI 16.73–1/40: 74.68 %; SI 54.91), but negative for 
clavunalate (100  μg/ml: 3.55  %; SI 1.26–200  μg/ml: 3.98  %; SI 1.41). A 
threefold increase occurred when the mononuclear cells were treated 
with amoxicillin, 2.5-fold increase with clavulanate and tenfold increase 
when the samples were treated with amoxicilline clavunalate. Serolo-
gies showed positive IgG for Epstein-Barr, herpes and parvovirus.
Fig. 4 Positive patch test to ornidazole on previously affected skin 
site
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Conclusions: Delayed adverse reactions to amoxicillin and amoxicillin 
clavulanate may be diagnosed by alternative tests such as basophil and 
lymphocyte activation tests when conventional in  vivo and vitro tests 
show negative results. We hypothesize that specific IgG may induce ana-
phylactic reactions through basophil activation. Although the role of T 
cell activation is not clear, we observed a synergic effect of both drugs.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
P137 
Systemic photosensitivity from fenofibrate in a patient 
photo‑sensitized to ketoprofen
Liesbeth Gilissen, An Goossens
University Hospitals Leuven, Leuven, Belgium  
Correspondence: Liesbeth Gilissen
Clinical and Translational Allergy 2016, 6(Suppl 3):P137
Background: Fenofibrate is widely used in the treatment of hypercho-
lesterolemia and hypertriglyceridemia. Cutaneous side effects such as 
pruritus, rash, urticarial lesions, but also cases of photosensitivity have 
been previously described (1–3).
A 47-year old female patient presented with a severe vesicular erup-
tion involving the sun-exposed body areas, except under the wrist-
watch. The face was only slightly affected to which she had applied 
a sunscreen. She had been taken several medications, i.e., fenofi-
brate (Lipanthyl®, Mylan EPD, Wavre, Belgium), metformine (Metfor-
max®, Menarini, Zaventem, Belgium), spironolactone, and allopurinol 
(Zyloric®, Laboratoires SMB, Brussels, Belgium).
Materials and methods: Patch tests with the European baseline series 
and photo-patch tests with the European photo-patch test series were 
performed, using IQ Ultra® Chambers (Chemotechnique Diagnostics, 
Vellinge, Sweden).
Results: A strong positive photo-patch test to ketoprofen (D2 −, D4 
+++, D8 +++) and also a positive patch test to benzophenone-3 (D2 
+, D4 ++) were obtained.
Conclusions: Photo-allergic contact dermatitis from ketoprofen often 
gives rise to simultaneous reactions to other nonsteroidal anti-inflam-
matory drugs (NSAIDs), sunscreens, and fragrance components (4), as 
well as to fenofibrate (5), which, administered systemically, may induce 
photosensitivity. The benzophenone moiety is responsible for the 
photosensitization reaction (3.5).
Keywords: Fenofibrate; Patch testing; photo-allergic contact dermati-
tis; Systemic contact dermatitis
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images (Fig. 5).
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Background: Cross-intolerance to nonsteroidal anti-inflammatory 
drugs (NSAIDs) is a class of hypersensitivity reaction in which NSAIDs-
induced urticaria and/or angioedema (NIUA) is the most frequent 
entity. It is thought to involve dysregulation of the arachidonic acid 
(AA) pathway. However, this mechanism has not been confirmed for 
NIUA. In this work we assessed copy number variations (CNVs) in 8 of 
the main genes involved in the AA pathway and their possible genetic 
association with NIUA.
Materials and methods: CNVs in ALOX5, LTC4S, PTGS1, PTGS2, PTGER1, 
PTGER2, PTGER3 and PTGER4 were analyzed using TaqMan copy num-
ber assays. Genotyping was carried out by real time quantitative PCR. 
Individual genotypes were assigned using the CopyCaller™ Software. 
Statistical analysis was carried out using GraphPad prism 5, PLINK, EPI-
DAT and R version 3.1.2.
Results: 151 cases and 139 controls were analyzed during the dis-
covery phase and 148 cases and 140 controls were used for replica-
tion. CNVs in open reading frames were found for ALOX5, PTGER1, 
PTGER3 and PTGER4. Statistically significant changes in CNVs between 
NIUA and controls were found for ALOX5 (pc  =  0.017) and PTGER1 
(pc = 1.22E−04). Moreover, we described that there was not a correla-
tion between the presence of a deletion in ALOX5 with the presence of 
a deletion in PTGER1 (R2 = 0.274).
Conclusions: This study represents the first analysis showing an asso-
ciation between CNVs in exonic regions of ALOX5 and PTGER1 and 
NIUA. This suggests an important role of CNVs in this pathology that 
should be further explored in future studies.
Fig. 5 Systemic photosensitivity from fenofibrate (arm, wrist) follow‑
ing ketoprofen photo‑sensitization
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Background: NSAIDs are the first cause of drug hypersensitivity reac-
tions (DHRs), being those mediated by non-specific immunological 
mechanisms (cross-intolerance, CI) the most frequent. Skin is the most 
commonly affected organ and NSAIDs-induced urticaria/angioedema 
(NIUA) the most frequent clinical entity. Galectin-3 plays an important 
role in the biological responses of skin cells, and it is being regarded as 
a novel therapeutic target for a variety of skin disorders. We analyzed 
the association of several nonsynonymous single nucleotide polymor-
phisms (SNPs) in LGALS3 with CI in a large group of patients with dif-
ferent clinical entities, including NIUA, NSAIDs-exacerbated respiratory 
disease and a mixed pattern of response that includes both skin and 
respiratory involvement.
Materials and methods: The population studied was obtained from 
two Allergy Services integrated into the Spanish network RIRAAF. 
Cases included had to develop more than two episodes of CI after 
the intake of two or more NSAIDs from different chemical groups. We 
studied several SNPs in LGALS3 using TaqMan® probes. s both skin and 
respiratory involvement.
Results: A total of 504 subjects with CI to NSAIDs were included 
and 271 age and sex-matched healthy controls. Statistically sig-
nificant associations were found between NIUA and LGALS3 rs11125 
(p < 0.001) and rs4644 (p = 0.032).
Conclusions: Our results suggest a role for SNPs in LGALS3 in NIUA, 
the most important clinical entity induced by HRDs. The association of 
such genetic variants with NIUA provides us with new clues for under-
standing their underlying mechanisms. Further studies are required 
to analyze the potential role of other genetic variants in galectins and 
related genes in HRDs to NSAIDs.
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Background: Ticlopidine is an anti-platelet drug used in the treatment 
of atherothrombosis and is known to cause idiosyncratic drug induced 
liver injury (DILI). The recent identification of human leukocyte antigen 
(HLA)-A*33:03 as a susceptibility factor and the delayed nature of the 
liver injury are both indicative of an immune pathogenesis. However, 
the role of the adaptive immune system in ticlopidine-induced DILI 
has not yet been defined.
The aim of this study was to investigate whether drug-specific T cell 
responses could be detected in healthy volunteers who expressed HLA-
A*33:03. Any T cell responses would then be fully characterized for drug 
specificity, HLA restriction and the mechanism(s) of antigen presentation
Materials and methods: Peripheral blood mononuclear cells were iso-
lated from HLA-typed healthy volunteers who did or did not express the 
risk allele: HLA-A*33:03. Subsequently, naïve T-cells were separated and 
co-cultured with autologous monocyte-derived dendritic cells (DCs) in 
the presence of the ticlopidine for a period of 8 days, to expand the num-
ber of drug-responsive T-cells. T-cells were then harvested and incubated 
with freshly prepared dendritic cells and drug to test their antigen speci-
ficity using readouts for cell proliferation and cytokine secretion. T-cell 
clones were also generated following priming and drug-specific T cell 
clones analysed for cytokine secretion and HLA restriction.
Results: Using the DC priming assay all four HLA-A*33:03 positive 
donors showed ticlopidine-specific proliferation and IFNγ secre-
tion. However, no ticlopidine-specific responses were detected in 
HLA-A*33:03 negative donors. Around one thousand CD8 positive 
clones were generated from three HLA-A*33:03 positive donors, but 
ticlopidine specific clones were only obtained from one donor. These 
CD8 positive clones showed ticlopidine-specific IFNγ secretion. This 
response was restricted by HLA-A*33:03 and was not dependent on 
the presence of antigen presenting cells.
Conclusions: In conclusion, ticlopidine-specific T-cells were detected 
in healthy volunteers expressing the risk allele HLA-A*33:03 using the 
DC priming assay.
P141 
Epistasis approaches to identify novel genes potentially involved 
in NSAIDs hypersensitivity
James Richard Perkins1, Jose Antonio Cornejo García1, Oswaldo Trelles2, 
Inmaculada Doña3, Esther Barrionuevo3, María Salas3, María Auxiliadora 
Guerrero3, Miguel Blanca3, Alex Upton2
1Research Laboratory, IBIMA, Regional University Hospital of Malaga, 
UMA, Malaga, Spain; 2Department of Computer Architecture, University 
of Malaga, Malaga, Spain; 3Allergy Unit, IBIMA, Regional University Hospi‑
tal of Malaga, UMA, Malaga, Spain  
Correspondence: James Richard Perkins
Clinical and Translational Allergy 2016, 6(Suppl 3):P141
Background: A handful of genome wide association studies (GWASs) 
have been performed to detect genetic variation associated with 
NSAID hypersensitivity, by comparing the frequencies of hundreds 
of thousands of single nucleotide polymorphisms (SNPs) between 
NSAIDs hypersensitive subjects and control individuals. This is done on 
a SNP-by-SNP basis, meaning that each variant is considered indepen-
dently. However, the effect of a single SNP on phenotype is influenced 
by other factors, including the individual’s genetic background. An 
alternative approach to analyse this data is the use of epistasis meth-
ods, which look for associations between pairs of SNPs and a pheno-
type that are stronger than the sum of the individual SNP-phenotype 
associations, suggesting an interaction between the SNPs.
Materials and methods: We analysed data from an NSAIDs hypersen-
sitivity GWAS using an epistasis detection method, MBMDR. The result-
ing pairs of interacting SNPs were used to build networks, both at 
the SNP level and at the gene level, by mapping SNPs to their closest 
protein coding gene (within 500 kb). These networks were analysed to 
identify SNPs and genes with a potential role in NSAIDs hypersensitiv-
ity using graph metrics. This approach identifies important hub nodes 
based on the strength and number of connections they have, which 
can be interpreted as the number of distinct pair-wise interactions 
they are involved in.
Results: Our approach identified a number of genes with potential 
roles in NSAIDs hypersensitivity, including genes potentially involved 
in asthma (KCNB2, PPP1R3C and CSMD1), rhinitis (SCN11A) and immune 
system functioning (TSPAN33). It also found a number of genes with 
a potential role in lipid related processes, such as SGSM2 and BUB3. 
The gene CGNL1, whose expression has been shown to change following 
aspirin intake, was also identified. Additionally, pathway analysis of the 
networks found enrichment for ALK1 and TGF-beta signalling.
Conclusions: The study presented here shows how weighted epistatic 
analysis approaches can complement traditional SNP-by-SNP analy-
ses. Additional studies are necessary to replicate these findings, and 
they should be applied to other NSAIDs hypersensitivity pathologies. 
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Moreover, the mechanisms by which the SNPs and genes identified 
here affect NSAIDs hypersensitivity must be investigated further.
Keywords: NSAIDs-hypersensitivity; GWAS; Genetics; Epistasis; Sys-
tems biology
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Background: Stevens–Johnson syndrome (SJS) is an acute inflam-
matory vesiculobullous reaction of the skin and mucosa such as the 
ocular surface, oral cavity, and genitals. In patients with extensive skin 
detachment and a poor prognosis, the condition is called toxic epi-
dermal necrolysis (TEN). Severe ocular complications (SOC) appear in 
about 40 % of SJS/TEN patients diagnosed by dermatologists. Among 
SJS- and TEN patients, especially those with SJS/TEN with SOC, cold 
medicines (CM) including multi-ingredient cold medications and non-
steroidal anti-inflammatory drugs were the main causative drugs. We 
reported that in the Japanese, CM-SJS/TEN with SOC was strongly 
associated with HLA-A*02:06 and significantly associated with HLA-
B*44:03; in Indian and Brazilian caucasian populations it was associ-
ated with HLA-B*44:03, and in Koreans with HLA-A*02:06. In our 1st 
genome-wide association study, we analyzed our SJS/TEN with SOC 
patients using the Affymetrix GeneChip Mapping 500 K array set, and 
found an association between prostaglandin E receptor 3 (PTGER3) and 
SJS/TEN with SOC, and subsequently found that this association was 
stronger in patients with CM-SJS/TEN with SOC than in patients with 
all SJS/TEN with SOC. In this study, we performed the 2nd genome-
wide association study using the Japanese CM-SJS/TEN with SOC.
Materials and methods: We performed a genome-wide association 
study of Japanese 117 CM-SJS/TEN with SOC patients and 691 controls 
using the Affymetrix AXIOM Genome-Wide ASI 1 array. For the exami-
nation of 17 SNPs in regions near TSHZ2, we genotyped 101 of the 
patients and 200 of the 691 controls.
Results: Manhattan plots showed that the HLA-A region was most 
strongly associated with the susceptibility for CM-SJS/TEN with SOC. 
Outside of the HLA region, there were 60 SNPs with a value of p < 10−3 
in either allele frequency, the dominant-, or the recessive model. 
Among the 11 SNPs of 8 genes with p < 10−5, IKZF1 manifested particu-
larly low p values [rs897693 (CC + CT vs TT), OR 5.0, p = 2.1 × 10−8]. 
Among the 11 SNPs of 8 genes whose value in our second genome-
wide association study was p < 10−5, TSHZ2 also had especially low p 
values [rs4809905 (AA + AG vs GG), OR 0.3, p = 1.5 × 10−7]. Further-
more, we have examined 17 SNPs in regions near TSHZ2 using 101 CM-
SJS/TEN patients and 200 controls, and found that 8 SNPs exhibited a 
significant genome-wide association with CM-SJS/TEN with SOC.
Conclusions: TSHZ2 is one of the susceptibility gene for CM-SJS/TEN 
with SOC in the Japanese.
Keywords: Stevens–Johnson syndrome (SJS); Toxic epidermal necroly-
sis (TEN); Severe ocular complications (SOC); Cold medicines (CM); 
Genetic predisposition
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Background: Dapsone is regarded as the treatment of choice for 
infections, various dermatological diseases and inflammatory diseases. 
Drug hypersensitivity syndrome is considered as a severe cutaneous 
adverse drug reaction which is commonly precipitated by dapsone. 
A previous publication showed that the HLA-B*13:01 allele is a strong 
marker for dapsone-induced hypersensitivity syndrome of leprosy 
patients in China. Although dapsone-induced hypersensitivity reac-
tions is common, however there are no data describing whether 
HLA-B*13:01 could be used as a genetic marker for prediction of dap-
sone-induced hypersensitivity reactions in Thai.
Objective: The aim of this study was to investigate the predisposi-
tion of dapsone-induced DHS, conferred by HLA-B*13:01 in a Thai 
population.
Materials and methods: A total of 22 patients, included 11 patients in 
dapsone-induced hypersensitivity syndrome, 11 patients in dapsone-
tolerant control group (dapsone treatment for more than 6  months 
but without any episode of dapsone-induced hypersensitivity syn-
drome) and 986 healthy Thai population group. HLA-B genotype were 
determined by two-stage sequence-specific oligonucleotide probe 
system (SSOP). This study was approved by the Ethics Committee of 
Ramathibodi hospital.
Results: The results presented HLA-B*13:01 allele in patients of 
dapsone-induced hypersensitivity syndrome, dapsone tolerant con-
trols and healthy Thai population were 63.64 (7/11), 18.18 (2/11) and 
13.59 % (134/986) respectively. The HLA-B*13:01 allele were not signifi-
cantly different between DIHS cases and dapsone tolerant controls (p 
value 0.0805, OR 7.88, 95 % CI 1.11–56.13), but there were significant 
different between DIHS cases and healthy Thai population (p value 
0.0002, OR 11.13, 95 % CI 3.21–38.52).
Conclusions
Discussion: Although the samples size of DIHS cases and dapsone 
tolerant controls in this research were limited, there were found the 
HLA-B*13:01 allele could predisposition toward to dapsone-induced 
hypersensitivity in Thailand.
Keywords: HLA-B*13:01; Dapsone; Thai; Dapsone induced hypersensi-
tivity reactions; DISH
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Background: Lamotrigine (LTG) is one of the antiepileptic drugs 
(AEDs) commonly used in the treatment of epilepsy for partial seizures 
and psychiatric patients in clinical practice. Several HLA alleles have 
been associated with Lamotrigene-induced cutaneous adverse drug 
reactions (cADRs) in different populations, however, this has not been 
investigated in Thai.
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Objective: The aims of this study were to determine the possible asso-
ciations of lamotrigine-induced cADRs with the HLA-B alleles in Thai 
patients.
Materials and methods: A total of 645 patients, including 16 patients 
with lamotrigine-induced cADRs, vary from maculopapular exanthema 
(MPE) to Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/
TEN), 50 lamotrigine-tolerant controls and 580 healthy controls were 
included in this study. HLA-B genotyping was performed. This case–
control study was approved by the Ethics Committee of Ramathibodi 
Hospital.
Results: The differences in the starting dosage of LTG among the SJS/
TEN, MPE, and LTG-tolerant control groups were not statistically signifi-
cant. HLA-B*15:02 allele was present in 33.3 % (1/3; LTG-induced SJS/
TEN group), 38.5 % (5/13; LTG-induced MPE group) of Thai patients but 
only 12.0 % (6/50) of lamotrigine-tolerant controls and 14.8 % of 580 
healthy controls. There was significant difference in the frequency of 
subjects with the HLA-B*1502 allele between SJS/TEN and LTG-tolerant 
groups (p  <  0.05, OR 3.559, 95  % CI 1.71–7.40), and healthy controls 
(p = 0.003, OR 2.75, 95 % CI 1.38–5.47). Significant difference between 
the MPE group and LTG-tolerant group (p  <  0.05, OR 4.613, 95  % CI 
2.23–9.51), and healthy controls (p < 0.05, OR 3.565, 95 % CI 1.80–7.03).
Conclusions: In conclusion, in this study, we found a statistically sig-
nificant association between the HLA-B*1502 allele and LTG-induced 
cADRs in Thai population. Therefore, an application of HLA-B*1502 as a 
screening test before prescribing LTG will help to prevent LTG-induced 
cADRs in Thailand (Tables 2, 3, 4).
Keywords: Lamotrigine; HLA-B*1502; Cutaneous adver sereactions; 
Stevens–Johnson syndrome; Toxic epidermal necrolysis
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Background: Some HLA-I alleles are risk factors for the development 
of severe cutaneous adverse drug reactions (SCARs). HLA-B1502 is 
strongly associated with the development of Stevens Johnson syn-
drome/toxic epidermal necrolysis (SJS/TEN) to carbamazepine (CBZ) 
in Southeast Asian populations where the allele is prevalent. On the 
other hand, HLA-A3101 has been found to be a risk factor for (CBZ)-
induced drug reaction with eosinophilia and systemic symptoms 
(DRESS) in European and Asian patients. HLA-A3101 has been weakly 
associated to CBZ-induced SJS/TEN in Europeans, and no association 
has been found with other aromatic antiepileptic drugs (AEDs). No 
HLA-I alleles have been definitely associated with lamotrigine (LTG)- or 
phenytoine (PHE)-induced SCARs in Europeans
Materials and methods: To explore the association of HLA-I allele 
frequencies with SCARs to AEDs in our population, 12 patients with 
DRESS and 14 cases with SJS/TEN included in the Spanish registry 
PIELenREd were studied. Six cases were related to LTG (3 SJS/TEN; 3 
DRESS), 6 were related to CBZ (2 SJS/TEN; 4 DRESS), and 14 cases were 
induced by PHE (9 SJS/TEN; 5 DRESS). DNA was prepared from total 
blood and four digits HLA typing was performed. The frequencies of 
HLA-I alleles in patients with LTG-induced SCARs were compared with 
frequencies in patients within the other groups, and with previously 
Table 2 Clinical characteristics of  LTG‑induced cADRs 
group and LTG‑tolerant group
No significant differences were observed in gender, mean age, and mean 












Mean age (years) 35.5 ± 21.7 38.2 ± 19.0 0.646
52.3 ± 24.0 (SJS/
TEN)
0.415
32.0 ± 20.9 (MPE) 0.353
Starting dosage of 
LTG (mg/day)
51.6 ± 26.6 77.6 ± 62.0 0.109
41.7 ± 14.4 (SJS/
TEN)
0.325
53.8 ± 28.6 (MPE) 0.186
Table 3 Comparison of  HLA‑B*15:02 frequency among   
groups
a OR: odds ratio






p value ORa 95 % CIb
LTG‑induced SJS/TEN LTG‑tolerant group 0.0004 3.559 1.71–7.40
LTG‑induced SJS/TEN Healthy control 0.003 2.750 1.38–5.47
LTG‑induced SJS/TEN LTG‑induced MPE 1.000 0.800 0.06–11.29
LTG‑induced MPE LTG‑tolerant group <0.05 4.613 2.23–9.51
LTG‑induced MPE Healthy control <0.05 3.565 1.81–7.03
Table 4 The association of  individual HLA‑B allele 
with  lamotrigine induced cutaneous adverse drug reac‑
tions (cADR)
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published HLA-I frequencies in 253 Spanish individuals (Balas et al. Tis-
sue Antigens, 2010).
Results: HLA-B3801 allele was present in all three cases of LTG-induced 
SJS/TEN suggesting a strong association (OR 37.92; 95 % CI 5.4–269.53; 
p < 0.0001). Only 2 out of 9 SJS/TEN cases induced by PHE were carriers 
of HLA-B3801 (OR 4.74; 95 % CI 0.67–25.12; p = 0.09). None of the 12 
DRESS cases analyzed were carriers of HLA-B3801. On the other hand, 
the 3 LTG-induced DRESS patients were carriers of HLA-A2402 showing 
a significant association as compared to the control sample (OR 5.25; 
95 % CI 1.0–24.75; p = 0.04). HLA-A2402 was found in 3 out of 5 cases 
of PHE-induced DRESS (OR 4.5; 95 % CI 0.88–20.27; p = 0.054) and was 
absent in all CBZ cases and in SJS/TEN cases to PHE.
Conclusions: Our results suggest that HLA-B3801 may be a risk fac-
tor for LTG-induced SJS/TEN, in agreement with previous data (Lon-
jou et al. Pharmacogenetics and Genomics 2008). On the other hand 
HLA-A2402 might be related with LTG-induced DRESS or exantematic 
reactions, as recently published in the Norwegian population (Shirzadi 
et al. Epilepsy Research 2016).
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Background: HLA class I and class II genotyping has identified 
patients at risk for both T-cell mediated and IgE/mast cell mediated 
severe drug hypersensitivity (HSR). Class II HLA-DRA variants have 
been associated with immediate allergic reactions to beta-lactams 
and the HLA-DRB1*07:01 allele has been associated with IgE-mediated 
reactions to asparagine. Up to 27 % of women exposed to 6 or more 
cycles of carboplatin present with immediate HSR and 50 % of these 
reactions are anaphylactic. BRCA1/2 mutations have been found to 
be more common among patients who develop immediate reactions 
to carboplatin and these reactions, including anaphylaxis, have been 
successfully addressed by rapid drug desensitization (RDD). We sought 
to evaluate the HLA profile of patients who presented an initial carbo-
platin-induced severe hypersensitivity reaction including anaphylaxis, 
had a positive skin test and were treated with the BWH rapid drug 
desensitization 3–4 bags protocol.
Materials and methods: HLA ABC DR DQ DP typing was conducted for 
a cohort of Caucasian ovarian cancer patients (n = 11) with a history of 
grade 2 or 3 type I HSR to carboplatin undergoing RDD and a control 
group of Caucasian ovarian cancer patients treated with carboplatin, 
who tolerated 8 or more cycles (n = 12). Allele carriage amongst cases 
and controls was compared using Fisher’s exact test. The Haploblocks 
program was used to generate cobygram visuals of HLA co-carriage.
Results: Among allergic patients, 36  % (4/11) had grade 2 and 64  % 
(7/11) grade 3 initial HSR. All successfully tolerated the RDD and 
were able to complete their treatment plans. We found that the HLA-
DRB1*15:01 allele was more prevalent among allergic patients (5/11, 
45  %) than among the control group (1/12, 8.3  %) (p =  0.06). Coby-
gram analysis suggests that the HLA class II association may extend to 
the DQA1*01:02-DQB1*06:02-DRB1*15:01 haplotype (Fig. 6).
Conclusions: In this Caucasian cohort of ovarian cancer patients, a 
specific HLA class II allele, DRB1*15:01, was suggested to be associ-
ated with immediate hypersensitivity to carboplatin. Further carbo-
platin HSR cases and carboplatin tolerant controls are currently been 
accrued to verify the validity of this association and assess its exten-
sion to the DQA1*01:02-DQB1*06:02-DRB1*15:01 haplotype.
Keywords: HLA genotyping; Rapid drug desensitization; Carboplatin; 
IgE-mediated reaction; Drug allergy
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Background: In case of immediate reactions to beta-lactams, aller-
gological work up consists of detection of specific Immunoglobulin-E 
(Ig-E) against beta-lactams in serum and skin tests, i.e. prick test and 
intradermal tests with major and minor antigenic determinants of 
penicillin, amoxicillin, ampicillin and benzilpenicillin. Levels of specific 
Ig-E decrease after the reaction and they are no more detectable after 
some years. It is recommended to perform in  vivo and in  vitro tests 
after 3 weeks and no later than 6–12 months after the reaction. Sen-
sitivity of tests then decreases and false negative result may occur. In 
case of remote history of immediate reaction to beta-lactam, if tests 
are negative, a provocation test with the culprit drug is necessary and 
should be followed by repetition of skin tests.
Report: We report the case of a woman aged 61  years who experi-
enced a systemic reaction (urticaria, vomit, diarrhea, fatigue) 15  min 
after intake of amoxicillin/clavulanic acid. Four months later, she 
underwent a visit in our Allergy Unit and serological and skin tests 
were scheduled.
Serological specific Ig-E against penicilloyl G, penicilloyl V, ampicillin, 
amoxicillin, cefaclor as well as skin tests gave negative result. They 
were performed respectively 5 and 9 months after the reaction. A drug 
provocation test (DPT) with amoxicillin was then performed and was 
considered positive for the occurrence of generalized pruritus 20 min 
after the intake of the last dose (cumulative dose 875 mg). Skin tests 
were repeated with positive results to both amoxicillin and ampicillin, 
at the concentration of 1 and 20 mg/ml, respectively.
How this report contributes to current knowledge: Specific Ig-E 
levels against beta-lactams decrease after immediate-type reactions. 
Guidelines recommend to perform allergological work up within 
6–12 months. Our case shows how this period might be too long and 
false negative tests can occur even if performed within one year. DPT 
should always follow negative skin tests to obtain a correct diagnosis.
Fig. 6 Overrepresentation of DQA1*01:02‑DQB1*06:02‑DRB1*15:01 
haplotype in the allergic group
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Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: There are no good epidemiological data regarding opi-
oid allergy (OA). Many side effects can occur with this group of drugs. 
These are often misinterpreted as an IgE-mediated OA. As a conse-
quence, many patients receive an unsubstantiated diagnosis of OA 
and avoid opioid unnecessarily. Diagnosis of OA can be challenging 
as skin tests (ST) and opioid-specific IgE have a poor predictive value. 
Drug provocation tests (DPT) remain the gold standard for the diagno-
sis of OA. However, there are almost no studies of opioid DPT and no 
validated opioid DPT protocols.
Materials and methods: 30 suspected cases of OA (12 morphine, 
18 codeine) were studied using detailed history and oral DPT. Opioid 
ST and specific IgE were not performed. Standardised local protocols 
were used. For morphine: 2, 3, and 5 mg morphine sulphate oral solu-
tion (10  mg/5  ml) was administered at 30  min interval with 120  min 
monitoring. For codeine: 10, 20 and 30 mg codeine phosphate syrup 
(25 mg/5 ml) was administered at 30 min interval with 60 min of moni-
toring. All DPT were performed on a specialist allergy unit.
Results: 25 females and 5 males (median age of 46.5) experienced 
various symptoms reported as OA. Opioids were prescribed mainly for 
analgesia. 20 patients (67 %) had cutaneous symptoms: angioedema: 
5, urticaria: 4, angioedema and urticaria: 2, unspecified rash: 5, angi-
oedema, unspecified rash and pruritus: 3, angioedema and unspeci-
fied rash: one. 11 patients (37  %) experienced symptoms suggestive 
of anaphylaxis: dyspnoea, tachycardia, hypotension, dizziness and col-
lapse. 2 of these (18 %) experienced cutaneous symptoms too. Other 
non-specific symptoms included nausea: 2, paraesthesia: 2, tremor: 1, 
anxiety: 1. DPT were negative in 23 patients (77 %). 6 patients (20 %) 
had symptoms of intolerance: pruritus, nausea, dizziness, tremor to 
morphine (2) and codeine (4). Only 3 % of DPT were positive: 1 patient 
experienced angioedema with codeine.
Conclusions: DPT-confirmed OA appears to be very rare (3  %). Most 
symptoms misinterpreted as OA could be due to a dose-dependent 
mast cell degranulation, genetic polymorphism of CYP2D6 gene or the 
underlying acute illness. Morphine and codeine DPT are a safe and reli-
able diagnostic tool. Our ongoing multi-centre study will endeavour 
to validate this approach in a larger cohort of suspected OA patients 
(including other opioids) and produce standardised DPT protocols to 
improve the diagnosis of OA in Europe and worldwide.
Keywords: Anaphylaxis; Codeine; Drug provocation test; Morphine; 
Opiod allergy
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Background: Specific IgE against β-lactams by CAP FEIA system 
(Thermo Scientific®) used to use the cut-off of 0.35 kU/l, but now we 
can get a detection limit of the assay of 0.10 kU/l. We pretend to evalu-
ate if this change of cut-off from 0.35 to 0.10 kU/l improves the sensi-
tivity without compromise its specificity.
Materials and methods: 74 patients older than 18  years evalu-
ated in the allergy outpatient clinic since January 2011 to April 2014 
were studied. They were classified as allergic by history and skin tests 
positive to β-lactamic antibiotics. Specific IgE against penicilloyl G, 
penicilloyl V, amoxicilloyl and ampicilloyl were analyzed by CAP FEIA 
system (Thermo Scientific®). With these IgE values and positive or 
negative diagnosis of allergy, sensitivity and specificity of both cut-
offs (0.35 and 0.10  kU/l), the ROC curves were obtained. In addition, 
the AUC value (with their confidence interval) was calculated. The SPSS 
(v19.0) and “Analyse-it”-Excel were used.
Results: Tables 5, 6, 7.
Conclusions: The cut-off of 0.10 kU/l may be more appropriate to use 
in the clinical practice because it improves the correct classification of 
b-lactams allergy patients. The amoxicilloyl obtains the best perfor-
mance with this new cut-off.
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Background: The time of determination of specific IgE (sIgE) to poten-
tial culprit drugs, as an aid in the diagnosis of peri-operative anaphy-
laxis, is not well defined for all drugs.
Report: A 62-year old man experienced an anaphylaxis within 15 min 
after receiving a gelatin-containing plasma expander during general 
anesthesia for hip surgery after a high velocity trauma. Decontami-
nation was performed with chlorhexidine, and propofol, lidocaine, 
sufentanil, rocuronium, dexamethasone, was adminstered 2h15 and 
cephazolin 1h45 prior to the event. The gelatin infusion was stopped 
and treatment with epinephrine, norepinephrine, promethazine, 
hydrocortisone, and saline fluid expansion installed. Serum tryptase 
Table 5 ROC results
Specific IgE AUC value CI 95 %
Penicilloyl G 0.780 0.66–0.90
Penicilloyl V 0.748 0.638–0.858
Ampicilloyl 0.783 0.674–0.892
Amoxicilloyl 0.844 0.758–0.930
Table 6 Sensitivity and  specificity with  the 0.10 kU/l cut‑
off
Specific IgE Sensitivity (%) Specificity (%)
Penicilloyl G 55.6 85.7
Penicilloyl V 47.1 80.0
Ampicilloyl 74.2 69.0
Amoxicilloyl 74.2 74.4
Table 7 Sensitivity and  specificity with  the 0.35 kU/l cut‑
off
Specific IgE Sensitivity (%) Specificity (%)
Penicilloyl G 33.3 94.6
Penicilloyl V 23.5 97.5
Ampicilloyl 35.5 97.6
Amoxicilloyl 45.2 93.0
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was transiently increased (95.7  ng/dl 1h30 after the onset of the 
reaction vs 6.0 ng/dl > 24 h after the event). ImmunoCAP sIgE (Ther-
mofisher—Phadia, Sweden) to gelatin, galactose-alpha-1,3-galactose, 
ethylene oxide, latex, and chlorhexidine was negative on the sample 
obtained 1h30 after the event, and independently confirmed. How-
ever, repeat sampling 16 days after the event with a serial dilution of 
the gelatin-containing plasma expander, mimicking the timing of the 
initial testing, demonstrated the inhibition of sIgE determination with 
a 50 % inhibitory concentration (IC50) of 0.02 %. No serum before the 
anaphylaxis was available to confirm a pre-existing sensitization. Skin 
testing 4 weeks after the event was positive for the 4 % gelatin-con-
taining plasma expander (3 and 5 mm wheal diameter after skin prick 
testing at a 1:10 and 1:1 dilution respectively) and negative for chlo-
rhexidine, latex, and cephazoline.
How this report contributes to current knowledge: A rare case of IgE-
mediated gelatin allergy is reported. We hypothesized that the initial 
sIgE for gelatin was false negative due to competition of infused gelatin 
with the gelatin-immunoCAP assay rather than a boostin phenomenon 
had taken place, suggesting careful interpretation of sIgE determina-
tions very early after the event, at least in the case of gelatin-sIgE.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Beta-lactam (BL) antibiotics are the drugs most fre-
quently involved in IgE-mediated allergic reactions. Skin testing is the 
most widely used diagnostic method to evaluate IgE mediated reac-
tions to BL. Skin test respond to penicillin determinants vary in differ-
ent populations over time related with pattern of consumption. But 
precise studies The aim of our work is to study the variation of the skin 
response over long time in a well-defined series of allergic to BL.
Materials and methods: All patients submitted to our centre, in 
10 year period (1999–2009) with a compatible history of beta-lactam 
allergy underwent allergy work-up according to the ENDA protocols 
for immediate reactions.
Skin tests (prick and intradermal) with the classical penicillin reagents 
[Allergopharma Reinbeck, Germany (1999–2005)] and from 2005 (Dia-
ter reagents DAP, Madrid, Spain): penicilloyl polylysine (PPL), minor 
determinants mixture (MDM: benzylpenicillin and sodium benzylpeni-
cilloate) and benzylpenicillin (penicillin G) and Semi-synthetic penicil-
lins (amoxicillin, amoxicilin/clavulanic acid and ampicillin) were also 
systematically tested, as well as any other suspected beta-lactam. 
In the case of negative results, we perform provocation tests with 
the suspected drug. Considering the temporal variation for imme-
diate reactions in terms of skin test positivity, Patients were classi-
fied according to the year they referred the reaction, in four periods 
(>1980, 1980–1990, 1991–2000 and >2001–2009)
Results: From a total of 2716 patients initially evaluaed, 296 were 
finale confirmed as inmediate reactions to Betalactamic. A total of 247 
were diagnosed by skin testing, this represents 83 % of total (247/296).
Considering the temporal variation for immediate reactions in terms 
of skin test positivity, the analysis of the AX determinants showed that 
there was a gradual increase over the years that varied from 38.5 to 
81.2 %. Statistical analysis confirm a strong signification p < 0.0001. In 
parallel a decreased of antigenic determinants of penicillin (including 
PPL, MDM and Benzylpenicillin) from 30.8 to 12.7 % also statistic sig-
nificance p < 0.007.
Conclusions: Our study confirm that the variation of beta-lactam pat-
tern consumption modify the skin test response in a long series over 
10 years.
Strong statistical significance of amoxicillin skin tests rising p < 0.001 
correlates with the progressive increase in amoxicillin consumption 
since 2001.
Keywords: β-Lactams; Amoxicillin; Skin test; Allergy; Inmediate 
reaction
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Background: ln order to emulate the recognition process work-
ing in  vivo, much effort have been made to prepare hapten(drug)-
carrier(protein) conjugates attempting to work like the antigen 
responsible for the allergic drug reaction.
Materials and methods: In our efforts to exploit the dendrimer prop-
erties in the interaction with the immunological system, we have pre-
pared a series of Dendrimeric:Antigens (DeAn), to study the dendritic 
cell (DC) maturation as a test to detect allergy reactions to amoxicillin.
Recently our research group developed a new kind of dendrimer, 
called BAPAD, that we have used in this work to obtain the dendrim-
eric moiety of the target molecule. To this avail we synthesized a gen-
eration two BAPAD dendrimer using cystamine as core. Then, the free 
amine groups on the surface of the dendrimer were functionalized 
with an amoxiciloyl group (AXO). The fluorescent DeAn has been fully 
characterized by NMR and MS techniques, and their fluorescent prop-
erties well established in aqueous biological media using confocal 
microscopy. The fluorescent dendron (De) without the haptenic moi-
eties at the periphery has been also obtained and fully characterized 
as a control assay. The fluorescent DeAn and De was used in dissolu-
tion and supported in solid surface (cellulose disk). The solid conju-
gates were immunologically evaluated by RAST inhibition using sera 
from 7 patients allergic to amoxicillin. DC from four amoxicillin allergic 
patients have been incubated with fluorescent DeAn and De and stud-
ied with a flow cytometer to determine whether or not the cells were 
able to uptake both compounds.
Results: Flow cytometry and confocal microscopy show that these 
dendrimeric structures interact with DC and are internalized by them 
to the cellular cytoplasm. The maturation of DC was tracked by by flow 
cytometry. In all cases, low maturation induced by DeAn in allergic 
patients is observed. This effect can be due to two factors: (1) that the 
concentration of compound that enters the DC is low and (2) that the 
hapten density presented in DeAn is low. The RAST inhibition studies 
of solid supported DeAn showed a higher RAST inhibitions values for 
allergic patients compare with negatives controls. This value was also 
compared with solid surfaces conjugated with PLL-AXO showing simi-
lar results.
Conclusions: These dendrimeric structures assayed in RAST inhibi-
tion studies letting us check that inhibition occurred, so recogni-
tion existed between IgE of patients allergic to amoxicillin and DeAn 
structures.
Keywords: Confocal microscopy; Dendritic cell; Maturation
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Background: Diagnosis of penicillin allergy is based on case history, 
skin testing (ST, prick and intracutaneous tests) and measurement of 
specific IgE (s-IgE) to a penicillin and challenge with penicillin. If ST or 
s-IgE is positive, the patient is classified as allergic to penicillin accord-
ing to the European Network of Drug Allergy guidelines and challenge 
is omitted. Therefore, the true sensitivity and specificity of ST and s-IgE 
are presently not known.
The aim of this study was to investigate the clinical relevance of a posi-
tive skin test and s-IgE to penicillin.
Materials and methods: Forty-four patients with a positive ST and/or 
s-IgE were included; ST with penicillin was done and s-IgE was meas-
ured in all 44 patients at the time point designated T0. Challenge with 
the culprit penicillin was performed immediately hereafter although 
abstained in patients with recent anaphylaxis to penicillin (n = 8), sys-
temic reactions to ST (n =  3) or development of delayed positive ST 
(n = 8). These were classified as allergic to penicillin; thus, 25 patients 
were challenged.
18 of the patients had been evaluated previously (T−1) and reproduc-
ibility of the results were compared to T0 and again 4 weeks post chal-
lenge (T1).
Results: Nine of the 25 challenged patients were positive. There was a 
significantly increased probability of being allergic to penicillin if both 
skin test and s-IgE were positive at T0 (p = 0.007). Positive ST or s-IgE 
alone did not predict penicillin allergy (p = 0.313/p = 0.051).
Among the 18 patients repeatedly tested, only 12/26 (46.2 %) of posi-
tive skin tests at T−1 were reproducibly positive at T0, and only one 
further ST became positive at T1. For s-IgE, 14/24 (58.3 %) of positive 
measurements were still positive at T0 and seven further became posi-
tive at T1, although s-IgE levels at T0 and T1 did not differ significantly 
(p = 0.599).
Conclusions: In this study, the best predictor for a positive penicillin 
challenge was history combined with both positive ST and s-IgE. There 
was a relatively low reproducibility of a previously positive ST and s-IgE.
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Background: Perioperative drug hypersensitivity (PDH) presents a 
major problem resulting in unexpected, often severe anaphylactic 
reactions. Diagnosis of anaphylaxis during anaesthesia mainly relies 
on skin testing, since assays for the detection of IgE-antibodies are 
not available and provocation tests are not feasible for most of the 
involved drugs. Neuromuscular blocking agents (NMBAs) are recog-
nized as the most prevalent elicitors of PDH, however, skin tests with 
NMBAs might result in false-positive results due to unspecific, non-IgE-
mediated release of histamine.
Materials and methods: To further investigate this subject, we evalu-
ated the potential of NMBAs eliciting positive results in individuals with 
known NMBA-tolerance in both skin prick (SPT) and intracutaneous 
tests (ICT) and compared these with the reactivity in basophil activa-
tion tests (BAT). Eleven individuals [5 females, 6 males; 25–60 years old, 
median (m) = 50] without known allergy to NMBAs, but tolerant to a 
recently perioperative applied NMBA were included in this study. The 
NMBAs Suxamethonium, Rocuronium, Cis-Atracurium and Mivacurium 
were tested by both titrated SPT and ICT, and NMBAs eliciting a positive 
skin reaction were further analyzed by BAT with the individuals’ serum.
Results: SPT yielded positive results in 0/11 participants for Suxame-
thonium, Rocuronium and Cis-Atracurium and in 2/11 for Mivacurium. 
ICT was positive in 2/11 for Suxamethonium, 9/11 for Rocuronium, 
8/11 for Cis-Atracurium and in 11/11 for Mivacurium. BAT analysis con-
firmed the positive skin tests in only one individual, while it was nega-
tive for the NMBAs in all others.
Conclusions: These findings show that skin test results with NMBAs 
have to be carefully interpreted regarding their clinical relevance and 
the implementation of more reliable test systems would be helpful for 
diagnosis of PDH.
Keywords: Perioperative anaphylaxis; Anaesthesia; Neuromuscular 
blocking agents; Skin test; Basophil activation test
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Background: β-lactam antibiotics (BLAs) are the drugs most associated 
with immune-mediated hypersensitivity reactions (drug allergy). They 
can elicit all types of allergic reactions i.e., types I, II, III and IV. Although 
the immediate IgE-mediated reaction has been well studied, the patho-
physiology of non-immediate hypersensitivity reactions is not well 
understood. Cross-reactions among BLAs with different side chains are 
variable. The diagnosis and prediction of BLAs-induced allergic reac-
tions is challenging and based mostly on clinical history. The lympho-
cyte toxicity assay (LTA) and the in  vitro platelet toxicity assay (iPTA) 
are in vitro tests with a potantial value for diagnosis and prediction of 
drug allergy. Their value in diagnosis of reactions to BLAs, however, is 
still unknown. This work is an attempt to evaluate the performance of 
in vitro toxicity testing for diagnosis of different types of allergy to BLAs 
and to investigate the their different underlying pathophysiology.
Materials and methods: One hundred and seventy individuals (85 
drug allergy-suspected patients and 85 healthy volunteers) were 
included in this study. Patients were identified from clinical records 
and included using a rigorous internationally recognized inclusion 
criteria based on their clinical presentation and available diagnos-
tic investigations (i.e., skin testing and RAST). The LTA and iPTA tests 
were performed after resolution of the reaction symptoms. Data was 
expressed as percentage of cell death compared to control (vihicle 
without the drug) after incubation with the suspected drug in pres-
ence of rat microsomes (MICs).
Results: Patients were grouped according to their exhibited symptoms 
into 3 groups constituted of 8 patients type I, 28 patients type III and 
49 patients type IV. Patients with type IV reactions exhibited higher 
degrees of cell death than the other 2 groups (p  <  0.05) with type I 
patients exhibiting the lowest degree of cell death among all groups.
Conclusions: Using the in vitro toxicity testing (LTA and iPTA) we were 
able to identify patients susceptible to develop allergy to BLAs. In 
addition, cells isolated from patients with different types of reactions 
exhibit variable degrees of cell death, which indicate possible distinct 
pathophysiological mechanisms. The LTA and iPTA can be a useful tool 
to both diagnose drug allergy to BLAs and investigate its underlying 
pathophysiology (Table 8).
Keywords: Drug allergy; Drug hypersensitivity; In vitro diagnosis
P156 
Enzyme linked immunospot assay used in the diagnosis of severe 
cutaneous adverse reactions to antimicrobials
Alec Redwood1, Jason Trubiano2, Rebecca Pavlos1, Emily Woolnough2, 
Kaija Stautins1, Christina Cheng2, Elizabeth Phillips3
1Institute of Immunology and Infectious Diseases, Murdoch University, 
Perth, Australia; 2Department of Infectious Diseases, Alfred Health, Mel‑
bourne, Australia; 3Vanderbilt University Medical Center, Nashville, United 
States  
Correspondence: Alec Redwood
Clinical and Translational Allergy 2016, 6(Suppl 3):P156
Background: The ability to define drug causality in cases of Severe 
Cutaneous Adverse Reactions (SCAR) where multiple antimicrobials 
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are implicated remains problematic. We describe a case of toxic epi-
dermal necrolysis (TEN) in the setting of multiple implicated antimi-
crobials and the utility of T-cell enzyme linked immunospot assay 
(ELISpot) to define antimicrobial causality.
Report: A 20-year old man was admitted to a tertiary referral trauma 
centre for management of wound sepsis and femoral stump osteomy-
elitis in the setting of recent below-knee amputation following a high-
speed motorbike accident. Whilst receiving escalating antimicrobial 
treatment, for bacteraemia and fevers >38.3 °C, he developed a blister-
ing rash involving >30  % of body surface area (BSA) associated with 
a positive Nikolsky sign, consistent with TEN. Multiple antimicrobials 
were administered prior to onset of TEN, four of which—vancomycin, 
meropenem, linezolid and teicoplanin—were temporally associated 
with the onset of TEN.
How this report contributes to current knowledge: We sought to 
use cellular assays, IFN-γ ELISpot and flow cytometry, to identify the 
causative agent of TEN in a patient receiving multiple antibiotics. Fol-
lowing informed consent, patient whole blood was collected on day 4 
post onset of TEN. PBMCs were extracted and cryopreserved. HLA ABC 
DR DQ DP typing was performed and the PBMCs were used for ex vivo 
ELISpot testing. PBMCs were also incubated with candidate drugs for 
18–20 h at 37 °C in 5 % CO2 and assessed by flow cytometry for upreg-
ulation of the T cell activation marker CD137.
Patient HLA was HLA-A*01:01 and 02:02, HLA-B*37:01 and 41:01, HLA-
C*10:01 and 17:01, HLA-DPB1*10:01, HLA-DQA1*01:01 and 02:01, HLA-
DQB1*02:02 and 05:01, HLA-DRB1*07:01 and 10:01. Positive ELISpot 
responses were reproducibly produced only to the glycopeptide anti-
biotic teicoplanin, with up to 300 SFU/million cells. ELISpot data were 
confirmed by flow cytometry analysis, where only teicoplanin induced 
up-regulation of the activation marker CD137 (0.3  % of total CD8+ 
T-cells). All other antibiotics including vancomycin and meropenem 
were negative by ELISpot and flow cytometry.
We believe this to be the first reported use of T-cell ELISpot to assign 
isolated teicoplanin causality to TEN.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: The drug-induced lymphocyte stimulation test (DLST), 
or lymphocyte transformation test (LTT), is used to identify the culprit 
drug in cases of cutaneous adverse drug reactions (cADR). While DLST 
is widely used as in vitro diagnostic tool, its sensitivity and specificity 
are unsatisfactory. Determination of antigen-specific IFN-γ produc-
tion by enzyme-linked immunospot assay (conventional IFNγ-ELISpot) 
is well-established diagnostic method for tuberculosis infection, 
and recent reports suggested that drug-induced conventional IFNγ-
ELISpot is useful for identifying the culprit drug of cADR cases. The aim 
of this study was to establish a novel diagnostic method for identifying 
the culprit drug in cADR patients through the efficient detection of the 
drug-specific IFN-γ production by IFNγ-ELISpot.
Materials and methods: Ten cases of cADR caused by clinically con-
vincing culprit drugs were enrolled in this study. Peripheral blood 
mononuclear cells (PBMCs) from all 10 patients were used for both 
DLST and drug-induced conventional IFNγ-ELISpot. In addition, drug-
induced IFNγ-ELISpot was also performed by using PBMCs which were 
non-specifically stimulated with monoclonal antibodies for 7  days 
before exposing culprit drugs (modified IFNγ-ELISpot) in all cases.
Results: Drug-induced IFN-γ production was detected by modified 
IFNγ-ELISpot in 5 patients of which DLST and conventional IFNγ-
ELISpot were both negative. Moreover, IFN-γ secretion was observed 
by modified IFNγ-ELISpot in all 4 patients of which DLST were positive.
Conclusions: Modified IFNγ-ELISpot using expanded PBMCs is more 
sensitive than conventional IFNγ-ELISpot for detecting drug-induced 
IFN-γ production. Therefore, this novel IFNγ-ELISpot could be a useful 
in vitro tool for identifying culprit drugs in cADR cases.
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Background: Stevens–Johnson syndrome (SJS), toxic epidermal 
necrolysis (TEN) and drug-induced hypersensitivity syndrome/drug 
reaction with eosinophilia and systemic symptoms (DIHS/DRESS) are 
life-threatening adverse drug reactions. For prevention of relapse, it is 
mandatory to determine the causative drug. Patch test and lympho-
cyte stimulation test (LST; also known as DLST in Japan) are frequently 
used for this purpose, but their positivity ratios are not sufficiently 
high. We sought to explore a novel method using skin-infiltrating T 
cells for determination of causative drugs because it is considered that 
antigen-specific T cells infiltrate in skin lesions of the severe drug erup-
tions and participate in its pathogenesis.
Materials and methods: We expanded skin-infiltrating T cells from 
4-mm biopsied lesional skin samples of severe drug eruption using 
anti-CD3/CD28 antibodies and IL-2. More than 107 T cells/specimen 
were obtained by 2-week cultivation. To investigate their cytokine pro-
duction by in vitro stimulation with causative drugs, the expanded T 
cells were co-cultured with drugs peripheral blood mononuclear cells 
(PBMCs) from the same patient, and IFN-g production was assessed 
by ELISpot assay. Moreover, to see the drug-induced T-cell prolifera-
tion, the expanded T cells were labeled with CFSE and cultured with 
drugs and X-ray-irradiated PBMCs for a week, and the proliferation 
was assessed by flow cytometry. The cytokine profile of the cells which 
proliferated in response to drugs was also assessed by flow cytometry.
Results: The ELISpot assay showed a significantly high number of 
T cells produced IFN-g by drug stimulation as compared to no addi-
tion control. The CFSE assay revealed that both CD8+ and CD4+ T 
cells proliferated in response to causative drugs in SJS/TEN and DIHS/
DRESS. Notably, the majority of CD8+ T cells proliferating to causative 
drugs expressed IFN-g in SJS/TEN.
Conclusions: Our study suggests that the use of ex  vivo expanded 
skin-infiltrating T cells can yield a novel method for determination of 
causative drugs in the severe drug eruptions.
Keywords: T cells; IFN-γ
Table 8 Diagnostic value of  the lymphocyte toxicity 
assay (LTA) and  the in  vitro platelet toxicity assay (IPTA) 
for ß‑Lactam allergy
Characteristic Value
Sex [female/male; n (%)] 53/31 (63.1/36.9)
Age [mean; year (range)] 24 (1–88)
Type of reaction [n (%)]
Type I 8 (9.4)
Type III 28 (32.9)
Type IV 49 (57.6)
Total 85 (100)
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Background: T cells play a major role in delayed-type of hypersensi-
tivity reactions. Their reactivity can be assessed by lymphocyte trans-
formation test or upregulation of cell surface activation markers, 
and those tests are of limited practicability or diagnostic sensitivity. 
Some previous report suggested that in  vitro secretion of cytokines 
by peripheral blood mononuclear cells (PBMC) could be a promis-
ing tool for improved detection of T-cell sensitization. For that reason 
we wanted to test this methodology in patients with well-defined 
delayed-type nickel hypersensitivity.
Materials and methods: PBMC of 10 nickel hypersensitive patients 
and 9 healthy controls were incubated for 48 h with two different con-
centration of NiSO4  ×  6H2O (0.5–5  μg/ml). IL-2, IL-5, IL-13 and IFN-γ 
concentrations were measured in supernatants with multiplex flow 
cytometry CBA Flex Array.
Results: We showed a significantly increased secretion of IL-2 (median 
182 vs 3 ng/ml), IL-5 (9 vs 0 ng/ml), IL-13 (36 vs 0.5 ng/ml) in response 
to NiSO4 ×  6H2O in patients nickel hypersensitivity when compared 
with healthy controls. The response in the patients was concentration 
dependent. No difference was evident for IFN-γ. The ROC curve analy-
sis demonstrated the highest AUC of 0.99 for IL-2 and IL-13, followed 
by AUC of 0.91 for IL-5.
Conclusions: The measurement of IL-2 and IL-13 appearing to be a 
superb approach to identify antigen reactive T cells in the peripheral 
blood of patients with the hypersensitivity reactions. This cytokine 
approach could be now tested on the clinical important issue of the 
diagnosis of the delayed-type hypersensitivity reactions to drugs.
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Background: T cell mediated drug hypersensitivity requires three 
essential components, a target drug, a scaffold for the drug (MHC class 
I or class II) and a pathogenic T cell receptor (TCR). For several drugs 
including, abacavir and carbamazepine, two components of this tri-
molecular complex have been defined. For abacavir hypersensitivity 
reaction (HSR) the associated MHC is HLA-B*57:01 and for carbamaz-
epine induced Stevens–Johnson syndrome/toxic epidermal necrolysis 
(SJS/TEN), the associated MHC is HLA-B*15:02. In the former instance 
the association of drug with MHC has been further defined with the 
successful resolution of the crystal structure of the abacavir com-
plexed to HLA B57:01.
To fully understand T cell mediated hypersensitivity reactions the 
nature of the T cells involved and ultimately the mechanism by which 
the TCR interacts with MHC plus drug must be elucidated. This study 
seeks to sequence and clone the TCR mediating drug hypersensitivity 
in response to a series of drugs.
Materials and methods: Working from a cohort of cryopreserved 
PBMCs on HLA-typed patients with confirmed histories of T-cell 
mediated drug hypersensitivities (abacavir hypersensitivity and 
carbamazepine SJS/TEN and DRESS) we performed flow cytometry, 
single cell cloning and single cell TCR sequencing and used these to 
develop and interrogate T-cell responses. PBMC samples with con-
firmed T-cell reactivity (ELISpot) were treated with drug for 18–20  h. 
Upregulation of the activation marker CD137 was used to sort drug 
reactive CD8+ or CD4+ T cells. T-cells lines or clones were produced 
and individual T-cells were sorted for single or bulk TCR sequencing.
Results: We have developed a pipeline for the identification of patho-
genic TCRs. T-cell lines maintained reactivity to candidate drugs. TCR 
sequencing from abacavir HSR patients (n  =  3) identified no public 
TCR, rather multiple putative pathogenic TCRs have been identified. 
For carbamazepine induced SJS/TEN (n  =  1) and DRESS (n  =  1) we 
have also identified multiple putative pathogenic TCR.
Conclusions: Several candidate pathogenic TCRs have been identified 
in patients with hypersensitivity to abacavir or carbamazepine. These 
putative TCRs will be cloned into Jurkat T-cell lines to determine if 
multiple T-cell clones contribute to hypersensitivity or if only a single 
clone in each patient is pathogenic. Ultimately these cloned TCR will 
be used to define the crystal structure of the trimolecular complex of 
drug/MHC/TCR.
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Background: DRESS (drug reaction with eosinophilia and systemic 
symptoms) is a severe cutaneous adverse reaction (cADR). Causality 
assessment is often a problem in polymedicated patients. The prob-
ability algorithm of the Spanish Pharmacovigilance System (Capellá 
and Laporte 1993) establishes different categories of causality after 
scoring of chronology, bibliography, drug withdrawal, re-exposure, 
and alternative causes (unlikely: <0, conditional: 1–3; possible 4–5, 
probable: 6–7, definite: >8). LTT has been used as a tool to deter-
mine the causality of cADR. LTT specificity and sensitivity are difficult 
to ascertain as the gold standard (re-challenge) is not acceptable in 
severe cases.
Materials and methods: A total of 34 LTT assays were performed with 
suspected drugs in 15 DRESS cases included in the Spanish registry 
PIELenRED. Results were considered positive if stimulation indexes (SI) 
were ≥2, except for betalactam antibiotics (SI ≥ 3) or iodinated con-
trast media (SI ≥ 4). The Spanish Pharmacovigilance System algorithm 
(SPA) was applied and suspected drugs were divided into two catego-
ries: unrelated (SPA score ≤3) and related (SPA score ≥4).
Results: Positive LTT results were obtained in all patients. In 19 out 
of 23 positive LTT assays the drugs were related to the adverse reac-
tion (SPA score ≥4). Ten out of the 11 drugs that tested negative were 
predicted to be unrelated to the adverse reaction (SPA score ≤3). A 
contingency table was built (Table 9). Fisher’s exact test was used to 
analyze the data. There was a significant agreement between the 
two methods (OR 47.5; 95  % CI 3.9–1342.94). If the pharmacovigi-
lance algorithm was considered as gold standard, 95 % sensitivity and 
71 % specificity were obtained for LTT assays, with a positive predic-
tive value (PPV) = 82 % and negative predictive value (NPV) = 90 % 
(p < 0.001). On the other hand, if LTT was considered as gold standard, 
82 % sensitivity and 90 % specificity was obtained for the SPA, with a 
PPV = 90 % and NPV = 70 % (p < 0.001).
Conclusions: Although this is a small case series, the results indicate 
that LTT is a sensitive tool for causality assessment in DRESS. Moreover, 
the probability algorithm of the Spanish pharmacovigilance system 
can be useful to identify the culprit drug during the acute disease.
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Background: Antigen-specific T cells are important in the aetiology 
of cutaneous drug hypersensitivity. Classical Th1/Th2 phenotypes are 
used to classify drug hypersensitivity reactions, though these do not 
fully characterise the function of immune cells as the newer Th subsets 
such as Th9, Th17 and Th22 have not been studied.
Materials and methods: The aim of this study was to use the β-lactam 
antibiotic piperacillin as a paradigm to fully characterise the pheno-
type and function of drug-specific T cells. T cells were cloned from 
both blood and inflamed skin of hypersensitive patients and naïve T 
cells from healthy donors were primed to piperacillin using dendritic 
cells.
Results: Drug-specific clones were generated from both blood 
(n = 570, 84 % CD4) and skin (n = 96, 83 % CD4) from patients hyper-
sensitive to piperacillin. All clones secreted high levels of IFNγ and IL13 
following drug stimulation. Interleukin-22, perforin and granzyme B 
were also secreted by over 50 % of clones. In contrast, IL17A secretion 
was not detected. Naïve T cells primed to piperacillin using autologous 
dendritic cells, proliferated in the presence of drug (p = 0.001, SI > 2) 
and had a similar pattern of cytokine secretion to clones generated 
from hypersensitive patients. Significant differences in chemokine 
receptor expression were observed between the different popula-
tions of T cell clones. CLA, CXCR6 and CCR1 expression was higher 
on piperacillin-specific skin-derived clones when compared to non 
piperacillin-specific skin-derived clones (p = 0.01). CCR2, CCR4, CXCR1 
and E-cadherin were higher on skin-specific clones when compared 
to blood-specific clones (p  =  0.01). Piperacillin-specific clones iso-
lated from blood and skin of hypersensitive patients, as well as piper-
acillin-specific T cells from healthy donors migrated in the presence 
of chemokines specific to their respective cell surface receptors, with 
migration to CCR4 and CCR10 most prevalent. Finally, regulation of the 
cytokine secretion through modulation of nuclear receptor signalling 
was studied. Inhibition of the aryl hydrocarbon receptor during naïve T 
cell priming abrogated the drug-specific cytokine response.
Conclusions: Our data describe a subset of piperacillin-specific T-cells 
that secrete IL-22, IFNγ, perforin and granzyme B, but not IL-17, in 
response to antigen challenge. Taken together this suggests that IL-22 
is important in the progression of β-lactam hypersensitivity.
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Background: Glycopeptide antibiotics, vancomycin and teicoplanin, 
share a similar structure and are the mainstay of therapy for severe 
gram-positive organisms. Hypersensitivity responses to vancomycin 
are well recognised but the risk of cross-reactivity with teicoplanin is 
unclear. Our study aims to examine the role of T cell responses in van-
comycin hypersensitivity reactions and explore the potential for cross-
reactivity between vancomycin and teicoplanin.
Materials and methods: Our cohort comprised of vancomycin 
exposed allergics who had suffered delayed skin drug hypersensitivity 
reactions n = 17; non-allergic previously vancomycin exposed controls 
n = 5; and vancomycin naïve controls n = 12. We tested ex vivo drug 
induced lymphocyte proliferation and cytokine release. Vancomycin-
specific T cell lines were grown to test for teicoplanin cross-reactivity.
Results: In our cohort of vancomycin allergics, vancomycin hyper-
sensitivity reaction patterns were drug exanthems (47.1  %), DRESS 
(29.4  %), or SJS/TEN (23.5  %). Circulating IFN-γ vancomycin-specific 
T cells were identified at higher frequency than naïve controls: (IFN-γ 
p < 0.0001; SI p = 0.042). Interestingly, detectable frequencies in van-
comycin exposed controls were higher than naïve controls (p < 0.0001; 
SI p = 0.12) suggesting that low frequency responses were the result 
of vancomycin priming even in the context of a non-allergic individ-
ual. This was confirmed by the expansion of short term T cell lines in 
vancomycin exposed controls (IFN-γ p =  0.008; SI p =  0.016). Cross-
reactivity against teicoplanin was found to be minimal (42.7 × 10−4 % 
IFN-γ and SI 1.0 in vancomycin-specific T-cell lines compared to 
48 × 10−4 % IFN-γ and SI 1.3 in non-vancomycin-specific T-cells lines).
Conclusions: Circulating vancomycin specific-T cell frequencies 
were found to be higher in vancomycin allergics than vancomy-
cin exposed controls, which in turn were higher than naïve controls. 
Using vancomycin-specific T cell lines we did not see any evidence of 
teicoplanin cross-reactivity despite the similar molecular structures 
of the two drugs. We also showed that low-level of vancomycin-spe-
cific responses identified ex  vivo in exposed controls were able to 
efficiently expand on short term culture, confirming that they were 
genuine vancomycin-specific T cells. This suggests both immune 
predisposition and potentially adaptive regulation may be impor-
tant in regulating the development of hypersensitivity reactions to 
vancomycin.
Keywords: Drug hypersensitivity reactions; T cell; Vancomycin; In-vitro 
diagnostic tests
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Table 9 Drug causality data in DRESS patients







Positive LTT 19 4 23
Negative LTT 1 10 11
Total 20 14 34
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Background: Neuromuscular blocking agents (NMBAs), latex and anti-
biotics are the most frequent agents causing hypersensitivity reactions 
(HR) in the perioperative setting, followed by hipnotics and opioid 
analgesics. The diagnostic approach is complex and relies on sugges-
tive history and skin tests (ST), since basophil activation test (BAT) has 
not yet been validated and drug provocation test has limited indica-
tions because of the pharmacological effects of these drugs. Our aim 
was to characterize a series of subjects with suspected HR during gen-
eral anaesthesia (GA) and to evaluate the concordance between ST 
and BAT in patients submitted to both diagnostic procedures with the 
suspected drugs: fentanyl (F), propofol (P) and rocuronium (R).
Materials and methods: Retrospective analysis of medical records 
from patients referred to our department, from 2009 to 2015, with 
suspected HR during GA. The data collected were: demographic data, 
atopy, clinical manifestations, results from ST and BAT. ST and BAT 
were performed in the following concentrations: 0.05 mg/ml for F and 
10 mg/ml for P and R (SPT); 1/100 dilution for R and 1/10 for F and P 
(ID); 25, 12.5 and 6.25  μg/ml for F; 100, 50 and 10  μg/ml for P; 10, 5, 
2.5 μg/ml for R (BAT).
Results: From a total of 34 patients referred to our department, we 
enrolled 15: mean age 44 (± 21) years; 8 female; 5 atopic; 1 had asthma 
and 3 had hypertension. Cutaneous reactions were reported by 7 
patients, anaphylaxis by 6 and isolated respiratory symptoms by 2. BAT 
and ST to F were performed in 12 patients, to P in 13 and to R in 12. SPT 
and ID performed with F (12) and P (13) were all negative. In the case of 
R SPT were positive in 1 out of 12 tests and ID were positive in 2 out of 
11. TAB performed with F (12) was negative in 10 cases, positive in 1 and 
in determined in another one. TAB performed with P (13) was negative 
in 9, positive in 3 and indetermined in 1. In the case of R (12) TAB was 
negative in 10 and positive in 3. Results to ST and BAT were concordant 
in 83 % of patients tested with F, 69 % with P and 67 % with R. Allergy 
was excluded by subsequently administration of the suspected drugs in 
5 patients (1 F, 4 P). One of them had negative ST and positive BAT (P).
Conclusions: ST and BAT to the suspected drug were concordant in 
the majority of cases (83 % F, 69 % P, 67 % R). According to this results 
BAT seems to be a valuable contribution in the diagnostic approach of 
these patients.
Keywords: Basophil activation test; General anaesthesia
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Background: The mechanism of drug desensitization is scarcely 
understood. The aim of the study is to observe the cytokine lev-
els in the serum of patients who underwent a successful drug 
desensitization.
Materials and methods: Patients with a hypersensitivity reaction to 
any culprit drug and therefore has to be desensitized with the drug 
were included into the study. IL-4, IL-5, IFN γ and IL-10 levels were 
determined with ELISA in the peripheral serum samples of the patients 
before the desensitization to any culprit drug and within 24  h after 
the procedure. The results were compared with the serum samples of 
patients who could tolerate the same drugs and healthy subjects who 
were not exposed to these drugs.
Results: 26 patients who experienced allergic reactions due to vari-
ous drugs and therefore had to be desensitized, 10 patients who 
could tolerate the same drugs and 5 healthy subjects were included. 
The diagnosis of the patients were as follows: malignancy (14 
patients), multiple sclerosis (2 patients), metabolic storage disorders 
(2 patients), iron salt deficiency (2 patients) and Basedow Graves dis-
ease (1 patient), coronary heart disease (1 patient), and congenital 
adrenal hyperplasia (1 patient). The drugs used for desensitization in 
the order of the most frequent to the least were as follows: paren-
teral or per oral chemotherapeutics, aspirin, corticosteroids, storage 
enzymes, iron salts and anti-thyroidal drugs. Skin prick tests were 
positive in 5 patients with parenteral chemotherapeutics, 2 patients 
with iron salts, 2 patients with storage enzymes and in one patient 
with methylprednisolone. The baseline cytokine levels were not 
statistically different between the three groups. The desensitization 
was not successful in 4 of the patients and because of this insuffi-
cient patient number their cytokine levels were not further analyzed. 
The IL-10 levels after the successful desensitization procedure in 22 
patients significantly increased when compared to their baseline 
levels (p: 0.006). The rise in IL-10 levels were greater in chemothera-
peutic desensitizations than the desensitizations with other drugs 
(p: 0.005) whereas the other three cytokines did not significantly 
change.
Conclusions: Successful desensitization can be related with increase 
in IL-10. In order to further elucidate the mechanism of successful 
desensitization, cells secreting IL-10 should be examined.
Keywords: IL-10; Desensitization
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Background: The incidence of allergic reactions to proton pump 
inhibitors (PPI) has increased in recent years. Most publications 
describe isolated cases and limited data are available about the 
value of skin tests. Therefore, the diagnostic approach is the drug 
provocation test (DPT), which is not risk free, especially for severe 
reactions. The aim of the study was to assess the value of the baso-
phil activation test (BAT) for the diagnosis of immediate allergic reac-
tions to PPI.
Materials and methods: We evaluated 49 patients with immediate 
allergic reactions to PPI. Twenty-two subjects with good tolerance to PPI 
were included as controls. Patients with anaphylaxis or shock were diag-
nosed by clinical history, once other possible causes were ruled out, and 
those with urticaria-angioedema or pruritus, by DPT. BAT with omepra-
zole and pantoprazole at 3 different concentrations (2, 0.2 and 0.02 mg/
ml) using CD193 (CCR3) and CD203c for basophil selection and CD63 as 
activation marker, was performed in all patients and controls.
Results: The PPIs involved were omeprazole (N =  43), pantoprazole 
(N = 1) lansoprazole (N = 2) and esomeprazole (N = 2), one patient 
had two reactions, one with omeprazole and other one with pantopra-
zole. A total of 20 cases (40.81 %) reported anaphylaxis, 12 (24.48 %) 
anaphylactic shock, 13 (26.53 %) urticaria-angioedema, and 4 (8.16 %) 
pruritus. BAT was positive in 36 cases (73.46 %): 14 to omeprazole and 
pantoprazole (28.5 %), 19 to omeprazole (38.7 %) and 3 to pantopra-
zole (6 %). BAT was negative in control patients, indicating a specificity 
of 100 %. BAT sensitive was 82 %.
Conclusions: Immediate hypersensitivity reactions to PPI do occur, 
with omeprazole being the most frequently involved. Anaphylaxis is 
the most common clinical entity. BAT is a useful method for diagnos-
ing these patients with a good sensitivity and specificity.
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Background: There is no consensus on an optimal cutoff point (COP) 
of blood tryptase during the reaction (TDR) to discriminate IgE- from 
non-IgE-mediated reactions. We aimed to compare the diagnostic 
accuracy between TDR and TDR/basal tryptase (TDR/BT) index for dis-
criminating IgE- from non-IgE-mediated reactions, and to estimate a 
COP for the best of these tests.
Materials and methods: Patients with an immediate allergic reaction 
treated in Clínica Universidad de Navarra (Spain) from 2009 to 2015. 
Allergological study was performed to classify the reaction into IgE- or 
non-IgE-mediated. The area under de curve (AUC) of the receiver oper-
ating characteristic (ROC) analysis was calculated to indicate the dis-
criminative power of each test.
Results: We included 102 patients (45 % men; aged 3–99 years; 48 % 
with IgE-mediated reaction; 54  % with anaphylaxis criteria) who had 
an allergic reaction (emergency room, n = 27; hospitalization, n = 15; 
perioperative, n = 44; other hospital areas, n = 16).
The median TDR for the IgE-mediated reactions was 7.6 µg/l (p25–75: 
4.9–13.8 µg/l) and 5.2 µg/l (p25–75: 3.6–7.5 µg/l) for the non-IgE-medi-
ated reactions (p = 0.047).
The median TDR/BT ratio was 2.6 (p25–75: 1.7–4.3) in IgE-mediated 
reactions and 1.2 (p25–75: 1.0–1.6) in non-IgE-mediated reactions 
(p = 0.001).
The TDR/BT ratio showed the greatest ability to discriminate IgE from 
non-IgE meditated reactions compared with TDR (AUC TDR/BT = 0.78 
and AUC TDR = 0.65; p = 0.003). The optimal COP for TDR/BT to dis-
criminate between IgE and non-IgE reactions was 1.66.
Conclusions: TDR/BT ratio showed a significantly better diagnostic 
performance than TDR to discriminate IgE from non-IgE mediated 
allergic reactions. An optimal TDR/BT ratio threshold around 1.7 may 
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Background: Fluoroquinolones (FQ) are the second most frequent 
cause of hypersensitivity to antibiotics after betalactams. Most reac-
tions induced by FQ were immediate. For the in  vitro diagnosis only 
the basophil activation test (BAT) has shown to be useful although with 
suboptimal sensitivity. The aim of our study was to analyze the BAT to 
FQ using two different activations markers, CD63 and CD203c, in the 
evaluation of patients with immediate allergic reactions to these drugs.
Materials and methods: Seventeen patients with confirmed immedi-
ate allergic reactions to FQ (6 to Ciprofloxacin and 11 to Moxifloxacin) 
were included in the study. Eighteen controls with tolerance to FQ 
were also included. BAT was performed with Moxifloxacin and Cip-
rofloxacin at 2 and 0.2  mg/ml using CD203c and CD63 as activation 
markers. Positive results were considered when SI > 3 to at least one of 
the concentrations used in the test.
Results: Data indicated that although both Ciprofloxacin and Moxi-
floxacin are able to induce both activation marker expression (CD63 
and CD203c), there is a predominance in the expression of each one 
depending on the drug included in the test. Thus Ciprofloxacin was 
able to mainly increase the expression of CD63 (40  %, p  =  0.0053) 
whereas Moxifloxacin mainly increase the expression of CD203c (10 %). 
In addition, analyzing the expression of both markers in basophils 
from Moxifloxacin allergic patients stimulated with the culprit drug, 
we found a higher expression of CD203c in patients suffering anaphy-
lactic shock (7 %), whereas was CD63 the marker that showed a higher 
up-regulation in patients with anaphylaxis (17  %). When we analyzed 
the sensitivity and specificity of the test using these activation mark-
ers we can see that the best results were observed using the culprit 
drug and CD203c as activation marker for Moxifloxacin (S = 36.4 % and 
E = 94.4 %) and CD63 for Ciprofloxacin (S = 83.3 % and E = 88.9 %).
Conclusions: The BAT must be performed using the culprit drug and 
CD203c for Moxifloxacin or CD63 for Ciprofloxacin as activation marker 
to diagnose Quinolone Allergy. Although this differential expression 
of both activation markers seems to be also related with the culprit 
drug and clinical entity. Using this criteria and a cut-off of 3, we have 
obtained a better sensitivity for Ciprofloxacin.
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Background: Celecoxib, is a specific COX-2 inhibitor which is an alter-
native treatment for patients with intolerance to NSAIDs.
Report: We present two cases of anaphylaxis due to Celecoxib. The 
first is a 57 year old male who was taking Celecoxib as an alternative 
medication for sciatic pain since he had poor gastric tolerance with 
NSAIDs. He had a history of idiopathic recurrent urticaria. He had an 
episode of anaphylactic shock 30 min after taking 1 tablet of Celecoxib 
which prompted him to sought consult at the emergency room 
wherein he was administered with Epinephrine IM. On follow up after 
1 month, prick test with Celecoxib revealed negative. Because the sus-
picion that the reaction was caused by allergy to Anisakis, a challenge 
test with Celecoxib was done that resulted positive, and epinephrine 
was administered. Basophil activation test was positive with Celecoxib 
and negative to Parecoxib. Two months later, he presented with hives 
2 h after taking 750 mg of acetylsalicylic acid (ASA). Tolerance test with 
Meloxicam and Nabumetone were performed which the patient toler-
ated well.
The second case is a 58 year old male who had an episode of anaphy-
laxis 3  h after taking Celecoxib for headache. Tryptase was elevated, 
19.9  μg/l. A month earlier, he had generalized itching after taking 
one tablet of celecoxib. He took Metamizol previously which he tol-
erated well. No history of atopy nor allergy to medications. Skin tests 
to NSAIDs were negative. Basophil activation test was positive with 
celecoxib and negative to ASA, Metamizole, Paracetamol, Parecoxib 
and Dexketoprofen. He underwent challenge test with Aspirin with 
positive result. Both patients were diagnosed with intolerance to 
NSAIDs and anaphylaxis secondary to Celecoxib.
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How this report contributes to current knowledge: Anaphylaxis 
due to Celecoxib is considered a rare entity as patients with intoler-
ance to NSAIDs usually tolerate Celecoxib and other COX-2 inhibitors. 
The positive result in the basophil activation test together with a com-
patible clinical history makes us hypothesize that these are cases of 
a selective hypersensitivity to Celecoxib, instead of the fact that both 
patients were finally NSAIDs intolerant. Hence, BAT can be useful for 
the diagnosis, given the low sensitivity of skin tests.
Consent: Written informed consent was obtained from the patient for 
publication of this abstract and any accompanying images.
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Background: Basophil activation test (BAT) is reported to be a use-
ful and very promising technique in the diagnosis of immediate type 
drug hypersensitivity reactions. It is used in combination with in vivo 
and in vitro diagnostic tools and may contribute to the sensitivity of 
the diagnostic work out.
Materials and methods: In order to investigate the role of BAT in the 
diagnosis of immediate type drug hypersensitivity to betalactam anti-
biotics we analyzed all BATs performed with betalactam antibiotics in 
our department during the period from 2009 to 2012. We compared 
the results of in  vivo diagnostics (skin prick test, intracutaneous test, 
patch test) and in vitro diagnostics (specific IgE) with the results of the 
BAT under the aspect, if BAT represent a useful tool for assessment 
of the individual risk of the patient to experience another immediate 
type drug hypersensitivity reaction on reexposure to the tested drug.
Results: We performed BAT with betalactam antibiotics in 64 cases: 
20 % (n = 13) with penicillin (PEN), 38 % (n = 24) with aminopenicilins 
(AMP) and 42 % (n = 27) with cephalosporins (CPH).
In the PEN-group 23 % (n = 3) of the patients had at least one positive 
in vivo test, but negative BAT and 15 % (n = 2) had positive BAT, but 
negative in vivo tests.
In the AMP-group 17  % (n =  4) of patients had at least one positive 
in vivo test, but negative BAT and 17 % (n = 4) had positive BAT, but 
negative in vivo tests. Only 8 % (n = 2) of patients had positive both 
BAT und at least one in vivo test. 4 % (n = 1) of patients had both posi-
tive at least one in vivo test and specific IgE, but negative BAT.
In the CPH-group 22 % (n = 6) of the patients had positive BAT, but no 
other positive test results and 4 % (n = 1) had positive both BAT und at 
least one in vivo test.
Conclusions: In case of the negative in  vivo and in  vitro test results 
(inclusive BAT) the individual risk of the patient to experience another 
immediate type drug hypersensitivity reaction on reexposure to the 
tested drug was considered to be low, so drug provocation test (DPT) 
as the next diagnostic step was recommended: from overall of 41 such 
cases DPT was performed in 32 % (n = 13) and was unremarkable in 
100 % (n = 13).
Our results confirm that BAT may be an important tool to increase the 
sensitivity of the diagnostic and make the better risk assessment pos-
sible. However, the limitation of this study is that we didn’t perform 
DPT in patients with positive in vivo or in vitro results and therefore are 
not able to estimate the frequency of false positive BATs.
Frequency of positive in vivo and in vitro results in the diagnostic work 
out of immediate type drug hypersensitivity reactions to betalactam 
antibiotics in Department of Dermatology and Allergology at the Univer-
sity Hospital of Aachen, Germany during the period from 2009 to 2012.
Positive BAT results in patients with negative in vivo tests and specific 
IgE may provide important information for assessment of the indi-
vidual risk of the patient to experience another immediate type drug 
hypersensitivity reaction on reexposure to the tested drug (Table 10).
Keywords: Basophil activation test; Betalactam antibiotics; Immediate 
type drug hypersensitivity
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Background: The factors governing inter-individual susceptibility to 
drug hypersensitivity remain ill-defined. Although the association of 
specific HLA alleles with hypersensitivity is important, for most drugs, 
the majority of individuals who are positive for an HLA risk allele do 
not develop a reaction. Thus, predisposition is likely mediated by other 
parameters, which may include T-cell co-inhibitory pathways. As poly-
morphisms in co-inhibitory pathways are associated with dysregu-
lated immune responses, we investigated the role of these pathways 
during drug (SMX-NO)-specific T-cell responses. Programmed death-1 
(PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4) are 
considered to be key immune checkpoints, and TIM-3 is of current 
interest due to its reported upregulation alongside PD-1.
Materials and methods: Naïve and memory T-cells from healthy 
donors were incubated for 8  days with SMX-NO and dendritic 
cells ± PD-L1, CTLA4, TIM-3 blocking antibody. Antigen-reactivity was 
then assessed by T-cell cytokine secretion and proliferation. Cell phe-
notype was assessed by flow cytometry. T-cell clones were then gener-
ated from these cultures.
Results: While blockade of PD-L1 or CTLA4 enhanced the activation of 
SMX-NO-primed naïve T-cells, only the blockade of CTLA4 enhanced 
the proliferative response of antigen-stimulated memory T-cells sug-
gesting a greater regulatory role for CTLA4 during secondary T-cell 
responses. Blockade of TIM-3 had no effect on T-cell activation of 
either naïve or memory cells. While all receptors were upregulated on 
T-cells after antigen exposure, PD-1 was upregulated at earlier time 
points than CTLA4 and TIM-3 indicating a differential role for these 
receptors during early and late stage T-cell activation. High expression 
of individual co-inhibitory receptors has previously been associated 
with exhausted T-cells, while other studies indicate that these cells 
are highly functional. We found no correlation between the level of 
Table 10 The role of basophil activation test in the diagno‑
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individual co-inhibitory receptor expression and the strength of T-cell 
activation in the T-cell clones.
Conclusions: Drug-induced stimulation of naïve T-cells was signifi-
cantly enhanced by blocking PD-L1 or CTLA4. However, the co-inhib-
itory pathways did not have a great effect on memory T-cell responses. 
Any differences in the control of the different T-cell co-inhibitory path-
ways may be important in determining whether a particular individual 
develops a hypersensitivity response to a drug.
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Background: Piperacillin is a b-lactam frequently used to combat bac-
terial infections in patients with cystic fibrosis. However, its use is asso-
ciated with high incidence of delayed-type hypersensitivity reactions. 
Previous studies have identified lymphocyte proliferative responses 
and cytokine secretion from PBMCs isolated from approximately 75 % 
of hypersensitive patients but not from tolerant controls. The drug 
forms a hapten that binds covalently to specific lysine residues on 
serum albumin (HSA).
Aim: To generate a synthetic piperacillin-HSA conjugate and to quan-
tify the level of modification at specific lysine residues. Furthermore, 
the activation of T-cells with free drug and the drug-protein conjugate 
was assessed.
Materials and methods: Piperacillin was incubated with HSA at dif-
ferent molar ratios (10:1–250:1 drug:protein). Mass spectrometry was 
used to characterize modification at specific lysine residues. PBMCs 
from hypersensitive patients were cultured in the presence of parent 
drug and the piperacillin-HSA conjugate and T-cell clones generated 
by serial dilution. T cell clones were analysed for antigen-specific pro-
liferative responses, cytokine release and TCR-Vb usage.
Results: Cyclised and hydrolysed forms of piperacillin hapten were 
detected on over 10 lysine residues of HSA. Quantitative analysis 
revealed that 3–23 % of lysine 541 was modified with piperacillin hap-
tens. Sixty CD4+ clones displayed reactivity against piperacillin-mod-
ified HSA but did not respond to free piperacillin or to other b-lactam 
HSA adducts. T cell activation was dependent on protein processing by 
antigen presenting cells and the level of modification with the pipera-
cillin hapten, as low levels of modification failed to activate the clones. 
A further sixty CD4+ clones were responsive to free piperacillin and 
were not activated with the piperacillin-HSA conjugates. T-cell clones 
secreted a variety of molecules: IFN-γ (72 % of clones), IL5 (48 %), IL13 
(37 %), perforin (48 %), granzyme B (26 %) and FasL (52 %) and showed 
a restricted expression of TCR-Vb9 (68 %).
Conclusions: We have shown that drug hapten-responsive CD4+ 
T-cells with divergent antigen specificities circulate in hypersensitive 
patients. These data have important implications for studies inves-
tigating the nature of the drug antigen. It is necessary to synthesize 
conjugates with different drug haptens to fully investigate the antigen 
specificity of the T-cell repertoire.
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Background: Telaprevir is antiretroviral drug developed for the treat-
ment of hepatitis C. Human exposure is associated with a high fre-
quency of cutaneous side effects varying in severity from mild rash 
(56  %) to Stevens Johnson syndrome/toxic epidermal necrolysis 
(<1  %). Telaprevir interconverts to an R-diastereomer (VRT-127394), 
which is the major metabolite. There is no known HLA risk allele asso-
ciated telaprevir hypersensitivity. However, this does not rule out a 
role for antigen-specific T-cells in mediating hypersensitivity.
Aim: The aims of this study were to (1) generate T-cell clones with 
specificity for telaprevir and/or its metabolite and (2) explore the 
nature of the induced response.
Materials and methods: The optimal T-cell priming concentration 
of telaprevir and its metabolite was identified using a PBMC toxicity 
assay. Naïve T-cells from 3 normal volunteers were primed with autol-
ogous dendritic cells (DCs) and telaprevir or VRT-127394 for 10  days. 
Alternatively, PBMCs from 3 normal volunteers were cultured with 
telaprevir or VRT-127394 for 14  days. T-cells from both experimen-
tal procedures were cloned by serial dilution and repetitive mitogen 
stimulation. T-cell proliferative responses were assessed using [3H] thy-
midine incorporation and IFN-γ. Antigen-specific clones were pheno-
typed for CD4, CD8 and TCR Vb expression.
Results: T-cell responses to telaprevir or VRT-127394 were not 
detected using the DC priming assay. However, 13 telaprevir-respon-
sive T-cell clones were isolated from PBMC cultures from one volun-
teer. All 13 clones were stimulated to proliferate in the presence of 
telaprevir and its metabolite in a dose-dependent manner at a simi-
lar concentration range. Clones were not activated in the presence of 
antigen presenting cells pulsed with telaprevir for 1–16  h. 11 clones 
secreted IFN-γ when activated with telaprevir. 10 clones were CD4+ 
and 3 were CD8+. Clones expressed a restricted pattern of TCR-Vb 
which was dominated by Vb2 and Vb22.
Conclusions: The data presented here shows that telaprevir-respon-
sive T-cells were detected in healthy volunteers. CD4+ and CD8+ 
clones were activated with both telaprevir and the major metabolite 
VRT-127394. Future work will focus on assessing the nature of the 
T-cell response in hypersensitive patients.
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Background: The strongest associations reported to date between 
adverse drug reactions and specific Human Leukocyte Antigen (HLA) 
allotypes are between HLA-B*57:01 and abacavir hypersensitivity 
syndrome, HLA-B*58:01 and allopurinol hypersensitivities, and HLA-
B*15:02 and carbamazepine induced Stevens–Johnson Syndrome/
Toxic Epidermal Necrolysis. A lesser association also exists between 
HLA-A*31:01 and carbamazepine induced hypersensitivities. In this 
study we examined the diversity of the T cell response to these drugs 
(and metabolites) by characterising the T cell receptor (TCR) signatures 
of drug-responsive CD8+ T cells at a single cell level in patients and 
healthy donors. These studies were complimented by analyses of the 
diversity and perturbation of the HLA peptide repertoire following 
drug/metabolite exposure.
Materials and methods: To characterise drug responsive TCR signa-
tures, peripheral blood mononuclear cells were stimulated with the 
parent drug or metabolite in vitro and drug-responsive T cells char-
acterized (phenotype and function) by flow cytometry. Single-cell 
flow cytometric sorting of drug-responsive CD8+ T cells was per-
formed prior to a paired analysis of TCR alpha and beta chain varia-
ble regions using a novel multiplex nested RT-PCR methodology. To 
assess the influence of drugs/metabolites on peptide presentation 
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by HLA molecules, HLA transfected B-Lymphoblastoid cell lines were 
grown to high density in the presence of the molecule of interest. 
5–10 ×  108 cells were harvested, the HLA molecules immunoaffin-
ity purified, and the peptide/small molecule ligands dissociated and 
analysed using Liquid Chromatography Tandem Mass Spectrometry.
Results: Our data demonstrated that the TCR signatures for abacavir-
responsive CD8+ T cells were oligoclonal, correlating with previous 
reports of a large and diverse perturbation in HLA-B*57:01 peptide 
repertoire during abacavir exposure. Interestingly, whilst both carba-
mazepine and allopurinol hypersensitivities are postulated to occur 
via a direct interaction of the HLA-peptide-drug-TCR at the cell sur-
face, and cause minimal change of the HLA peptide repertoire, their 
TCR usage profiles are divergent with carbamazepine being more 
restricted and allopurinol/oxypurinol exhibiting greater diversity.
Conclusions: These data suggest a spectrum of diversity in the T cell 
response that may correlate with altered modes of drug presentation 
in HLA associated drug hypersensitivity.
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Background: An association between HLA genotype and the devel-
opment of certain forms of DILI is well established. Furthermore, it 
is now apparent that drug-specific T-cells are activated in certain 
patients with DILI. The cross-talk signals between hepatocytes and the 
immune cells resident in the liver and circulation are likely to be criti-
cal in determining the outcome of drug exposure and development 
of immune-mediated DILI. However, tissue-specific immune signal-
ling with respect to human DILI remains largely unexplored. Thus, the 
aim of this study was to profile the signals released by fresh human 
hepatocytes upon drug exposure and to characterise the impact of 
these molecules (cytokines and chemokines) on the phenotype and 
function of antigen presenting cells (APC).
Materials and methods: Fresh human hepatocytes were exposed to 
three test compounds implicated in DILI (flucloxacillin, amoxicillin and 
isoniazid) and one reactive metabolite, nitroso-sulphamethoxazole 
(SMX-NO), and end-points of hepatocyte toxicity, cell viability and oxi-
dative stress assessed.
Results: HMGB1 and LDH release as well as ATP depletion occurred 
in a drug- and concentration-dependent manner. Furthermore, com-
pound-specific activation of Nrf2 marker genes was observed with 
each of the test drugs. SMX-NO differentially induced the expression 
of NQO1, TXNRD1 and SRXN1 responsible for cytoprotection against 
chemically reactive metabolites. Also, the expression of AKR1B10, 
SRXN1 and LOC344887 were significantly increased by all the test 
compounds. Hepatocytes cultured with test drugs released a mixture 
of pro-inflammatory (IFN-γ, GM-CSF, IL-12p40, IL-12p70, IL-1β, TNF-α, 
TNF-β, IL-8 and MCP-1) and anti-inflammatory cytokines (IL-1RA, IL-10 
and IL-13). Co-culture of APC with supernatant from drug treated 
hepatocytes resulted in a highly drug-dependent release of cytokines 
as well as significant changes in expression of MHC class II and CD86 
on the cell surface of dendritic cells.
Conclusions: In conclusion, our study begins to define the various fac-
tors that might be important in determining whether drug exposure 
in patients results in an immune response and tissue injury. We found 
that cross-talk signals were highly drug specific. The development of a 
liver/immune cell culture system will be an important step forward in 
advancing our understanding of the molecular mechanisms underlin-
ing the development of idiosyncratic DILI.
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Background: Exposure to the reverse transcriptase inhibitor abacavir 
has been associated with hypersensitivity reactions mediated by 
CD8+ T-cells in individuals carrying the human leukocyte antigen 
(HLA-B*57:01) risk allele. It has been shown that abacavir can interact 
directly with the antigen binding cleft of HLA-B*57:01, altering its con-
formation and thereby causing an alteration of the peptides displayed 
on the cell surface. It has been hypothesized that these alternative 
self-peptide sequences trigger the CD8+ T-cell response in abacavir 
hypersensitive patients.
We examined whether it is possible to synthesize compounds that 
retain antiviral activity, but do not bind to HLA-B*57:01 and activate 
CD8+ T-cells.
Materials and methods: Twenty-five abacavir analogues were syn-
thesized with modifications around the cyclopropyl group with com-
pounds divided into three main groups. Abacavir responsive CD8+ 
T-cell clones were generated from healthy donors positive for the 
HLA-B*57:01 risk allele. IFN-g secretion was measured when the clones 
were cultured in the presence of autologous antigen presenting cells 
and abacavir or abacavir analogues using an ELISpot assay. Anti-viral 
activity of the analogues was assessed using a range of established 
assays. In silico docking studies were carried out to find potential 
binding orientations of the abacavir analogues within the F-pocket of 
HLA-B*57:01.
Results: CD8+ T-cell clones proliferated and secreted IFN-g in response 
to abacavir. Several analogues in groups 1 and 2 displayed some anti-
viral activity without triggering CD8+ T-cell responses. Molecular 
docking studies of these analogues to HLA-B*57:01 demonstrated a 
quantitative relationship between the protein binding and the T-cell 
response. These data prompted us to synthesize a 3rd group of com-
pounds where the NH-cyclopropyl group of abacavir was replaced 
with substituted cyclic amine derivatives. This third series was sub-
jected to additional antiviral activity and T-cell response assays and 
several molecules were shown to be devoid of T-cell activity, whilst 
maintaining a favourable antiviral profile.
Conclusions: These studies demonstrate that modification of the 
cyclopropyl moiety of abacavir may result in compounds that retain 
the antiviral activity, without generating an unwanted T-cell response. 
This approach represents an exciting approach to the design of safe 
antiviral drugs eliminating the need for personalised medicine therapy 
regimes.
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Background: Dapsone is an antibiotic commonly used in the treat-
ment of leprosy. Its use is associated with development of hyper-
sensitivity in 0.5–3.6  % patients. HLA-B*13:01 is associated with an 
increased susceptibility to dapsone hypersensitivity but no studies 
have been carried out to determine the immunological mechanism(s) 
underlying the reactions and/or the role of the HLA risk allele in anti-
gen presentation. The aims of this study were to: (1) Prime naive T-cells 
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to dapsone and nitroso-dapsone (2) Generate dapsone-and nitroso-
dapsone-specific T-cell clones from healthy donors and (3) Character-
ize the pathways of drug-specific T-cell activation.
Materials and methods: Peripheral blood mononuclear cells (PBMCs) 
were isolated from healthy volunteers, and CD14+ monocytes and 
naïve T-cells were isolated by magnetic bead separation. Monocyte-
derived dendritic cells (DC) were used to prime naïve T-cells in the 
presence of either dapsone or nitroso dapsone using an established 
DC priming assay. Drug-specific T-cell clones were generated by serial 
dilution and repetitive mitogen stimulation. Antigen specificity was 
assessed by measurement of proliferation and cytokine release using 
[3H]-thymidine release and IFN-γ Elispot, respectively.
Results: Moderate priming of naive T-cells to both dapsone-and 
nitroso-dapsone was detected but only five dapsone-specific T-cell 
clones were generated from one out of three donors tested. No 
nitroso-dapsone-specific T-cell clones were detected in any of the 
three donors. The dapsone-responsive clones were stimulated to pro-
liferate is a dose-dependent manner, but showed no cross reactivity 
with nitroso-dapsone or three closely related structures. The clones 
secreted IFNgamma, IL-5 and IL-13 alongside the cytolytic mole-
cule granzyme B. All of the dapsone-specific clones were CD4+, and 
showed MHC class II-restricted activation. Use of fixed or pulsed anti-
gen presenting cells suggested that activation of T cell clones by dap-
sone did not require antigen processing.
Conclusions: Naïve T cells were primed to both dapsone and nitroso 
dapsone. Dapsone-specific T-cell clones were activated via a process-
ing independent pathway, thus suggesting a non-covalent interac-
tion between drug, MHC and T cell receptor. On-going studies using 
PBMCs from volunteers ezxpressing HLA-B*13:01 will investigate the 
role of HLA*B13:01 in the activation of dapsone- and nitroso-dapsone-
specific T cells.
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Background: Allergic reactions to drugs are often unpredictable and 
may have many side effects including anaphylaxis. According to the 
hapten hypothesis, drug of low molecular weight can bind to pro-
teins and form immunogenic complexes. Antigen presenting cells, 
such as dendritic cells (DCs), recognize and internalize drug hapten 
complexes, and digest them into benzylpenicillin-hapten peptides 
(BP-P), which are presented on HLA molecules to drug-specific T-cells. 
This lead to the immunization of the exposed person. There is in vitro 
evidence that T-cells from allergic patients react to benzylpenicillin-
Human Serum Albumin (BP-HSA) bioconjugate and our group has 
recently shown the existence of naïve CD4+ T lymphocytes specific to 
BP-HSA in healthy donors. In this context, we were interested in identi-
fying BP-P from HSA able to immunize patients to BP thus contributing 
to hypersensitivity reactions.
Materials and methods: We have considered HSA as a good model 
for BP haptenization since BP is known to bind covalently to HSA and 
because HSA is the most abundant protein in the sera. We have syn-
thetized BP-HSA bioconjugate, investigated BP-HSA-specific naïve 
CD4+ T-cell responses in healthy donors and identified BP binding 
positions on HSA using mass-spectrometry. Twelve 15-mer BP-P were 
identified as potential T-cell epitopes using the predictive IEDB com-
putational approach and were synthesized using an original BP-lysine 
monomer. Naïve CD4+ T cells from non-allergic donors were stimu-
lated once a week with autologous DCs loaded with BP-HSA or BP-P 
to amplify BP-HSA- or BP-P-specific T-cells respectively. Activation of 
specific CD4+ T-cells was detected using interferon-γ ELISpot and their 
frequency was calculated using the Poisson distribution.
Results: In this study, BP-HSA- and BP-P-specific naïve CD4+ T cells 
were detected in 15/16 and 11/14 of the tested healthy donors respec-
tively. Most donors responded to 3 peptides with BP covalently bound 
on lysines 159, 212 and 525 respectively. Two of these benzylpenicil-
linoylated peptides (lysines 159 and 525) were found to induce periph-
eral blood mononuclear cells (PBMC) proliferation in patients with 
allergic reaction to BP using the lymphocyte transformation test.
Conclusions: This study showed the capacity of BP-HSA to be recog-
nized by naïve T-cells from multiple healthy donors and allowed the 
identification for the first time of BP-P responsible for naïve T-cell acti-
vation and immunization of allergic patients to BP.
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Background: Toxic epidermal necrolysis (TEN) is a life-threatening and 
blistering adverse drug reaction, characterized by an acute epidermal 
necrolysis. Diverse studies have reported that the onset of TEN corre-
lates with skin infiltration by cytotoxic lymphocytes (T, NK cells) and 
inflammatory monocytes.
Materials and methods: To further characterize the phenotype 
of skin-infiltrating lymphocytes at the acute phase of TEN, we con-
ducted a prospective study on the blood and blister fluids from 11 TEN 
patients, using flow and mass cytometry, as well as next generation 
TCR sequencing.
Results: Our results confirm that conventional CD8+ T cells (CD45+ 
TCRab+ CD8b+) and, at a lesser extend CD4+ T cells, were the main 
leucocyte subsets found in recent TEN blisters. Consequently, the 
CD4/CD8 ratio was inversed in blisters (mean: 0.8) compared to blood 
(mean: 2). However, we failed to repeatedly detect NK (CD45+ TCRab+ 
NKP46+) or NKT cells (CD45+ TCRab+ TCRVa24+) in TEN blisters. 
Strikingly, deep sequencing of the T cell receptor CDR3 repertoire 
revealed massive clonal expansions of T cells in blister cells of 6 TEN 
patients, which were confirmed at TCR-Vb usage level by flow cytom-
etry. Over-represented TCR-Vb+ blister cells were mainly effector 
memory CD8+ CD45RA-CD27+ T cells and displayed a poly-cytotoxic 
phenotype since they co-expressed Granulysin, Granzyme B, Gran-
zyme A, Perforin and TWEAK, as demonstrated by mass cytometry.
Conclusions: Our results highlight a massive skin recruitment of clo-
notypic and poly-cytotoxic CD8+ T cells in TEN patients, which could 
explain the severity of this life-threatening disease.
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Background: Life-threatening severe cutaneous adverse reactions 
(SCAR), including drug reaction with eosinophilia and systemic symp-
toms (DRESS), Stevens–Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) are known as T cells-mediated drug hypersensitivity, 
some of which showed strong HLA genetic predisposition. Our previ-
ous studies have discovered that HLA-B*15:02, HLA-A*31:01, and HLA-
B*58:01, are the genetic markers of carbamazepine-induced SJS/TEN, 
-DRESS, and allopurinol-SCAR, respectively. Although we recently 
also have identified that HLA can directly interact with the drugs and 
metabolites (JACI 2012; JACI 2015), the role of TCR and immune syn-
apse of HLA-drug-TCR in SCAR remain unclear.
Materials and methods: We enrolled patients with SCAR caused by 
carbamazepine, allopurinol, phenytoin, lamotrigine or antibiotics, and 
collected the blister cells from skin lesions or PBMC from patients in 
the acute or recovery stage. We applied the technology of next-gen-
eration sequencing to investigate the TCR repertoire of SCAR. Real-
time quantitative PCR was used to measure and validate the gene 
expression of TCR. We generated the recombinant TCRalpha/beta 
fusion protein, TCRalpha/beta transfectants, and used in vitro cell cul-
tures to examine the molecular interaction of HLA-drug-TCR in drug 
hypersensitivity.
Results: We found that different drugs-induced SCAR showed vari-
ous profiles of TCR usage. Particularly, limited and shared drug-spe-
cific CDR3 clonotypes were predominantly expressed in the blister 
cells and PBMC of SCAR patients. The in  vitro drug-expanded T cells 
highly expressed the specific CDR3 clonotypes and produced gran-
ulysin upon drug stimulation. Furthermore, we generated drug-
specific TCRalpha/beta recombinant protein, and found it could 
directly interact with the drug antigen and show cross-reactivity to 
the structure-related compounds or metabolites. Using in  vitro cell 
culture and ELISPOT assays, we found that the specific TCRalpha/beta 
transfectants were activated upon drug stimulation, and the response 
was facilitated by the co-culture of antigen-presenting cells with the 
expression of matched HLA transgene.
Conclusions: Our data suggest that clonotype-specific TCRalpha/beta 
directly interacts with drug antigens presented by HLA in the T cells-
mediated drug hypersensitivity. This study provides a new insight into 
the pharmaco-immunological synapse of HLA-drug-TCR in SCAR.
Keywords: Immune synapse; TCR; HLA; Drug antigen; SCAR
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Background: Amoxicillin-clavulanate (AC) is one of the most common 
causes of drug induced liver injury (DILI) in Europe and the US. The 
mechanisms of amoxicillin-clavulanate–induced liver injury (AC-DILI) 
remain to be defined, however, recent studies have shown that AC-
DILI is associated with both HLA class I and class II alleles, indicating 
immune-mediated mechanisms have been involved.
Materials and methods: In order to investigate the molecular basis 
involved in AC-DILI, we have characterized the binding of AC to 
proteins in  vitro and in patients receiving amoxicillin-clavulanate 
therapy using novel mass spectrometric methods. Clavulanic acid 
was incubated with N-acetyl lysine in phosphate buffer and the 
structures of adducts were characterised by mass spectrometry. 
In addition, amoxicillin and clavulanic acid were incubated with 
human serum albumin (HSA) in  vitro to identify possible adducts 
formed on proteins, and the protein adducts formed in cell culture 
medium and in patients were also characterised by mass spectro-
metric methods.
Results: Amoxicillin formed adducts with lysine residues on HSA 
in  vitro, with K190, K199 and K525 being the most reactive sites. In 
addition, amoxicillin-modified K190 and K525, and novel adducts 
derived from amoxicillin dimmer were also detected in plasma sam-
ples from patients, and more extensive modification was observed in 
patients that had been administered higher doses of amoxicillin. The 
binding of clavulanic acid to HSA was rather complicated compared 
to amoxicillin. A total of seven types of adducts were identified when 
clavulanic acid was incubated with HSA at high concentration in vitro, 
including that formed by direct binding of clavulanic acid to lysine 
residues, novel pyrazine adducts derived from binding to the degra-
dation products of clavulanic acid, and a cross-linking adduct. Impor-
tantly, stable adducts derived from formylacetic acid and pyrazine 
were also detected in all patients.
Conclusions: The finding of distinct novel types of AC haptens formed 
in patient is vital for further exploration of the immunological conse-
quences to define the mechanisms of drug hypersensitivity exempli-
fied by AC.
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Background: Benzylpenicilloyl-dendrimer conjugates are recognized 
by IgE specific to BP (benzylpenicillin). Dendrimers are monodisperse 
synthetic carriers, which chemical structure can be perfectly charac-
terized. Their use compared to the conventional poly-l-lysine carrier 
improves the reproducibility and sensibility of in  vitro tests to diag-
nose allergy. Moreover, increasing understanding of the immuno-
logical recognition of drug-carrier conjugates in  vitro would help to 
improve diagnostic tests. Herein we include other penicillin epitope, 
AX (amoxicillin), and study Dendrimeric Antigen (DeAn) conjugates 
that contain two types of epitopes, BP and AX, in the same carrier den-
drimer molecule. We hypothesize that the orientation and tridimen-
sional disposition of the peripheral epitopes in the DeAn may play key 
roles in the IgE recognition.
Materials and methods: Synthesis of DeAn conjugates was accom-
plished by reaction of generation 4 PAMAM (PolyAMidoAMine) den-
drimers with either one kind of penicillin (BP or AX) or both penicillins 
(BP and AX). Their chemical and tridimensional structures were studied 
by mono- and bi-dimensional NMR (Nuclear Magnetic Resonance) and 
MDS (Molecular Dynamic Simulation). The conjugates were immu-
nologically evaluated by RAST (Radio-Allergo-Sorbent-Test) inhibi-
tion using sera from 6 patients allergic to penicillins (selective and 
cross-reactive).
Results: Spatial conformation showed differences between ben-
zylpenicilloyl, with a hidden side chain, and amoxicilloyl, exposing the 
entire molecule outside the dendrimeric skeleton. Concerning immu-
nological assays, at the maximum conjugate concentration, serum 
allergic to BP showed 80  % of RAST inhibition to both BP-DeAn and 
biepitope-DeAn, and negative to AX-DeAn. Sera allergic to AX showed 
90  % of inhibition to both AX-DeAn and biepitope-DeAn, with no 
inhibition to BP-DeAn. All sera with cross-reactivity to both penicil-
lins inhibited above 90 % to both AX-DeAn and biepitope-DeAn and 
above 60 % to BP-DeAn.
Conclusions: Experimental data show less recognition of benzylpeni-
cilloyl compared to amoxicilloyl units in those biepitope-DeAn, 
probably due to the different accessibility of the side chain of both 
penicillins to IgE recognition. Therefore there is a correlation between 
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the tridimensional chemical structures of penicillin epitopes and the 
way DeAn are recognized by sIgE. Moreover, the biepitope DeAn con-
jugates could represent the basis of a novel method for screening a 
wider proportion of allergic patients with a single test.
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Background: Complex functional materials consisting of bioactive 
molecules immobilized on solid supports present potential applica-
tions in biosensoring. Advances in the fabrication of these surface 
materials are of growing interests in antibody-based diagnostic. We 
describe recent progress in the preparation of new materials for biosen-
sor applications where Dendrimeric Antigens (DeAn), synthetic anti-
gens where the role of the carrier protein is performed by a dendrimer, 
were supported on silica particles to assemble DeAn@SiO2 composites. 
DeAn@SiO2 containing the allergenic determinant to amoxicillin (AXO) 
has been studied for quantifying IgE specific to Amoxicillin.
Materials and methods: We report on the use of silica particles as a 
solid support for Radio-Allergo-Sorbent-Test (RAST) with a view to its 
use as a complementary diagnostic method for identifying allergic 
responses to penicillin. We prepared nanoconjugated Dendrimeric 
Antigens (DeAn) consisting of second-generation PAMAM dendrim-
ers (PAMAM-G2) peripherally decorated with the suspected amoxicillin 
hapten (AXO). These organic–inorganic hybrid materials were carefully 
characterized and the preparation methodology was checked to be 
highly reproducible. To study the potential of those composites in the 
detection and quantification of antibodies, they were clinically tested 
by RAST using sera from allergic patients and control individuals tol-
erant to this drug, according to conventional protocols applied in the 
clinical practice.
Results: 0.4  mg of DeAn@SiO2 composites were used in each assay, 
producing positive RAST results (7  %) in sera from three allergic 
patients. No signal was obtained in the RAST on two control individu-
als (even though being one of them with diagnosed immediate allergic 
reaction to benzylpenicillin), ensuring a high specificity in the detec-
tion of antibodies. Additionally, larger amounts of composites (1 and 
1.6 mg) were used in the assays, increasing the RAST level for patients 
allergic (14 and 18  % respectively), which successfully improves the 
sensitivity of the test. The percentage of RAST obtained with the con-
trol gave negatives values, maintaining the specificity of the test.
Conclusions: DeAn@SiO2 composites, containing the allergenic 
determinant to AXO, proved effective in detecting and quantifying 
IgE in sera from patients allergic to amoxicillin, in a specific and selec-
tive way. This new material is thus promising candidate for improving 
in vitro clinical diagnostic practice.
Keywords: IgE quantification; Dendrimers; Dendrimeric antigens
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Background: A small proportion of adverse drug reactions (ADRs) 
are due to drug hypersensitivity where the immune response causes 
an unexpected and sometimes severe clinical reaction. Genome-wide 
screens have identified many different genetic associations between 
drugs and ADRs. Of particular interest to hypersensitivity reactions are 
the HLA Class I and Class II risk alleles. Not all individuals with a HLA 
risk allele will develop hypersensitivity. Thus, the frequency/severity of 
a reaction is a function of the chemistry of the drug, the biology of the 
immune system, the genotype of the individual and the underlying 
medical condition.
Drug hypersensitivity reactions are rare and are rarely detected dur-
ing clinical trials. It is only once the drug is widely prescribed that 
these reactions become apparent. Since hypersensitivity reactions 
that target skin and liver are a major cause of drug withdrawal from 
the market, there is a need to develop a screening assay which could 
potentially detect these reactions during drug development.
Materials and methods: We have established a biobank of lympho-
cytes isolated from 1000 HLA-typed volunteers and have developed 
a DC priming assay which can prime naïve T cells to various drugs. 
The current form of the DC assay is labour intensive, requires large 
numbers of cells, uses different plate formats, has multiple readouts 
and takes 3–4 weeks to run. The aim is to modify this into a screening 
assay using a single plate with a single readout. We have selected up 
to 5 donors expressing seven different HLA Class I risk alleles: A*3101, 
A*3303, A*6801, B*1301, B*1502, B*5701 and B*5801. Ten donors with-
out the HLA risk alleles will be included as negative controls and a 
unique donor exposed to nitroso-sulfamethoxazole (SMX-NO) will be 
used as a positive control.
Results: Initial development has concentrated on using the SMX-NO 
and 2 β-lactam antibiotics as positive controls to optimise the assay 
conditions, to assess the frequency of T-cell responses and to meas-
ure the strength of the response induced. Early results show that pro-
liferative responses to SMX-NO have been detected in the screening 
assay at a similar intensity to that detected in the existing form of the 
assay. Further work will concentrate on reproducibility and inter-donor 
variation.
Conclusions: Once established, the screening assay will be used to 
investigate responses to ticlopidine, dapsone, carbamazepine, fluclox-
acillin allopurinol and abacavir.
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Background: Amoxicillin (AX) is the most frequent antibiotic elicitor of 
allergic reactions to drugs. It is widely accepted the requirement of the 
binding of the AX to a carrier molecule for its optimal IgE recognition. 
Although the carrier molecule seems to form part of the antigenic 
determinant, its contribution in the pattern of response is not fully 
known. The aim of this work was to study the recognition of different 
structures derived from AX by IgE antibodies from allergic patients to 
this drug.
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Materials and methods: Patients (N = 21) with an immediate allergic 
reaction to AX and radioallergosorbent test (RAST) values >7 % were 
included. The IgE recognition study was performed by RAST inhibition 
using on the solid phase AX bound to poly-l-lysine and in the fluid 
phase the following inhibitors: AX, amoxicilloic acid, AX bound to but-
ylamine (AXO-BA) and to human serum albumin (AXO-HSA), and frac-
tions of different molecular weights of human serum modified with 
AX.
Results: Two well-defined patterns of recognition were observed: 
A group of patients in whom AX itself was significantly higher rec-
ognized (Group A, N  =  8) and another group of patients who pref-
erentially recognized AXO-BA and AXO-HSA (Group B, N  =  13). No 
significant differences were observed for amoxicilloic acid, being 
significantly the lowest recognized structure in both groups. Regard-
ing the pattern of recognition of different fractions from AX-modified 
human sera, groups A and B showed differences, with a higher recog-
nition of the lowest molecular weight fraction (<3 kDa) in Group A and 
no differential recognition in Group B.
Interestingly, all patients classified as Group A had selective allergic 
reactions to AX, and all those in Group B had cross-reactive reactions.
Conclusions: Although both AX derivatives and carrier molecules are 
important for the IgE recognition, differences exist between patients 
with a selective or a cross-reacting response. In selective patients, 
it is necessary that the side chain of the AX was preserved in the AX-
carrier adducts and exposed to the IgE, and this fact is influenced by 
the conditions in the formation of adducts. However, for cross-reactive 
patients, whose IgE antibodies recognize the AX side chain and part of 
the common structure of penicillins, the conditions for the generation 
of AX-carrier adducts seem not to be relevant for their recognition. The 
poor recognition of the amoxicilloic acid reinforces the need for bind-
ing the AX to a carrier molecule for an optimal recognition.
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Background: Immune-related severe adverse drug reaction (ADR) 
is widely hypothesised triggered by the combination of HLA, drugs, 
peptides, and T-cell receptor (TCR) molecules. Currently, numerous 
types of severe ADRs are reported to be related to particular HLA 
polymorphisms, such as HLA-B*15:02 allele associated with carba-
mazepine-induced Steven’s Johnson syndrome (SJS) and HLA-B*58:01 
allele associated with allopurinol-induced severe cutaneous adverse 
reactions (SCARs). The use of TCR by drug-specific T cells is also con-
sidered a co-factor responsible for severe ADR. The major challenges 
of using Sanger sequencing, for high-throughput typing of HLA and 
TCR gene in large cohort studies, is the high cost involved. Moreover, 
it is unknown whether CBZ-SJS or allopurinol-SCARs is linked to more 
specified HLA types. Our aim was to identify which specified HLA types 
and TCR profiling correlated with CBZ-SJS or allopurinol-SCARs based 
on using cost-effective next-generation sequencing approaches.
Materials and methods: We enrolled patients with CBZ-SJS, CBZ-
tolerant subjects, patients with allopurinol-SCARs, allopurinol-tolerant 
subjects, and healthy controls. For HLA typing, we developed an analy-
sis pipeline for illumina Miseq or PacBio sequencing platform. For TCR 
typing, a widely used primer set was used and an analysis pipeline for 
illumina Miseq or Hiseq sequencing platform was developed. Sanger 
sequencing for the validation of HLA and TCR was performed.
Results: We genotyped all major HLA regions, including HLA-A, HLA-
B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1, in all the subjects. 
Compared with sequence-based typing ($400 per sample) for HLA 
typing, the cost based on next-generation sequencing ($240 per 
sample) was reduced. CBZ-SJS patients or allopurinol-SCAR patients 
were HLA-B*15:02:01-positive or HLA-B*58:01:01-positive, respec-
tively. For TCR, we genotyped all the V beta subfamilies. Dominant 
CDR3 sequences were verified by Sanger sequencing. Compared with 
Sanger sequencing ($500 per sample), the cost based on next-genera-
tion sequencing ($50 per sample) was much lower. Additionally, novel 
TCR clonotypes, possibly associated with SJS patients, were identified.
Conclusions: A cost-effective method for high-throughput and high-
resolution typing of HLA and TCR was developed. HLA-B*15:02:01 
and HLA-B*58:01:01 were found as more specified HLA genotypes for 
developing CBZ-SJS and allopurinol-SCARs, respectively.
P190 
Identification and fate of intracellular proteins haptenated 
by amoxicillin
Francisco J. Sánchez‑Gómez1, Juan M. González‑Morena1, Yolanda 
Vida2, Ezequiel Pérez‑Inestrosa2, Miguel Blanca3, María J. Torres3, Dolores 
Pérez‑Sala1
1Department of Chemical and Physical Biology, Centro de Investigaciones 
Biológicas‑CSIC, Madrid, Spain; 2Department of Organic Chemistry, Uni‑
versity of Málaga, Málaga, Spain; 3Allergy Unit, IBIMA‑Regional Hospital 
of Málaga, Málaga, Spain  
Correspondence: Francisco J. Sánchez‑Gómez
Clinical and Translational Allergy 2016, 6(Suppl 3):P190
Background: The common use of beta-lactams during the last dec-
ades is leading to an increase in the prevalence of allergic responses. 
In the allergic response, the adduct formation between small drugs 
and proteins, called haptenation, allows drugs to be recognized as 
antigens by the immune system. Moreover, it has been hypothesized 
that structures from target proteins can also contribute to the forma-
tion of the antigenic determinants. Identification of protein targets for 
haptenation is relevant for their potential use in novel diagnostic tools 
as well as for understanding the complete mechanisms involved in 
antigen presentation and the role played by the cells that participate 
in allergy induction. In recent years our lab has undertaken the identi-
fication of targets proteins for the haptenation by beta-lactams.
Materials and methods: We have attempted the identification of pro-
tein targets for covalent modification by amoxicillin (AX) and a bioti-
nylated analogue (AX-B) as model compounds. To accomplish these 
aims, we decided to use a B-lymphocyte cell line as cellular model. The 
identification of the proteins haptenated by AX and AX-B has been 
approached with mass spectrometry experiments. In addition, inter-
cellular communication mediated by vesicular delivery of molecular 
messages has been explored by microscopy techniques.
Results: In our experiments we have observed a complex pattern of 
proteins modified by amoxicillin. Among them, we have isolated and 
identified several novel targets for haptenation by AX in B-lympho-
cytes. In addition, these haptenated proteins have been observed 
both intracellularly and in the conditioned medium, where they were 
found both in soluble and vesicular fractions.
Conclusions: Our results indicate that intracellular proteins may be 
haptenated by beta-lactam antibiotics and reach the extracellular 
medium. The importance of these targets in the development of aller-
gic reactions will be the subject of further investigations.
Funding: MINECOSAF2012-36519; ISCIII RD12/0013/0008
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Background: Idiosyncratic drug induced liver injury (iDILI) is a severe 
adverse reaction which manifests in some, but not all drug recipients. 
The incidence of these reactions is so low that these adverse events 
Page 73 of 74Clin Transl Allergy 2016, 6(Suppl 3):30
cannot be attributed to the normal pharmacological action of a drug, 
but are probably due to the individual biology of a patient. To support 
this claim, an increasing number of genetic associations have been 
found in cases of iDILI, and many of these are with HLA alleles. This 
indicates that iDILI may have an immunological aetiology and there 
is increasing evidence to support this. For example: the detection of 
T-cells in liver biopsies from iDILI patients and the isolation of drug 
specific T-cells in patients suffering from flucloxacillin and co-amox-
iclav induced liver injury. This sets a precedence to investigate other 
iDILI drugs such as terbinafine in the context of drug hypersensitivity 
reactions. Terbinafine can form a chemically reactive metabolite and 
like β-lactam antibiotics, may form drug-protein haptens to activate an 
immune response. Although the hapten model for drug hypersensitiv-
ity is well established, the precise nature of the drug antigen is unclear. 
The aim of this study is to investigate the formation of terbinafine 
adducts using a chemically reactive metabolite of terbinafine: allylic 
aldehyde, 7,7-dimethylhept-2-ene-4-ynal (TBF-A).
Materials and methods: TBF-A was incubated for 24 h at a 10:1 molar 
ratio for synthetic peptides and a 1:1 ratio for other molecules. Mass 
spectrometric analysis was conducted using an API 4000 or an QTRAP 
5500 hybrid quadrupole-linear ion trap mass spectrometer (AB Sciex). 
Conjugates were detected using multiple reaction monitoring and 
also enhanced product ion scanning methods
Results: TBF-A showed binding to N-acetyl cysteine and glutathione 
but not to N-acetyl lysine. Additionally, TBF-A was shown to bind 
covalently to glutathione s-transferase pi. Following incubation with 
human serum albumin, no conjugates were detected. Synthetic 
cysteine containing peptides were also generated and shown to bind 
TBF-A.
Conclusions: TBF-A binds to cysteine residues in small molecules, 
larger proteins and also in synthetic peptides. Thus, we are now con-
ducting additional studies to isolate TBF-A specific T-cells in order to 
investigate whether formation of this metabolite is important for the 
activation of the adaptive immune system in patients with iDILI.
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Background: Drug hypersensitivity reactions account for approxi-
mately 15 % of all adverse drug reactions, where the skin is the main 
organ affected generating an important health problem. During 
the last 20  years, we have gained insight into the immunological 
mechanism(s) behind different forms of cutaneous hypersensitivity, 
but our knowledge of post-transcriptional immune regulators remains 
poorly understood. MicroRNAs (miRNAs) play a key role in several 
immunological processes and in the pathogenesis of several diseases 
including severe skin conditions; nonetheless, their cellular origin and 
the changes in the expression as a result of drug exposure needs to be 
further investigated.
Materials and methods: Two allergic patients to sulfamethoxazole 
(SMX1 and SMX2) and one allergic patient to levofloxacin (LFV1) 
were enrolled in the study. Approval for the study was obtained from 
local research ethics committee, and informed written consent was 
obtained from each donor. The presence of drug specific T-cells was 
determined by LTT. Additionally, PMBCs (1.5 × 105 cells/ml) from each 
patient were incubated by triplicate in cell culture alone or in the pres-
ence of the culprit drugs at different concentrations. The change in the 
pattern of expression of the miRNAs was compare between drug free 
cells and drug incubated cells at 0, 12, 24 and 48  h by RT-PCR using 
commercial specific probes for miR-18a, -21, -142 and -155. The U6 
gene was used as reference, and the relative expression was calculated 
using the delta Cq method.
Results: Positive stimulation indexes were obtained from the three 
patients at different concentrations. Moreover, a significant increase 
in the expression of miR-18a, -21, -142 and -155 was detected after 
12–48 h in the PBMCs of all the patients. Quantitative relative expression 
of the different miRNAs showed a fold change between 2 and 100 dur-
ing the incubation time when compared with cells without drug. When 
a different drug, not related with the reaction, was used, the change in 
the pattern of expression was reduced or similar to basal levels.
Conclusions: Our findings clearly show that the incubation of the 
culprit drugs with PBMCs from hypersensitive patients modify the 
expression of miRNAs in a dose and time dependent manner. At the 
presence, we are evaluating the change in the pattern of expression 
of miRNAs in PBMCs of hypersensitive patients caused by anticonvul-
sants and in patients with severe cutaneous reactions (Table 11).
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Background: Some patients with a history of chronic spontaneous 
urticaria may suffer from an exacerbation of this pathology after aspi-
rin and other non-steroidal anti-inflammatory drugs (NSAIDs) intake, 
a condition termed NSAIDs-exacerbated cutaneous disease (NECD). In 
addition to the participation of COX-1 inhibition the underlying mech-
anism may be influenced by differential gene expression. To assess the 
genetic mechanisms potentially implicated in NECD we analysed gene 
expression patterns using microarrays technology.
Materials and methods: Total RNA was obtained during the acute 
phase from skin biopsies in 3 patients with NECD, and 14 heathy con-
trols. After quality control evaluation, gene expression patterns were 
compared through the GeneChip Human Gene 2.0 ST microarrays sys-
tem (Affymetrix).
Mechanism may be influenced by differential gene expression. To 
assess the genetic mechanisms potentially implicated in NECD we 
analysed gene expression patterns using microarrays technology.
Results: We found 163 differentially expressed transcripts in NECD 
patients from a total of 48,227 analysed (FDR p value <0.05, and a 
log fold change >1 or <1). Top upregulated transcripts were related 
to the structural integrity of epithelial cells (KRT16, KRT17), the HLA 
system (HLA-DQB1) and microRNAs (MIR4427). Some downregulated 
transcripts were also related to microRNAs (MIR3127) and microRNA-
mediated gene repression (DND1), adhesion and migration of epithe-
lial cells (POSTN), transcription factors (ZNF667), and collagen integrity 
(COL6A5).
Conclusions: We described a differential expression pattern in NECD 
suggesting intricate interactions in gene regulation affecting skin 
structural integrity, cell adhesion and migration, and the HLA system. 
Our results shed new light for understanding the mechanisms under-
lying this entity: (normal’ > KRT16, KRT17), the HLA system (HLA-DQB1) 
and microRNAs (MIR4427). Some downregulated transcripts were also 
related to microRNAs (MIR3127) and microRNA-mediated gene repres-
sion (DND1), adhesion and migration of epithelial cells (POSTN), tran-
scription factors (ZNF667), and collagen integrity (COL6A5).
Keywords: Drug hypersensitivity; NSAIDs; NECD; Gene expression
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Background: Allergy to beta-lactam antibiotics, specifically penicillins, 
is presented differently depending on the time spent from administra-
tion of the drug until the reaction. Thus we can classify these manifes-
tations as immediate, accelerated or delayed, or simply as immediate 
or not immediate.
Materials and methods: Patient who comes to be attended after 
having suffered 2 episodes of RAM after taking amoxicillin. Both epi-
sodes coursed with generalized skin rash, 8 days after taking amoxicil-
lin 500 per a picture of tonsillitis and the second 5  days after taking 
amoxicillin 500 per a tooth extraction. On both occasions the picture is 
manifested after a latency period of 48–72 h after the last intake. Skin 
tests with amoxicillin (DAP DIATER kit) by prick test and ID to 1:10 and 
1:100 and undiluted. Oral challenge test against Cefuroxime increas-
ing doses up to the maximum cumulative dose of 500 mg. RAST tests 
against penicilloyl G and V, ampicillin, amoxicillin and cefaclor.
Results: The skin tests were positive for amoxicillin ID undiluted, 1:10 
and 1:100 at 72 h. The oral food challenge to cefuroxime at the doses 
administered was negative. RAST tests against penicilloyl G and V, 
Ampicillin, Amoxicillin and negative cefaclor.
Conclusions: We report a case of delayed reaction to amoxicillin with 
tolerance to cefuroxime, where the history and skin tests were essen-
tial in the diagnosing of this case.
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Table 11 Clinical information and functional assays results 
from three hypersensivity patients to antibiotics
Relative expression results are presented as the Mean ± SD obtained by the 
delta Cq method
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